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Myelodysplastic syndromes (MDS) are a collection of clonal hematopoietic stem cell 
disorders with diverse phenotypes, characterized mainly by ineffective 
haematopoiesis. Refractory anaemia with ringed sideroblasts (RARS) is an acquired 
form of MDS with accumulation of mitochondrial iron that gives rise to ringed 
sideroblasts. In this study, whole-exome sequencing performed in 12 patients all of 
whom had >25% ringed sideroblasts identified mutations in one particular gene, 
splicing factor 3b subunit 1 (SF3B1), a component of the major and minor 
spliceosomes, in 11/12 cases. No SF3B1 mutations were observed in a single case of 
congenital sideroblastic anaemia, however, a constitutional mutation in ALAS1 gene 
was confirmed in this patient.  
Subsequently, amplicon sequencing using a 22 myeloid-gene panel in 154 MDS 
patients revealed 76% (n=117) of the patients had mutations in at least one of the 
genes, with 38% (n=59) having splicing gene mutations and 49% (n=75) patients 
harbouring more than one gene mutation. Interestingly, single and specific epigenetic 
modifier mutations tended to coexist with SF3B1 and SRSF2 mutations (p<0.03). 
Moreover, patients with splicing factor mutations alone had a better overall survival 
than those with coexisting additional mutations.  
Next, combination of techniques including xenotransplantation and single cell 
clonogenic assays were used to study the characteristics of SF3B1 mutant cells. 
Mutational analysis of hematopoietic stem/progenitor cells showed that SF3B1 
mutations arise in phenotypically defined CD34+CD38-CD45RA-CD90+CD49f+ stem 
cells, therefore revealing the existence of MDS-initiating stem cells that propagate 
mutations to myeloid progenitors only. A persistent engraftment restricted to myeloid 
lineage was observed which was initiated only via the xenotransplantation of HSCs. 
Genetically diverse evolving subclones of mutant SF3B1 were detected in mice, 
indicating a branching multi-clonal as well as ancestral evolutionary paradigm. 
Subclonal evolution in mice was also mirrored in the clinical evolution in patients. 
Sequential sample analysis uncovered a clonal evolution in hematopoietic progeny 
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1.1 Myelodysplastic syndromes  
Myelodysplastic syndromes (MDS) constitute a group of clonal hematopoietic stem-
cell disorders with diverse clinical phenotypes. These diseases are characterized by 
varying magnitude of ineffective haemopoiesis and bone marrow morphological 
dysplasia.  The sequelae of MDS result from the peripheral blood cytopenias and 
includes combinations of anaemia, thrombocytopenia and/or neutropenia (Mufti et al., 
2008). Approximately 30% of the MDS patients transform to acute myeloid leukaemia 
(AML). The incidence of MDS is 3-4 cases per 100,000, however it increases markedly 
with age, and the median age at diagnosis is 73 years. Men have a significantly higher 
incidence than women (4.5 versus 2.7 per 100,000 per year) (Mufti et al., 2008; Scott 
and Deeg, 2010) and the overall survival following a MDS diagnosis varies between 
few months to more than 10 years (Mufti et al., 2008).  
Several risk factors have been implicated in the pathogenesis of MDS including age, 
alcohol, smoking, ionizing radiation, immunosuppressive therapy, viral infection, 
benzene and other environmental leukaemogens. However, these risk factors seen 
occasionally are associated with up to 30% of the patients, who are often described 
as having secondary MDS. Moreover, majority of the secondary MDS cases are 
therapy-related MDS (tMDS) who have been previously treated with chemotherapy 
and/or radiotherapy.  
Much of the phenotypic heterogeneity in MDS is likely to be caused by a variety of 
genetic lesions that contribute to disease pathogenesis.  Recently, a multistep 
sequential model for the development of MDS has been proposed. According to this 
model (Figure 1), the interplay of mutations in the stem cells, epigenetic alternations 
within the bone marrow cells and the abnormal bone marrow microenvironment may 
allow for a predominant dysplastic clone to be established. The genetic alterations 
which lead to MDS are due to the dysregulation of genes involved in cellular pathways 





Figure 1: Pathogenesis of myelodysplastic syndromes 
Age-induced genetic susceptibility and somatic mutations in haematopoietic stem cells lead 
to oligoclonal expansion of myelodysplastic stem cells, with defective differentiation, 
characterised by increased apoptosis of bone marrow progenitors. However, subsequent 
micro-environmental changes, immune dysregulation and epigenetic changes contribute to 
phenotypic diversity and susceptibility to leukemic transformation. MDS- Myelodysplastic 
syndromes, HSC- Haematopoietic stem cells.  
 
1.1. MDS Classification  
The phenotypic heterogeneity and the highly variable prognosis of MDS patients 
makes it difficult to classify the disease subtype, and predict the survival, and likelihood 
of leukaemic transformation. Therefore, over the past two decades several MDS 
classification and prognostic scoring systems have been proposed (Mufti et al., 2008; 
Scott and Deeg, 2010; Tefferi and Vardiman, 2009). Among the widely accepted 
systems, the French-American-British (FAB) classification widely modified by the 
World Health Organization (WHO) in 2008 is extensively used to classify MDS 
subtypes (Mufti et al., 2008). According to the WHO classification system for 
haematological cancers, patients with MDS are classified into 8 broad categories 
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(Table 1): Refractory anaemia (RA), Refractory anaemia with ringed sideroblasts 
(RARS), Refractory cytopenia with multilineage dysplasia (RCMD), Refractory 
cytopenia with multilineage dysplasia and ringed sideroblasts  (RCMD-RS), Refractory 
anaemia with excess blasts-1 (RAEB-1), Refractory anaemia with excess blasts-2 
(RAEB-2), MDS associated with isolated del(5q) and Myelodysplastic syndrome 
unclassified (MDS-U) (Scott and Deeg, 2010).  
 







Bone marrow findings 
Refractory anaemia (RA) Anaemia 
No or rare blasts 
Erythroid dysplasia only 
<5% blasts 
<15% ringed sideroblasts 




Erythroid dysplasia only 
<5% blasts 
≥15% ringed sideroblasts 
Refractory cytopenia with 
multilineage dysplasia (RCMD) 
Cytopenias (bicytopenia or 
pancytopenia) 
No or rare blasts 
<1 × 109/L monocytes 
Dysplasia in ≥10% of cells in 2 or 
more 
myeloid cell lines 
<5% blasts in marrow 
<15% ringed sideroblasts 
Refractory cytopenia with 
multilineage dysplasia and ringed 
sideroblasts  (RCMD-RS) 
Cytopenias (bicytopenia or 
pancytopenia) 
No or rare blasts 
<1 × 109/L monocytes 
Dysplasia in ≥10% of cells in 2 or 
more 
myeloid cell lines 
≥15% ringed sideroblasts 
<5% blasts 
 




<1 × 109/L monocytes 
Unilineage  
5% to 9% blastsor multilineage 
dysplasia 
 
Refractory anaemia with excess 
blasts-2 (RAEB-2) 
Cytopenias 
5% to 19% blasts 
Auer rods  
<1 × 109/L monocytes 
Unilineage or multilineage 
dysplasia 





No or rare blasts 
 




MDS associated with isolated del(5q) Anaemia 
<5% blasts 
Platelets normal or 
increased 
Normal to increased 
megakaryocytes with hypolobated 
nuclei 







The WHO classification is supplemented by various prognostic scoring systems to 
predict the prognosis of the MDS patients. The most widely used prognostic scoring 
system used for stratification is the International Prognostic scoring System (IPSS) 
developed by Greenberg et al in 1997 (Greenberg et al., 1997). The IPSS is an 
important standard for assessing prognosis of primary untreated adult MDS patients 
and it groups patients into four risk categories based on the percentage of bone 
marrow blasts, number of cytopenias and karyotypic abnormalities detected by 
conventional cytogenetics (Table 2 and Table 3).  Over the last few years, several 
MDS cooperating groups have revised the IPSS. This revised IPSS (IPSS-R) system 
identifies five prognostic categories. Bone marrow cytogenetics, bone marrow blast 
percentage and cytopenias remain the basis of the new system, however, a more 
precise refinement of some of these features (depth of cytopenias, splitting of bone 
marrow blasts <5% and more precise cytogenetic subgroups) demonstrated better 
separation of prognostic categories (Greenberg et al., 2012; Voso et al., 2013). 
 
Table 2: The International prognostic scoring system (IPSS) values.  
 
0 0.5 1 1.5 2 
BM Blasts (%) <5% 5-10% - 11-20% 21-30% 
No. of 
Cytopenias+ 























Table 3: IPSS prognostic risk category clinical outcomes. 
 
Low Intermediate 1 Intermediate 11 High 
Risk score 0 0.5- 1.0 1.5-2.0 ≥2・5 
Proportion of 
patients (%) 
33% 38% 22% 7% 
Median survival 
(years) 
5.7 3.5 1.2 0.4 
Time to  AML 
evolution (years) 
9.4 3.3 1.1 0.2 
 
1.2 Spectrum of cytogenetic abnormalities in MDS 
Unlike chronic myeloid leukaemia (CML) where the translocation t(9;22)(q34;q11) is 
the key single genetic hallmark of the disease, cytogenetic abnormalities in MDS are 
diverse. Over the years, several large cytogenetic studies have been published. 
Greenberg et al in 1997 published a multicentre study in which cytogenetic analysis 
was performed on 800 patients with primary MDS, which later formed an important 
component for the establishment of the IPSS (Greenberg et al., 1997). This was 
followed by Spanish study of 968 patients (Sole et al., 2005) and more recently 
German–Austrian study Group of 2,124 patients (Haase et al., 2007). These along 
with other studies have reported recurring chromosomal aberrations in up to 70% of 
patients where the type and complexity of the abnormalities correlates with prognosis, 
disease progression, leukaemic transformation and response to therapy (Table 4). 
Over 90% of tMDS patients have complex karyotype. A loss of genetic material in the 
form of deletions and monosomies are most frequent abnormalities. However, gain of 
genetic material with the appearance of total or partial trisomies is also seen in a 
smaller number of patients. Furthermore, gain and/or loss of genetic material as 
observed in unbalanced translocations are observed in patients with multiple 
cytogenetic abnormalities. This heterogeneity does not only hamper the prognostic 
classification but also has an impact on the delineation of the molecular background 
of cytogenetic aberrations. It is noteworthy, a normal karyotype is found in up to 40% 
of the MDS cases at the time of diagnosis (Bejar et al., 2011; Raza and Galili, 2012; 











Risk of Progression to 
AML 
Del(20q) 2-5%  4.8 Good Low 
Del(5q) 15%  4.8 Poor High 
(The 5q syndrome)  Good Low 
Del7/(7q) 5-10% 2.7 Poor High 
17q 2-5%  2.7 Poor High 
Trisomy 8 5-8% 2.7 Medium Intermediate 
Monosomy Y 2-4% 2.7  Low 
11q23 6%  5.4 Medium Intermediate 
Complex Karyotype 10-15%  0.7 Poor High 
 
1.2.1 Deletion 5q 
Deletions of chromosome 5q (5q-) are the most frequent cytogenetic abnormalities in 
MDS deleted in approximately 15% of cases. The deletions vary in size between 
patients and are localized to two distinct commonly deleted regions (CDRs) on 
chromosome band 5q31. The proximal CDR at 5q31 is more centromeric and 
associated with bad prognosis, complex abnormalities and high-risk MDS as well as 
therapy-related MDS (tMDS). The more distal CDR in 5q33.1 is located in a more 
telomeric region and is associated with a clinical phenotype namely the 5q- syndrome. 
This is a good risk disease subgroup with a female predominance and, mainly 
characterized by severe macrocytic anaemia, normal/high platelet count, and a lower 
risk of leukaemic progression.  
Over the past few years extensive sequencing of del(5q) MDS patients has not 
identified any mutations in genes present on the remaining intact allele of chromosome 
5, therefore, suggesting that gene haplo-insufficiency might be the predisposition 
factor for the disease initiation. However, a recent study has reported mutations in 
18% of the patients with del(5q) in CSNK1A1 gene located within the CDR (Smith et 
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al., 2016) . In a separate study, CSNK1A1 knockout mouse developed characteristics 
of bone marrow failure, therefore demonstrating the potential role of this gene in 
del(5q) MDS patients (Schneider et al., 2014). On the other hand, deletion of genes 
on 5q may not be involved in the development of MDS and additional aberrations might 
be required to provide additive effect to this del(5q) clone which gives rise to MDS. 
Ebert et al performed a systematic functional RNA-mediated interference (RNAi)-
based screening of the CDR of 5q in primary haematopoietic CD34+ cells and 
identified RPS14 as a critical gene for the erythoid/megakaryocytic phenotype of the 
5q-syndrome (Ebert et al., 2008). The other genes implicated in the pathogenesis of 
del(5q) include EGR1 and CTNNA1. However, deletions of 5q are not always limited 
to the CDRs and often encompass both of these regions and beyond. NPM1 and APC 
are other genes that are located outside the CDRs but are lost with the deletions of 5q 
in MDS patients (Grisendi et al., 2005; Lane et al., 2010; Wang et al., 2010a). 
Moreover, other studies have demonstrated that haplo-insufficiency of two microRNAs 
located on chromosome 5q33, miR-145 and miR-146a, can cause elevated platelet 
counts and may provide a selective advantage to the del(5q) clone (Starczynowski et 
al., 2010).  
1.2.2 Chromosome 7 and 7q deletion 
Monosomy 7 or interstitial loss of 7q is the second most frequent distinct chromosomal 
abnormality in MDS and is associated with poor prognosis. Chromosome 7 
abnormalities, either in isolation or as part of a complex karyotype occurs in 
approximately 10% of the MDS patients (Haase et al., 2007). This frequency increases 
to 50% in tMDS patients who have a prior history of treatment with alkylating agents 
(Christiansen et al., 2004). Like del(5q) MDS, three common deleted regions on 7q 
have been identified including the band 7q22 and the more telomeric regions 7q31–
32 and 7q36 (Asou et al., 2009; Dohner et al., 1998; Le Beau et al., 1996).  
The underlying molecular mechanism driving the development of MDS in patients with 
chromosome 7 abnormalities are not well characterized. However, these interstitial as 
well as terminal deletions might be due to the cryptic unbalanced translocations. 
Previous studies have reported more than one different deletions in the same patients, 
either within the same copy of the chromosome 7 with retention of sequences between 
the deleted regions or within different mutant clones (Liang et al., 1998; Tosi et al., 
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1999). These observations underline the chromosomal instability which makes regions 
within chromosome 7 prone to structural aberrations. EZH2 gene localised to 7q36 is 
mutated in some patients with -7/del7q which alters the epigenetic state of 
haematopoietic stem cells (HSCs) by changes that occur in H3K27 trimethylation,a 
repressive mark in gene expression. However, conditional heterozygous deletion of a 
2.5-Mb chromosomal 7 region (syntenic to human 7q22) in murine hematopoietic stem 
cells had no MDS phenotype indicating that this locus may not harbour a critical tumour 
suppressor gene (Wong et al., 2010). Moreover, gene expression analysis of CD34+ 
cells from MDS patients with monosomy 7 has revealed over expression of HOX9A, 
PRAME, BMI-1, PLAB and the DNA repair gene BRCA2 (Chen et al., 2004). In the 
same study, tumour suppressor gene P21, GATA2 and MAP were found to be down 
regulated. It is noteworthy, additional abnormalities in monosomy 7 patients do not 
have such a profound impact on disease outcome unlike del(5q), since monosomy 7 
even in isolation confers a significantly bad prognosis (Bejar et al., 2011; Haase et al., 
2007). 
1.2.3 Trisomy 8 
Among the recurrent chromosomal abnormalities in MDS, trisomy 8 is the only 
chromosomal amplification observed in these patients. Trisomy 8 usually occurs in 
isolation in up to 8% of the MDS patients and is an intermediate-risk cytogenetic 
abnormality. Previous studies have reported over expression of anti-apoptotic genes 
in trisomy 8 cells and an expansion of Vβ-restricted CD8+ T cells (Barrett and Sloand, 
2009).  
1.2.4 Other Cytogenetic Lesions 
Several other recurrent cytogenetic abnormalities have been reported in MDS 
patients. These include del-Y, del20q, del3q26, del17p, isodicentric Xq13, and the 
t(6;9)(p23; q34) translocation that generates the DEK-NUP214 fusion gene (Bejar et 
al., 2011). Patients with isolated del20q or -Y abnormalities are considered to be in the 
same favourable cytogenetic risk group as patients with a normal karyotype (Bejar et 
al., 2011). Translocation(s) and inversion(s) of chromosome 3q26 occur rarely in MDS 
and are associated with a poor prognosis (Bejar et al., 2011; Haase et al., 2007). Rest 
of the chromosomal aberration are rare in MDS and are grouped together in the 
intermediate-risk prognostic group (Bejar et al., 2011).  
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Although the mechanism underlying the generation of chromosomal abnormalities in 
MDS is not known; however, chromosomal shattering and re-joining of segments has 
been observed in many types of cancers, including leukaemia (Bassaganyas et al., 
2013; Stephens et al., 2011). This process called chromothripsis, provides insights 
into the complex chromosomal abnormalities observed in MDS patients with abnormal 
karyotype and may be one of the mechanisms responsible for generating genetic 
diversity during MDS initiation and progression to AML. Chromothripsis (‘‘chromo’’ 
from chromosome; ‘‘thripsis’’ for shattering into pieces) is a term given to a process 
that involves massive de novo structural rearrangement in a one-step catastrophic 
genomic event.  This process leads to the formation of tens to hundreds of locally 
clustered rearranged DNA fragments interspersed with widespread losses of 
sequences (often tens to hundreds) of the genome. In some instances, sequence 
rearrangements can lead to the formation of small circular DNA molecules (double-
minute chromosomes), which may subsequently amplify if they harbour oncogenes. 
As a result of this, affected chromosomes show a characteristic pattern of copy-
number “oscillations”, in which only two or three copy-number states are observed 
along the chromosome in the context of a large number genomic rearrangements 
(Korbel and Campbell, 2013; Rausch et al., 2012; Stephens et al., 2011).  
1.3 SNP Karyotyping  
Recent application of sensitive technologies such as high-density single nucleotide 
polymorphism (SNP) arrays has led to the enhanced detection of smaller 
chromosomal aberrations, including micro deletions and discover uniparental disomy 
(UPD) with a neutral/overall loss of heterozygosity (LOH) occurring in up to 75% of 
MDS patients (Bejar et al., 2011). The first study where SNP arrays were used to 
screen MDS patients with normal karyotype detected frequent chromosomal 
aberrations with a high prevalence of UPD (Mohamedali et al., 2007) and this 
observation has been confirmed by other studies (Gondek et al., 2008; Heinrichs et 
al., 2009; Makishima et al., 2010b).  A recent study used a combination approach to 
screen 430 patients with myeloid malignancies using SNP arrays as well as 
metaphase cytogenetics (MC). Notably, SNP karyotyping identified cryptic aberrations 
in low risk patients that were an independent predictor of outcome (overall survival, 
event-free survival and progression-free survival) in a dose-dependent manner (Tiu et 
25 
 
al., 2009). Jerez et al used SNP arrays to screen 1155 del(5q) patients and showed 
that the affected region on 5q determines clinical characteristics, with larger deletions 
involving the centromeric and telomeric segments of 5q associated with aggressive 
disease phenotype and additional chromosomal aberrations such as 17p (Jerez et al., 
2012). In addition, large scale application of this technology in haematological 
malignancies has also led to the discovery of mutations in TET2 (Langemeijer et al., 
2009) (UPD 4q24), CBL (Dunbar et al., 2008) (UPD 11q) and EZH2 (Nikoloski et al., 
2010) (UPD 7q) genes. Although balanced translocations which are commonly found 
in haematopoietic malignancies cannot be detected by SNP karyotyping but this 
technology complements and even outperforms conventional metaphase cytogenetic 
analysis, potentially allowing for the detection of more accurate genetic abnormalities 
in MDS.  
1.4 Gene Mutations in MDS 
The clinical heterogeneity observed in MDS has long been considered to be due to 
the accumulation of genetic lesions that culminate in the final disease phenotype. The 
genetic lesions include mutations that alter the protein structure (nonsense mutations, 
stop codons, splice-site mutations and/or insertions/deletions), or mutations in the 
enhancer and/or promoter regions of the genes that modify gene expression. Over the 
last decade, a number of genes are found to be mutated in MDS patients and these 
include known oncogenes and tumour suppressor genes. Recent technological 
advances in genomic assessments utilizing highly sensitive and scalable array- and 
next-generation sequencing-based methodologies have led to the identification of a 
wide variety of genes that are frequently mutated in MDS including genes involved in 
epigenetic regulation and cell signalling pathway/transcription regulation. Up to 60% of 
MDS patients have defects in one or more of these pathways, suggesting an 
underlying genomic instability or aberrant transcription regulation during the evolution 
of the disease. However, establishing the pathogenetic relevance of these individual 
genetic alterations has been a major challenge, primarily because of the multifaceted 
nature of the MDS phenotype and the broad spectrum of known molecular changes, 
affecting multiple and diverse pathways. Current IPSS used for MDS patient 
stratification doesn’t not incorporate single or multiple gene mutations in the diagnostic 
classification or prognostic stratification systems, even though these mutations are 
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likely to be key drivers of clinical phenotypes and affect the overall survival and 
transformation to AML. However, as more mutations are identified and their 
consequences established, a profile of consequential genetic lesions has emerged 
that should allow genetic alterations to be incorporated into prognosis and risk 
stratification systems.  
1.4.1 Epigenetic modifier gene mutations  
The term ‘‘epigenetics’’ coined by Conrad Waddington is broadly used to describe 
chromatin-based events that regulate DNA-template processes such as DNA 
methylation, histone modification and nucleosome remodelling. Chromatin is the 
macromolecular complex acting as a scaffold for the packaging of human genome. 
The basic functional unit of chromatin is the nucleosome which contains 147 base 
pairs of DNA, which is wrapped around a core of histone octamer (2 each of Histones, 
H2A, H2B, H3, and H4). All these four histones have an amino-terminal tail that is 
lysine rich tail that protrude out of the nucleosome and is subject to posttranslational 
modifications (Luger et al., 1997). In addition, each nucleosome is separated by 
approximately 50 base pairs of DNA, which is packaged by the linker histone protein 
H1. Histones H2A and H2B are reported to play primarily a structural role, however, 
H3 and H4 are key integrators of a variety of signals that are involved in regulation of 
gene transcription. Histone modifications, especially the posttranslational 
modifications (such as acetylation, methylation, phosphorylation, ubiquitylation and 
sumoylation) occur within the “tails” or strings of amino acids that hang out of Histone 
proteins (H3 and H4). Studies have reported at least 16 classes of histone 
modifications (Table 5) (Dawson and Kouzarides, 2012). These post-translational 
modifications are important epigenetic mechanisms in controlling and maintaining 
chromatin structure and form a major category of epigenetic transcriptional control. 
These modifications can change chromatin structure by manipulating non-covalent 
interactions within and between nucleosomes which can either promote transcription, 
or result in gene silencing. They also serve as docking sites for specialized histone 
modifying proteins with unique domains that specifically recognize these 
modifications. These histone modifying protein are targeted to specific gene promoters 
by transcriptional activator/co-activator complexes in response to physiologic stimuli. 
Thus, histone modifications act as an “integral code” that combines signals for gene 
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activation/inactivation or silencing, therefore, enabling to predict the transcriptional 
activity of a given promoter by looking at the specific histone modifications.  
The best studied histone modifications are methylation and acetylation of specific 
histone residues. For example, methylation of specific residues on H3 and H4 are 
associated with either activation of transcription (H3K4) or silencing (H3K9, H3K27). 
While as Acetylation of specific residues within these histone proteins is typically 
associated with active gene transcription. The different modifications can also interact, 
e.g. H3K4 methylation promotes H3K9 acetylation. However, it has been reported that 
several possible methylation states within the same residue can exist which can add 
further complexity to the system (Bannister and Kouzarides, 2011; Esteller, 2008; 
Galm et al., 2006). Mono and dimethylation within the H3K9 are associated with 
euchromatin silencing, and trimethylation of the same residue has been related with 
pericentric heterochromatin silencing. This H3K9 trimethylation leads to silencing via 
the recruitment of a number of proteins including HP1 proteins (Smallwood et al., 
2007; Smith and Shilatifard, 2007; Tachibana et al., 2005). On the other hand, H3K27 
trimethylation has been reported to occur early in X-chromosome inactivation, and 



















Table 5: Known Chromatin Modifications and their Functions.  
me1, monomethylation; me2, dimethylation; me3, trimethylation; me2s, symmetrical 
dimethylation; me2a, asymmetrical dimethylation; and Cit, citrulline. MBD, methyl-CpG-
binding domain; PHD, plant homeodomain; MBT, malignant brain tumour domain; PWWP, 
proline-tryptophan-tryptophan-proline domain; BRCT, BRCA1 C terminus domain; UIM, 
ubiquitin interaction motif; IUIM, inverted ubiquitin interaction motif; SIM, sumo interaction 
motif; and PBZ, poly ADP-ribose binding zinc finger (Adapted from review on Cancer 
Epigenetics: From Mechanism to therapy (Dawson and Kouzarides, 2012) 
 






5-methylcytosine  5mC  MBD domain Transcription 
5-hydroxymethylcytosine  5hmC  Unknown Transcription 
5-formylcytosine  5fC  Unknown Unknown 
5-carboxylcytosine 5caC  Unknown Unknown 
Histone Modifications 









domain, MBT domain, 




Transcription and Repair 
Methylation (arginine) R-me1,  
R-me2s,  
R-me2a 
Tudor domain Transcription 
Phosphorylation 
(serine and threonine) 
S-ph,  
T-ph 
14-3-3, BRCT Transcription, Repair, 
and Condensation 
Phosphorylation (tyrosine) Y-ph SH2 Transcription and Repair 
Ubiquitylation K-ub UIM, IUIM Transcription and Repair 
Sumoylation K-su SIM Transcription and Repair 
ADP ribosylation E-ar Macro domain, PBZ 
domain 
Transcription and Repair 
Deimination R/Cit Unknown Transcription and 
Decondensation 
Proline isomerisation P-cis5 
P-trans 
Unknown Transcription 
Crotonylation K-cr Unknown Transcription 
Propionylation K-pr Unknown Unknown 
Butyrylation K-bu Unknown Unknown 
Formylation K-fo Unknown Unknown 
Hyroxylation Y-oh Unknown Unknown 
O-GlcNAcylation 








In human genome, DNA methylation is another crucial epigenetic modification 
involved in regulating many cellular processes including embryonic development, 
transcription, chromatin structure, X-chromosome inactivation, genomic imprinting and 
chromosome stability. Studies have reported at least four different DNA modifications 
(Table 5).  DNA methylation occurs only at cytosine bases that precede a guanosine 
in the DNA sequence (known as CpG dinucleotides) and is achieved by the covalent 
addition of a methyl group to the 5 position of a cytosine ring mediated by DNA 
methyltransferase (DNMTs) (Robertson, 2005). These CpG sites are asymmetrically 
distributed in the human genome, however there are small (0.5 kb to several kb) CpG-
rich DNA regions known as CpG islands which are often located in the 5′ promoter 
end of all housekeeping genes and many tissue specific genes and with the 3′ end of 
some tissue-specific genes (Galm et al., 2006). Studies have shown that DNA 
methylation represses transcription directly by inhibiting the binding of specific 
transcription factors (TFs), and also indirectly, by recruiting methyl-CpG-binding 
proteins and their associated repressive chromatin remodelling activities (Robertson, 
2005).  
Alterations in DNA methylation have been implicated in the pathogenesis of MDS. This 
has been supported by observations in various studies showing that the global 
methylation pattern of cytosine residues in CpG dinucleotide sequences of promoter 
regions differ between MDS bone marrow cells and normal controls (Figueroa et al., 
2009; Jiang et al., 2009; Shen et al., 2010). In addition, aberrant epigenetic 
modification of histone proteins have also been reported. There is now a growing 
genetic evidence that DNA methylation is important in MDS, because several genes 
that regulate cytosine methylation as well as histones are somatically mutated in MDS 
patients. These include DNA methyltransferase 3A (DNMT3A), Ten-eleven 
translocation 2 (TET2), isocitrate dehydrogenase 1 (IDH1) and IDH2, involved in Kerbs 
cycle and regulate the 5′ methylation of cytosines present in CpG dinucleotides in the 
genome. Two polycomb family member genes, additional sex-combs-like 1 (ASXL1) 
and enhancer of zeste homologue 2 (EZH2) that are involved in histone modifications 
are also mutated in MDS patients. 
The 5-carbon of cytosine nucleotides are methylated (5mC) by a family of three active 
DNA methyltransferases (DNMTs). Among them DNMT1 is a maintenance 
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methyltransferase that recognizes hemimethylated DNA generated during DNA 
replication. DNMT3A and DNMT3B, although also capable of methylating 
hemimethylated, are involved primarily in de novo methylation across the genome. 
DNMT3A is located on chromosome 2p23 and mutations of this gene were initially 
identified in normal karyotype AML. Subsequently, DNMT3A mutations were also 
found in a subset of MDS patients (<10%) with majority of mutations being 
heterozygous resulting in the amino acid substitution R882H.  In addition, nonsense, 
compound heterozygous and frame shift mutations spanning across the whole protein 
are also found in MDS patients, suggesting that a loss-of-function mutations do exist. 
These mutations are found in all MDS subtypes and are associated with poor 
prognosis as well as rapid progression to AML. Homozygous R882H mutation reduces 
the methyltransferase activity of DNMT3A in-vitro, however, it has not been studied in 
combination with the wild-type allele. Dnmt3a-/- mouse models demonstrate an 
accumulation of phenotypically normal haematopoietic stem cells but with a decrease 
in their differentiation capacity, however, no difference was found in 5mC levels 
compared to wild type mice (Challen et al., 2012). Notably, distinct hypomethylation 
patterns were observed at pluripotency gene loci at RUNX1 and GATA3 with an 
increase in their gene expression. Interestingly, MDS patients with DNMT3A mutations 
have normal global 5mC levels, however, hypomethylation is seen in several individual 
gene loci which do not correlate with reduced gene expression profiles.   
The TET protein family, initially found after the ten-eleven translocation 
(t(10;11)(q22;q23)) in human leukaemia’s, turned out to be a key regulator for DNA 
demethylation (Figure 2). This group of proteins are 2-oxoglutarate and Fe(II)-
dependent dioxygenases that have the capacity to converts 5-methyl cytosine (5mC) 
into 5-hydroxymethylcytosine (5hmC), which is then converted to unmodified cytosine 
through multiple mechanisms. TET proteins share the similar structural features with 
a carboxyl (C)-terminal that contains the catalytic double-stranded β-helix 
dioxygenase domain, which demonstrates oxidation activity against 5-methylcytosine 
(5-mC). This β-helix dioxygenase domain contains binding sites for α-ketoglutarate (α-
KG) and Fe++ which are critical for their catalytic function. TET proteins also have a 
cysteine-rich domain (unknown function) that resides next to the double-stranded β-
helix dioxygenase domain. The amino (N)-terminal region of TET1 and TET3 retains 
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an evolutionarily conserved CXXC-type domain that is critical for binding to 
unmethylated cytosine residues in DNA; however, this domain is absent in tet2 
proteins. 
TET2, localized on chromosome 4q24, is one of the most commonly mutated genes 
in MDS. Mutations of TET2 are present in up to 20%-26% of the MDS patients, 44% 
of patients with MDS/MPN, and 11%-24% with sAML (Abdel-Wahab et al., 2009; 
Gondek et al., 2008; Mohamedali et al., 2007; Smith et al., 2010). TET2 mutations 
(missense, nonsense and frameshift) result in loss of function are observed throughout 
the gene, with some clustering in the two conserved catalytic domains. Moreover, 
these mutations are associated with advanced age and normal karyotype (Smith et 
al., 2010). Unlike AML where TET2 mutations are associated with poor prognosis 
(Abdel-Wahab et al., 2009; Metzeler et al., 2011), mutations in MDS do not appear to 













     
Figure 2: Schematics of TET-mediated cytosine demethylation. 
Tet proteins sequentially oxidizes 5mC to 5hmC, 5fC and 5caC. 5caC and 5fC can be removed 
by thymine DNA glycosylase (TDG) and replaced by cytosine via BER. The other mechanisms 
of demethylation (shown by dotted line) shown in the figure are less well established, such as 
decarboxylation of 5caC, DNMT-mediated removal of the hydroxymethyl group of 5hmC and 
deamination of 5hmC (and 5mC) by the cytidine deaminases AID and APOBEC. Deamination 
of cytosine bases in DNA by AID enzymes produces uracil. It has been proposed that AID and 
APOBEC enzymes effect DNA demethylation by deaminating 5mC and 5hmC in DNA to 
produce thymine and 5hmU, respectively. As these are present as mismatched T:G and 
5hmU:G nucleotides, they have been proposed to be excised by or TDG or SMUG1. 5hmC, 
5-hydroxymethylcytosine; 5mC, 5-methylcytosine; 5fC, 5-formylcytosine; 5caC, 
5-carboxylcytosine; BER, base excision repair; AID, activation-induced cytidine deaminase; 
5-caC, 5-carboxylcytosine; DNMT, DNA methyltransferase; 5-fC, 5-formylcytosine; 5-hmC, 5-
hydroxymethylcytosine; TDG, thymine DNA glycosylase; 5-hmU, 5-hydroxymethyluracil; 5-
mC, 5-methylcytosine. SMUG1 - single-strand-selective monofunctional uracil DNA 
glycosylase; APOBEC, apolipoprotein B mRNA editing enzyme, catalytic polypeptide. 
 
Previous studies have shown reduced levels of 5hmC in the bone marrow cells of 
patients with TET2 mutations which is consistent with decreased catalytic activity of 
mutant TET2 protein. This observation is also supported by mouse models, whereby, 
deletion of TET2 leads to loss of 5hmC with a concomitant expansion of pluripotent 
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haematopoietic stem cells and a competitive growth advantage as well as a 
differentiation bias towards the myeloid lineage (Li et al., 2011; Moran-Crusio et al., 
2011; Quivoron et al., 2011). Moran-Crusio et al have shown that reduced activity of 
TET2 in haematopoietic stem and progenitor cells leads to clonal dominance, and 
enhances transformation to AML (Moran-Crusio et al., 2011). It is noteworthy that 
some of the MDS patients with wildtype TET2 show decreased expression of tet2 in 
progenitors, erythroid precursors and granulocytes, implying alternative mechanism of 
protein deregulation (Langemeijer et al., 2009).  However, xenotransplantation of 
CD34+ cells from patients with TET2 mutation showed expansion in NSG mice and 
TET2 knockdown in cord blood haematopoietic progenitor cells led to aberrant myeloid 
differentiation (Delhommeau et al., 2009). It is important to note that these mutant cells 
did not show AML transformation in these assays, therefore implying TET2-mutated 
CD34+ cells are not fully malignant, but rather behave as premalignant cells. In support 
of this observation, somatic mutations of TET2 have recently been observed in 
healthy, aging individuals without an overt haematological disorder despite the 
presence of clonal haemopoiesis (Busque et al., 2012; Jacobs et al., 2012; Laurie et 
al., 2012).  
Other recurrent genetic mutation in haematological malignancies include two key 
enzymes of tricarboxylic (TCA) cycle, IDH1 and IDH2. Initially, these genes were found 
to be mutated in a high proportion of glioma and secondary glioblastoma (Yan et al., 
2009). Subsequent studies using whole-genome sequencing (WGS) identified 
mutations of these genes in 16 of 188 patients with AML (Mardis et al., 2009) and 4% 
to 12% with MDS patients (Bejar et al., 2011; Kosmider et al., 2010; Thol et al., 2010). 
The mutations are heterozygous missense mutations of conserved codons (IDH1, 
R132; IDH2, R140/R172). No frame-shift or stop codon mutations were identified 
(Kosmider et al., 2010).  
IDH1 and IDH2 are homodimeric, nicotinamide adenine dinucleotide phosphate 
(NADP+) dependent enzymes that catalyse the conversion of isocitrate to 
α-ketoglutarate and reside in the cytoplasm and mitochondria, respectively (Mardis et 
al., 2009). Typical disease-associated mutations in these genes causes disruption of 
the isocitrate binding active site, resulting in the inability to make α-KG, instead 
reducing α-ketoglutarate to its homolog 2-hydroxyglutarate (2HG), which is a 
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metabolite normally found at very low concentrations in the normal cell (non-malignant 
cells) (Dang et al., 2009; Figueroa et al., 2010; Gross et al., 2010; Ward et al., 2010). 
The reduction in α-ketoglutarate results in DNA hypermethylation through the inhibition 
of multiple enzymes, including the tet proteins or jumonji D3, which require 
α-ketoglutarate and iron as a cofactor (Chowdhury et al., 2011; Xu et al., 2011). This 
report provides the biochemical basis for the mutual exclusivity of IDH1/2 and TET2 
gene mutations observed in haematological malignancies (Metzeler et al., 2011; 
Paschka et al., 2010; Raza and Galili, 2012; Xu et al., 2011). Notably, mutant IDH1/2 
does not act in a dominant negative manner to its wild-type counterparts (Jin et al., 
2011). Therefore, it has been proposed that disruption of TET2 function by 2HG might 
be one of the mechanism for oncogenesis facilitated by mutant IDH1/2. Aberrant DNA 
hypomethylation has also been reported in patients with mutations of IDH1/2 genes 
(Figueroa et al., 2010). Together, these findings suggest that instead of altering the 
expression of a single or a few specific genes, IDH1 and IDH2 mutations may change 
the expression of potentially large number of genes.  
Polycomb proteins form chromatin-modifying complexes that are involved in 
transcriptional silencing. Two main components of Polycomb-repressive complexes 
(PRCs) are PRC1 and PRC2.  The mechanisms by which PRCs repress target genes 
is poorly understood; however, it involves covalent modifications of histone tails 
catalysed by PRC1 (H2AK119 ubiquitination) and PRC2 (H3K27-me2,-me3), as well 
as direct chromatin modifications (Margueron and Reinberg, 2011; Simon and 
Kingston, 2009).  
Mutations in two polycomb family member genes, ASXL1 and EZH2, are relatively 
common in MDS. ASXL1 located on chromosome 20, is mutated in 10-20% of MDS 
and 5-25% of AML patients (Boultwood et al., 2010; Gelsi-Boyer et al., 2009). ASXL1 
gene belongs to a highly conserved three-member family of enhancers of trithorax and 
polycomb proteins (ASXL-1, -2, -3) which are involved in the maintenance of activation 
as well as the silencing of development-related genes through chromatin remodelling. 
ASXL1 contains the plant homeo domain (PHD) finger and nuclear receptor box 
domains, and functions as a ligand-dependent coactivator of the retinoic acid receptor 
(Fisher et al., 2006). Previous studies have shown that ASXL1 mediates its effects 
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through direct interaction with the histone demethylase encoded by LSD1 or histone 
acyltransferase encoded by SRC1 to control the chromatin state (Lee et al., 2010a).  
Mutations of ASXL1 are mostly localized to exon-12 which is a glycine-rich region and, 
cause premature truncation of the protein with loss of C-terminal part of the protein 
(Bejar et al., 2011).  ASXL1 gene locus does not have a high frequency of 
chromosomal aberrations unlike other genes (such as in case of del 5q and 7q-) which 
are commonly mutated in MDS, and appears to be excluded from the common deleted 
region of chromosome 20q (Boultwood et al., 2010; Gelsi-Boyer et al., 2009).  
The mechanism through which ASXL1 mutations contribute to the pathogenesis of 
MDS is still unknown. Targeted disruption of Asxl1 in mouse models have shown only 
mild haematopoietic abnormalities with reduced numbers of lymphocytes and modest 
splenomegaly; however, no evidence of myeloid dysplasia was observed (Fisher et 
al., 2010). Previous studies have shown that truncated ASXL1 protein is unable to bind 
methylated histone lysines and is also not able to interact with other chromatin 
modifiers. This results in the loss of polycomb repressive complex (PRC) mediated 
H3K27 trimethylation and activation of a HOXA gene expression signature (Abdel-
Wahab et al., 2012). This truncated protein with intact N-terminal motifs might be 
potentially generating a dominant negative protein that could inhibit its wild-type 
isoform as well as other members of the polycomb complex (Bejar et al., 2011).  In-
vitro studies in non-hematopoietic cells have suggested physical cooperativity of 
ASXL1 with HP1a and LSD1 to repress retinoic acid-receptor activity, and its 
interaction with peroxisome proliferator-activated receptor gamma (PPARg) to 
suppress lipogenesis (Cho et al., 2006; Lee et al., 2010a; Park et al., 2011). 
Interestingly, a recent study using gene expression profiling of ASXL1 mutant patients 
have revealed significant deregulation of retinoic acid receptor activation pathways 
(Boultwood et al., 2010). 
Another polycomb gene mutated in haematological malignancies is EZH2, a histone 
H1 and H3 methyltransferase gene that is a catalytic subunit of PRC2. Mutations of 
EZH2 are present in approximately 6-8% of the MDS patients. EZH2 alongside with 
other proteins (EED, SUZ12 and RBBP4) acts via a number of mechanisms to initiate 
polycomb-mediated gene repression. One of the mechanisms include direct inhibition 
of transcriptional machinery via RNA polymerase II and chromatin compaction, 
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therefore inhibiting the access and action of transcription factors.  EZH2 has also been 
reported to play a role in DNA methylation, by acting as a recruitment platform for DNA 
methyltransferases (Francis et al., 2004; Vire et al., 2006).  Following trimethylation by 
the suppressor of variegation 3–9, the histone mark H3K27me3 functions as a docking 
spot to recruit polycomb complex PRC1, which maintains gene repression via 
ubiquitination of H2AK119 (Cao et al., 2002; Wang et al., 2004). In recent studies, 
EZH2 has also been reported to regulate cell fate decisions by orchestrating 
expression of genes to control the balance between self-renewal and differentiation 
(Bracken et al., 2006). EZH2 stabilizes the chromatin structure and maintains long-
term self-renewal capacity of HSCs by turning off pro-differentiation genes and 
stimulating proliferation by increasing expression of cell cycle genes (Bracken et al., 
2003; Ezhkova et al., 2009; Kamminga et al., 2006).  
The occurrence of mutations within chromatin regulators such as EZH2 has been 
linked to aberrant gene expression and genomic instability. EZH2 missense mutations 
commonly occur within the C-terminus catalytic SET (suppressor of variegation, 
enhancer of zeste, trithorax) domain and cysteine-rich domain while truncation 
mutations have been reported throughout the gene (Nikoloski et al., 2010). This gene 
is located on chromosome 7 and mutations are associated with uniparental disomy 
(UPD) on 7q. In-vitro studies have suggested that the EZH2 mutations found in MDS 
patients are predominantly loss of function (resulting in reduced H3K27 trimethylation) 
and may be associated with relatively poor survival (Ernst et al., 2010; Makishima et 
al., 2010a).  A conditional Ezh2 ‘gain-of-function’ mouse model demonstrated that 
induction of wildtype Ezh2 expression increases the repopulation capacity of HSCs 
(Herrera-Merchan et al., 2012).  In another study, Mll-AF9 transformed AML cells from 
Ezh2-deficient mice showed compromised cell cycle progression, although cells still 
maintained some proliferative capacity. In this model, Ezh2 loss inhibited leukemic 
progression by reactivating Ezh2-repressed genes involved in myeloid differentiation 
(such as Egr1) (Tanaka et al., 2012). Another study has shown that loss of PRC2 
function increases hematopoietic stem cell activity and expansion (Majewski et al., 
2010), which may explain the role of EZH2 mutations in MDS.  
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1.4.2 Transcription regulation/Cell signalling pathway gene mutations 
The TP53 gene, located on chromosome 17p, is a prototypical tumour suppressor 
gene that is frequently mutated in nearly all tumour types and is often associated with 
genomic instability. In MDS, TP53 mutations occur predominantly in high risk disease 
subgroups, associated with complex karyotype, adverse prognosis, therapy-related 
disease and resistance to therapy.  However, TP53 mutations have also been reported 
in low risk MDS such 5q- syndrome (Jadersten et al., 2011). Alterations in the TP53 
gene occur in up to 15% of de novo MDS patients, however, the frequency is much 
higher in patients with prior exposure to alkylating agents and/or radiation 
(Christiansen et al., 2001; Pedersen-Bjergaard et al., 2006). In addition, a third to half 
of the MDS patients with complex karyotype have TP53 mutations. Notably, TP53 
mutations are associated with poor prognosis in MDS, even after adjustment of other 
prognostic variables in IPSS, including complex karyotypes (Horiike et al., 2003; Kita-
Sasai et al., 2001). Apart from its tumour suppressor activity, TP53 gene is also a 
transcription factor that reacts to cellular stress by activating various defensive 
pathways that cause cell-cycle arrest, induce apoptosis or trigger DNA repair. Loss of 
TP53 results in resistance to apoptosis and other cellular death signals. Barlow et al 
in a mouse model demonstrated that normally functional TP53 is essential to initiate 
apoptosis promoted by haploinsifficiency of RPS14 in del(5q) (Barlow et al., 2010). In 
this mice study, segmental haploidy CDR locus (5q- syndrome) residing in the interval 
between Cd74 and Nid67 resulted in features of 5q- syndrome (macrocytic anaemia, 
with prominent dysplasia within the erythroid lineage and monolobulated 
megakaryocytes).  Among the 8 genes which reside within the Cd74-Nid67 deleted 
segment, the Rps14 gene was the strongest candidate associated with this phenotype 
(Barlow et al., 2010), due to its association with 5q- syndrome (Ebert et al., 2008). A 
high population of bone marrow cells in Cd74–Nid67 deleted mice expressed higher 
amounts of Tp53 protein as compared to controls. Notably, the deletion of TP53 in 
Cd74–Nid67 deleted mice completely reversed the observed 5q- syndrome phenotype 
(Barlow et al., 2010). Therefore, TP53 is stabilized as a result of haploinsufficiency of 
RPS14 in del(5q) which causes disruption of ribosome assembly and accelerates 
degradation of MDM2.  
Another frequently mutated gene in MDS is RUNX1, which is a member of the 
transcriptional core-binding factor gene family that was originally identified as a 
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translocation partner t(8;21) in AML(M2). Mutations in RUNX1 gene are found in 
approximately 7%-15% of patients with de novo MDS and the frequency is much 
higher (up to 40%) in therapy-related MDS. The mutations are usually heterozygous 
missense and monoallelic (nonsense or frameshift), occur within the N-terminal while 
as few mutations have been reported in the C-terminal (trans-activation domain) of 
RUNX1 (Christiansen et al., 2004; Harada and Harada, 2009). Studies thus far have 
not investigated exons 7/8 in detail which encode for most of the C-terminal region. 
Thus, C-terminal mutations within RUNX1 may be underestimated. 
The RUNX1 contains a highly evolutionary conserved proximal Runt homology domain 
(RHD) which is essential for DNA binding, and a distal transactivation domain 
responsible for protein-protein interactions and recruitment of cofactors. Missense 
mutations of RUNX1 are observed within RHD, whereas stop codon and frame shift 
mutations are present throughout the gene and almost always disrupt the 
transactivation domain (Harada et al., 2004). This distinction may be physiologically 
relevant since mutations in the RHD impairs DNA binding and therefore function in a 
dominant negative manner. These mutations are able to diminish Runx1 activity much 
more than loss-of-function (Harada and Harada, 2009; Matheny et al., 2007). Runx1 
knockout mice are embryonically lethal with no evidence of definitive haemopoiesis 
(Dowdy et al., 2010; Okuda et al., 1996). However, heterozygous conditional deletion 
of this gene in the haematopoietic stem cells in mice lead to an increase in myeloid 
progenitors, lymphoid defects and ineffective megakaryopoiesis, but do not progress 
to AML (Growney et al., 2005). In contrast, mice overexpressing RHD mutant form 
shows increased bone marrow blasts and splenomegaly, and often die as a result of 
AML- like disease (Watanabe-Okochi et al., 2008).  
Genes involved the RAS signalling pathway (NRAS/KRAS) are mutated in up to 15% 
of MDS patients, with NRAS being the common aberration (Haferlach et al., 2011). 
RAS genes are involved in the regulations of growth and differentiation of several cell 
types. RAS mutations cause constitutive activation of the RAS signalling pathway by 
increasing the intracellular levels of RAS GTP. This increase in RAS GTP leads to 
activation of the RAS/PI3K and the RAS/Raf/MEK signalling pathways through 
interaction with many effector molecules such as phosphoinositide-3-OH kinase, Raf 
proteins and Ral guanine nucleotide dissociation stimulator proteins (such as  
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RalGDs). Oncogenic NRAS or KRAS in mice is sufficient to induce AML or a 
myeloproliferative disorder that resembles chronic myelomonocytic leukaemia 
(CMML) (Parikh et al., 2006). This phenomenon has been shown to occur in 
hematopoietic stem cells and not in the common myeloid progenitor compartment 
(Wang et al., 2013).  
C-CBL, located on chromosome 11 is a proto-oncogene that encodes a tyrosine 
kinase (TK)-associated ubiquitin ligase and negatively regulates signalling through 
these receptors by targeting them for degradation. It is mutated in approximately 5% 
of the MDS patients and most of these aberrations are missense mutations. Frame 
shift and early truncation mutations are rarely observed (Sanada et al., 2009). These 
CBL mutations occur in exons 8/9 and usually leave the rest of the gene intact, 
suggesting a gain-of-function/altered function effect of these mutations. C-CBL 
mutations have been shown to cause increased receptor TK levels and STAT5 
phosphorylation, which is believed to mediate the hypersensitivity of the mutated cells 
to cytokines and growth factors (Sargin et al., 2007; Saur et al., 2010). C-Cbl(-/-) 
haematopoietic stem/progenitor cells (HSPCs) show an increased sensitivity to a 
variety of cytokines, and transduction of C-CBL mutants into C-Cbl(-/-) HSPCs further 
augments their sensitivities to a broader spectrum of cytokines, including stem-cell 
factor, thrombopoietin, IL3 and FLT3 ligand (Sanada et al., 2009). Moreover, mouse 
cells deficient in CCBL show modest cytokine hypersensitivity (Rathinam et al., 2008). 
Activating mutations of JAK2 were first described in myeloproliferative disorders 
(MPDs) and form part of the diagnostic criteria for polycythemia vera and are found in 
up to 90% patients with polycytemia rubra vera. JAK2 V617F mutation is present in 
5% of the MDS patients, however, the frequency is much higher (upto 50%) in a 
particular subtype of MDS patients i.e. refractory anaemia with ring sideroblasts and 
thrombocythemia (RARS-T) (Boissinot et al., 2006; Malcovati et al., 2009; Szpurka et 
al., 2006). The mechanistic role of this JAK2 mutation in the RARS-T phenotype is 
unclear, and its contribution to prognosis is as yet not clearly defined.  
Although RARS-T and MPD appears to have entirely different pathophysiological 
mechanisms, the existence of conditions with overlapping features is well recognised 
(Steensma and Tefferi, 2008; Wardrop and Steensma, 2009). RARS patients develop 
thrombocythemia only after the acquisition of JAK2 V617F mutation (Malcovati et al., 
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2009). The high rate of JAK2 mutation in RARS-T patients points towards an unknown 
mechanism through which a cooperative advantage exists between those 
abnormalities responsible for the ring sideroblast phenotype and the constitutive 
activation of JAK2.   
1.5 Spliceosome  
 Majority of the eukaryotic genes consists of exons (coding sequence) and introns 
(non-coding sequence), and are initially expressed as precursor messenger RNA (Pre-
mRNA) that is converted to mRNA by a process called RNA splicing. This highly 
dynamic process is a crucial, ubiquitous and a complex step in gene expression in 
which introns are excised from pre-mRNA, and coding sequences (i.e. exons) are 
ligated together (Krummel et al., 2010; Ritchie et al., 2009; Wahl et al., 2009; Will and 
Luhrmann, 2011).  
Pre-mRNA introns in protein-encoding genes are precisely excised by a complex 
called the Spliceosome that requires hydrolysis of a large quantity of ATP. The 
spliceosome is approximately 4.8 MDa protein composed of 5 uridine-rich small 
nuclear RNAs (Sn RNAs) and up to 300 other distinct proteins. This large protein-RNA 
complex is assembled on pre-mRNA by the stepwise association of several small 
nuclear ribonucleoproteins (snRNPs) and non-snRNP factors, recognizing (1) the 
junction between 5/ exon and intron (5' splice-site), (2) a conserved sequence within 
the intron called branch point-site (BPS) located ~15–50 nucleotides upstream of the 
3'ss, and (3) the junction between the intron and 3' exon (3' splice-site) (Krummel et 
al., 2010; Ritchie et al., 2009; Wahl et al., 2009). Dinucleotides that form the 
intron/exon boundaries at 5' and 3' sites act as donor and acceptor splice sites (ss) for 
intron removal. In addition to being controlled by the primary splicing signals located 
at these exon/intron junctions, splice site choice is modulated by various cis-acting 
regulatory RNA elements that serve as either splicing enhancers or silencers. These 
cis-acting regulatory elements embedded in the pre-mRNAs recruit trans-acting 
splicing factors (bind to the cis-acting elements) that ultimately control assembly of 
other proteins involved in the splicing process. These cis-regulatory or splicing 
regulatory elements (SREs) are classified as exonic splicing enhancers (ESEs), 
intronic splicing enhancers (ISEs), exonic splicing silencers (ESSs) or intronic splicing 
silencers (ISSs) depending upon their location and activities. A well-studied example 
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is the oligo-G tracts which are known to enhance splicing from intronic locations by 
recruiting hnRNP H, but the same element when located in exons can inhibit splicing 
(Caputi and Zahler, 2001; Chen et al., 1999; Chou et al., 1999; McCullough and 
Berget, 1997).  
Two types of spliceosomes coexist in most eukaryotic cells: the U2-dependent 
spliceosome (major spliceosome), which catalyses the splicing of U2-type introns with 
the canonical dinucleotide GU–AG, and the rare U12-dependent spliceosome (minor 
spliceosome), which splices the rare U12-type class of introns with canonical 
dinucleotide AT–AC and GT–AC (Will and Luhrmann, 2011). The two spliceosomes 
share most of the snRNP proteins which are involved in splicing reactions; however, 
the minor spliceosome is 100-fold less abundant compared to major spliceosome 
complex. U1, U2, U4, U5 and U6 are core snRNPs in major spliceosome complex, 
which along with other non-snRNP factors form pre-complex E, Complex-A, Complex-
B, Complex-B* and Complex-C (Figure 3), respectively. However, in addition to the 
common U5 snRNP, the minor spliceosome contains other distinct snRNPs (U11, 
U12, U4atac, and U6atac), which are functionally similar to the U1, U2, U4 and U6 




       
Figure 3: Schematic diagram showing the mRNA splicing pathway. 
Major Spliceosome proteins catalyse RNA splicing, which leads to the ligation of flanking exonic regions. The GU dinucleotides at the 5′ splice-
site, branch point site (BPS) and AG dinucleotide at the 3′ splice-site are specific recognition sites for splicing. Various spliceosome components 
including U1, U2, U4/U5/U6 snRNPs and other additional non-snRNPs assemble in a step-wise manner to form 5 different complexes (E, A, B, 
B* and C). The rectangles and broken lines represent exonic and intronic regions, respectively.
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Although generally considered as a post-transcriptional process, mRNA splicing can 
also occur as a co-transcriptional process in the nucleus. Most of the components of 
the major spliceosomes are partly synthesized in the cytoplasm, however, some 
mature forms are mainly localized in the nucleus. In major spliceosome, the process 
of spliceosome assembly starts by U1 snRNP recognizing/binding at the 5'ss through 
base-paring interactions of the 5'end of the U1 snRNP to the 5'ss of the target intron, 
followed by the binding of some non-snRNP proteins to the BPS and 3' splice-site 
(such as U2AF) to form a pre-complex E. The interaction between the U1 snRNP and 
5'ss in pre-complex E is ATP independent and fairly weak; however, it is stabilized by 
the binding of other factors at 5'ss such as SR proteins such as SRSF2 and the cap-
binding complex. This pre-complex E enables the pre-mRNA to commit for splicing. 
Following on, associated factors such as splicing factor 1 (SF1) and U2 auxiliary 
factors (U2AFs), which are also components of complex E bind to the 3ʹss and BPS 
within the pre-mRNA (Matera and Wang, 2014; van der Feltz et al., 2012; Wahl et al., 
2009).  
Subsequently, U2 snRNP binds to the BPS in an ATP-dependent process catalysed 
by the DExD/H helicases pre-mRNA-processing 5 (Prp5) and Sub2, through base 
paring interaction with the target pre-mRNAs BPS, leading to the formation of 
complex-A. This base-paring is stabilized by heteromeric protein complexes SF3a and 
SF3b which are both part of the U2 snRNP. U1 snRNP intracts with the U2 snRNP 
which brings the 5'ss, BPS and 3'ss into close proximity. Recruitment of preassembled 
U4/U6-U5 tri-snRNPs follows along with non-snRNP such as ZRSR2, forming 
complex-B in a reaction catalysed by the DExD/H helicase Prp28. The resulting 
complex B goes through a series of conformational and compositional remodelling to 
form a catalytically active complex B (Complex-B*) and commits it for the first step of 
splicing reaction. Multiple RNA helicases (Brr2, 114 kDa U5 small nuclear 
ribonucleoprotein component and Prp2) are required during this process (Matera and 
Wang, 2014). Following on, some structural/compositional rearrangements occur 
within the complex which causes destabilization of U1 and U4 snRNPs, with U1 being 
displaced by U6 to form complex-C that catalyzes the final splicing reaction (Figure 3). 
This first splicing reaction yields the free exon (exon X) and the intron–exon (exon Y) 
lariat intermediate. Complex C undergoes further ATP-dependent rearrangements 
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before carrying out the second catalytic step of splicing reaction (dependent on Prp8, 
Prp16 and synthetic lethal with U5 snRNA 7) and this results in a post-spliceosomal 
complex that contains spliced exons (exon X and exon Y) and the lariat intron. 
Subsequently, the spliceosome dissociates, releasing the spliced mRNA into the 
cytoplasm for protein translation and this process is catalysed by the DExD/H helicase 
Prp22.  In addition, U2, U5, and U6 snRNPs are released from the complex which are 
later recycled for further rounds of splicing (Faustino and Cooper, 2003; Krummel et 
al., 2010; van der Feltz et al., 2012; Wahl et al., 2009; Will and Luhrmann, 2011). This 
disassembly of the post-catalytic spliceosome mediated by several RNA helicases 
(such as Brr2, Snu114, Prp22 and Prp43) is ATP-dependent (Matera and Wang, 2014; 
Wahl et al., 2009).  
In higher eukaryotes, most genes undergo differential splicing to give rise to large 
number of alternative mRNA isoforms, which generates functionally diverse protein 
isoforms with altered regulatory regions. These alternative splicing events are highly 
regulated, cell type-specific and controlled by numerous cis-acting regulatory RNA 
elements. Alternative splicing adjusts gene product in accordance with the 
physiological requirements of a cell, and more than 90% of genes with introns undergo 
alternative splicing, probably influencing all aspects of cell biology (Kalsotra and 
Cooper, 2011).   Human introns range from few hundreds to thousands of kilobases 
in length (~5 kb on average). These large intronic regions contain “decoy” splice-sites 
(i.e. sequences that have a similar degree of consensus matching to actual splice-
sites). A pair of these artificial “decoy” splice sites often leads to the formation of 
pseudo-exons that resembles authentic exons in terms of splice-site junction 
sequence but are very rarely, if ever, spliced. Thus, despite the prevalent decoy splice-
sites, the splicing process occurs with high fidelity, implying that additional sequence 
factors aside from core splicing signals contribute to definition of exon/intron junctions 
(Sun and Chasin, 2000). Many splicing factors function as auxiliary proteins in the 
spliceosome pathway and interact with its core components (such as U1, U2, U3, 
U4/U5/U6) to regulate splicing. A well-studied example is the splicing factor RNA-
binding motif 5 (RBM5) which interacts with a U2 snRNP component (U2AF65) and 
inhibits the transition from an exon definition to an intron definition complex (Bonnal et 
al., 2008). Therefore, alternative splicing can contribute to the genomic complexity of 
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the cell as well as the selective pressure that may occur in cancer genome (Hahn and 
Scott, 2012; Padgett, 2012; Ward and Cooper, 2010). 
Splicing of most of the introns happens co-transcriptionally, therefore, alternative 
splicing can effect factors that are involved in controlling transcription initiation and 
elongation processes and vice-versa. For example, studies have shown that splicing 
events can be affected by the rate at which the transcription elongation occurs with 
slow elongation rates generally promoting the inclusion of weaker exons (de la Mata 
et al., 2003; Robson-Dixon and Garcia-Blanco, 2004). In addition, splicing can also 
have effect on the upstream events, such as chromatin modification, and mRNA export 
as well as translation (Kim et al., 2011). This crosstalk which exists between the 
splicing machinery and the continuum of gene expression raises the possibility that 
disruption of splicing process can have determinative effects on other regulatory 
processes within the cell, and thereby affects the phenotype of the human disease 
through indirect mechanism(s). 
The mutations of the splicing machinery itself can give rise to pathological conditions 
such as spinal muscular atrophy (SMA) and autosomal dominant retinitis 
pigmentosum (adRP) (Padgett, 2012). SMA is caused as a result of mutation in SMN2 
splicing gene (Lefebvre et al., 1995) and sdRP is caused by the mutations of several 
spliceosomal genes (PRPF31, PRPF8, HPRP3, PAP1 and SNRNP200) (Mordes et 
al., 2006). The SMN2 gene product is necessary for maturation of the spliceosomes 
snRNPs and the mutations leading to a reduced level of this protein cause tissue 
specific death of spinal motor neurons (Lefebvre et al., 1995; Neuenkirchen et al., 
2008). Recently mutations in the U4atac gene were identified as a cause of MOPD1 
which is a multisystemic disease with growth retardation, abnormal bone morphology 
and severe brain malformation. U4atac snRNA is the RNA component of the minor 
spliceosome snRNP. Most of the U4atac mutations affect a highly conserved stem–
loop structure required for association of the 15.5 K protein that mediates binding of 
proteins necessary for catalysis of trans-esterification reactions in the splicing pathway 
(Nottrott et al., 2002).  
In addition, mutations within the consensus splice-site junction sequences between 
exons and introns of the target gene have also been reported, and are estimated to 
account for about 10% of human heritable disorders.  
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1.5.1 Splicing factor-3 b1 (SF3B1) 
SF3B1, a major component of the U2 snRNP, is a highly conserved 155-kDa protein 
which along with other splicing factors including SF3b2, SF3b3, SF3b4, SF3b5, 
SF3b14 and PHF5A forms a multiprotein complex called SF3b.  SF3B1 is the largest 
subunit of the Sf3b complex and plays an essential role in the recruitment as well as 
the stable binding of the U2 snRNP to the BPS near the 3' end of the intron, and helps 
to specify the site of splicing. In addition to being a component of the major 
spliceosome, SF3B1 also plays a major role in the minor U12-dependent spliceosome. 
SF3B1 is composed of two regions: the N-terminal domain (NTD, 1- 430AA) and the 
carboxy-terminus (431-1304AA). The N-terminal region of SF3B1 contains several 
TPR repeats and, functions as a scaffold to facilitate interactions with other splicing 
associated factors such as U2AF65, SF3b14, p14, Cyclin-E and Nipp-1 (Cass and 
Berglund, 2006; Yokoi et al., 2011). The p14 protein which is highly conserved in a 
wide variety of organisms forms a stable complex with SF3B1 and this protein complex 
acts as a core responsible for the BPS recognition. Importantly, p14 and SF3B1 
complex interacts directly with the BPS adenosine and the flanking regions on the 
target mRNA, respectively (Gozani et al., 1998; Query et al., 1996; Will et al., 2001). 
In addition to this, U2AF1 has also been suggested to interact with SF3B1; however 
the region and the mechanism of the interaction is not known (Gozani et al., 1998).  
The carboxy terminal (C-terminal) of SF3B1 is highly conserved and contains 22 non-
identical tandem repeats of the HEAT (huntingtin, elongation factor 3, protein 
phosphatase 2A, target of rapamycin 1) motif. A single HEAT motif contains 37-47 
amino acid residues forming two anti-parallel α-helices and two turns.  These HEAT 
repeats contain conserved arginine and aspartic residues, and short flexible linkers 
between repeats (Groves and Barford, 1999; Xing et al., 2006). This part of the protein 
mediates protein–protein interactions with proteins that are involved in mRNA 
translation, cell signalling and nucleo–cytoplasmic transport. Using electron 
microscopy, it has been demonstrated that SF3B1 HEAT repeats wrap around the 
entire U2 snRNP, marking out an S-shaped path around the overall shell-like form that 
stabilizes the U2 snRNP complex (Figure 4) (Golas et al., 2003).  
The three-dimensional structure of U11/U12 di-snRNP which also contains SF3B1 has 
recently been determined by electron microscopy. The electron microscopy of SF3b 
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complex revealed that only one side of this complex is able fit well with the U11/U12 
di-snRNP while as the other half of the complex showed a severe density mismatch in 
the region where SF3b complex interacts with U11/U12 di-snRNP. This is due to 
differences in the diameters of the outer wall of SF3b complex and U11/U12 di-snRNP. 
This observation led to the idea that SF3b complex has to undergo a conformational 
change in its second shell half in order to fit completely into the density of the U11/U12 
di-snRNP. Previous studies have demonstrated that the HEAT domains of nuclear 
transport factor importin-β can adopt different degrees of curvature, depending on the 
size of its binding partner such as importin-alpha, RanBP2. This possibility for 
changing the curvature of Sf3b1 HEAT domains is needed for the structural 
rearrangement of SF3b to fit it completely into the U11/U12 di-snRNP. Therefore, the 
potential opening of the two shell halves of the Sf3b complex may thus be assumed 







Figure 4: Three-dimensional structure of Sf3b complex and its structural rearrangement 
upon integration with U11/U12. 
 (A) Three out of seven proteins were located on the basis of their structural domains and their 
fit into the density map. The pattern of 22 tandem HEAT repeats of Sf3b1 were found wrapped 
around the SF3b complex in an S-shape. (B) In order for Sf3b to fit into the U11/U12 di-snRNP 
density, an opening of Sf3b is required. The Sf3b opening requires the movement of one shell-
like half of the complex to match the outer wall of U11/U12 di-snRNP (Golas et al., 2005; Stark 
and Luhrmann, 2006). 
 
Sf3b1 also contains several cdk consensus phosphorylation sites within its N-
terminus.  In in-vitro studies, it has been shown that Cyclin E-cdk2 uses Sf3b1 as a 
substrate and phosphorylation of Sf3b1 occurs prior or during the catalytic step II of 
the splicing pathway, suggesting a potential role for cdk regulation and a link to the 
cell cycle (Seghezzi et al., 1998). Furthermore, Sf3b1 also appears to be 
dephosphorylated by PP1/PP2A phosphatases concomitant with the second step of 
splicing. This indicates the importance of phosphorylation of Sf3b1 during splicing 








Antibody binding site 
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splicing process and hence provide additional opportunities for regulation (Wahl et al., 
2009). 
1.6 Refractory anaemia with ring sideroblasts and Iron metabolism 
The sideroblastic anaemia’s are a heterogenous group of acquired and inherited 
disorders mainly characterized by the presence of ring sideroblasts in the bone 
marrow. The term “sideroblast” was first introduced by Kaplan to describe an 
erythoblast with a cytoplasm in which siderotic granules could be seen by ordinary 
microscope. However, in 1953 Douglas and Dacie described the presence of large 
siderotic granules in the form of a ring structure surrounding the nucleus of an erythoid 
precursor (Douglas and Dacie, 1953).  
RARS, a subtype of MDS is an acquired form of sideroblastic anaemia, characterized 
by isolated anaemia, erythroid dysplasia and less than 5% bone marrow myeloblasts 
(Cazzola and Invernizzi, 2011). RARS is notable for more than 15% ringed 
sideroblasts which are basophilic and polychromatophilic erythroblasts characterized 
by accumulation of iron in the form of ferritin within the mitochondria that is visualized 
by Prussian staining as a blue perinuclear ring (Boultwood et al., 2008; Camaschella, 
2009; Cazzola and Invernizzi, 2011). 5-year survival rates in RARS exceeds 50% and 
a risk of transformation to AML is low (Cazzola and Invernizzi, 2011; Malcovati et al., 
2009; Novotna et al., 2008). RCMD-RS is phenotypically similar (i.e. ringed 
sideroblasts) to RARS but in addition 10% of non-erythroid lineage cells show 
dysplastic changes.  
The main clinical features of RARS is severe anaemia (present in >90% of the 
patients), necessitating chronic blood transfusions, with a subsequent risk of iron 
overload. Some RARS patients have infections related to granulocytopenia or 
haemorrhage i.e. complications due to thrombocytopenia. Hepatomegaly and/or 
splenomegaly are rare and red cell volume is often increased.  Peripheral blood film 
shows hypochromic or dimorphic red cells. Oval macrocytes, teardrop, fragments may 
also be present. Red cell elliptocytosis and basophilic stippling is also present to a 
variable degree.  
Interestingly, majority of RARS patients have a normal karyotype. However, studies 
involving X-chromosome inactivation in female patients have shown that RARS arises 
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from hematopoietic stem cell with the potential for lymphoid and myeloid differentiation 
(Cazzola et al., 2000; Cazzola and Invernizzi, 2011; Malcovati et al., 2009).  
Iron is an essential component for haem synthesis in maturing erythroblasts. It has the 
capacity to accept and donate electrons, therefore making it an effective component 
of oxygen-binding molecules, cytochromes, and a variety of other enzymes (Sheftel et 
al., 2009). However, this property can also lead to toxicity if its absorption, storage and 
transfer are not tightly regulated within the cell. Iron is transported within the serum 
bound to transferrin (Figure 5). Transferrin (Tf) binds to its receptor the transferrin 
receptor-1 (TfR1) on the cell surface. Receptor-ligand complex internalization via 
clathrin-coated pits ensues. Acidification of the endosome to pH 5.5 through the proton 
pump promotes the release of Fe3+ from Tf that remains bound to TfR1 on the cell 
membrane (Ohgami et al., 2005; Ponka et al., 1998; Richardson et al., 2010). The 
ferrireductase Steap3 reduces Fe3+ to Fe2+ (Ohgami et al., 2005), which is transported 
by divalent metal ion transporter 1 (DMT1) from endosome to the cytosol or, possibly, 
directly to mitochondria in erythroid cells (Richardson et al., 2010). Iron is then 
exported to the mitochondria where it is incorporated into protoporphyrin IX to form 
haem, or incorporated into nascent iron–sulfur clusters (ISCs). The mechanism by 
which iron is exported to the mitochondria remains unclear. However, studies have 
suggested a ‘kiss and run’ hypothesis, according to which transferrin-containing 
endosomes in erythroid cells might be involved in the transfer of iron directly to the 
mitochondria (Richardson et al., 2010). The conserved cytosolic glutaredoxins Grx3 
and Grx4 play an important role in intracellular iron sensing as well as trafficking, as 
their depletion in yeast leads to impaired iron transport to mitochondria and defects in 
iron-dependent pathways. SLC transporter mitoferrin (which is also known as 
SLC25A37) localizes to the inner mitochondrial membrane is also required for the 
entry of iron into mitochondria (Shaw et al., 2006). Alternatively, iron can be exported 
into the cytoplasm where it is incorporated into cytoplasmic ferroproteins or stored in 
cytosolic storage molecules, such as ferritin (Arosio et al., 2009). Free iron which is 
not bound to transferrin molecules usually accumulates within the cell when the iron-
binding capacity of transferrin is exceeded. This free iron circulates as a complex 






Figure 5: Iron traffic in erythroid progenitors that synthesise haem. 
Fe3+ is transported across the cell membrane as diferric transferrin by the transferrin receptor 
(TfR1) and then taken by endosomes. A proton pump acidifies the endosomes, resulting in 
the release of Fe3+. Steap3 reduces it to Fe2+, which is then exported by DMT1 to the 
cytoplasm. Fe2+ exported by DMT1 is delivered to mitochondrial mitoferrin-1 (Mfrn1) either by 
direct contact (the kiss-and-run mechanism, K&R) or through intermediate transport by as-yet 
uncharacterized cytoplasmic chaperones (Fe2þCh). Mitoferrin-1 imports iron into 
mitochondria where iron is incorporated into haem. Then, haem is exported via an unknown 
exporter (Haem export) and incorporated into globin chains to generate haemoglobin. Excess 
iron is stored in ferritin. Under some circumstances, iron is also exported as ferrous iron via 
ferroportin (Fpn) or as haem via feline leukaemia virus C receptor (FLVCR1). The apo-Tf–
TfR1 complex is transported back to the cell surface, where apo-Tf is released to capture 
plasma Fe3+. 
 
The production of haem starts with a series of reactions catalysed by enzymes that 
produce protoporphyrin IX (Figure 6). In the mitochondrial matrix, the first step in 
protoporphyrin IX production involves the condensation of glycine and succinyl 
coenzyme-A resulting in the formation of 5-aminolevulinic acid (ALA). This reaction is 
catalysed by ALA synthase (ALAS) which resides within the mitochondrial matrix. The 
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universal precursor ALA is exported to the cytosol and converted to 
coproporphyrinogen III in a series of four enzyme-catalysed reactions, which is then 
transported back to the mitochondria. Coproporphyrinogen III is converted to 
protoporphyrinogen IX and then to PPIX within the mitochondria. The final reaction in 
the haem synthesis pathway is the addition of one atom of Fe 2+ into protoporphyrin 
IX and this step is catalysed by ferrochelatase (FC) located at the inner mitochondrial 
membrane. Haem is then exported to the cytosol for incorporation into haemoproteins 













Figure 6: Haem biosynthesis pathway. 
Haem synthesis is initiated by the synthesis of ALA by the condensation of the amino acid 
glycine and succinyl CoA (from kerbs cycle) by the pyridoxal phosphate-requiring enzyme 
namely δ-aminolevulinic acid (ALA) synthase. This is a rate-limiting reaction and it is 
negatively regulated by glucose and haem concentrations. Following synthesis, ALA 
dehydratase dimerizes two molecules of ALA in the cytoplasm to produce the pyrrole ring 
compound porphobilinogen. Hydroxymethylbilane synthase catalyses the head-to-tail 
condensation of four molecules of porphobilinogen to produce the linear tetrapyrrole 
intermediate called hydroxymethylbilane. Once produced, hydroxymethylbilane is converted 
to uroporphyrinogen III with the help of enzyme uroporphyrinogen-III synthase.  Subsequently, 
uroporphyrinogen III is decarboxylated by the enzyme uroporphyrinogen decarboxylase and 
producing coproporphyrinogen III, a product with the methyl groups in place of acetate. 
Following its synthesis, coproporphyrinogen III is transported to the mitochondrion, where 2 
propionate residues are decarboxylated with the help of oxygen-dependent enzyme 
coproporphyrinogen oxidase. This reaction produces protoporphyrinogen IX. In the 
mitochondrion, protoporphyrinogen IX is converted to protoporphyrin IX by 
protoporphyrinogen IX oxidase. The oxidase reaction requires molecular oxygen and results 
in the loss of 6 protons and 6 electrons, producing a completely conjugated ring system, which 
is responsible for the characteristic red colour of the haem molecules. The final reaction of the 
pathway also takes place in the mitochondrion and involves the insertion of the ferrous iron 
(Fe2+) atom into the ring system generating haem with the help of enzyme ferrochelatase. Co-
ASH, Coenzyme A.  
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In addition to the haem synthesis, iron is also required for the biogenesis of all nuclear 
iron-sulphur protein clusters (ISCs) within the mitochondria (Figure 7). ISCs are 
metallocofactor prosthetic groups of multiple proteins involved in various metabolic 
reactions and are critical for the normal functioning of both mitochondrial proteins 
(respiratory chain complexes, ferrochelatase, aconitase) and cytosolic proteins 
(xanthine oxidase). ISCs are formed with the help of the mitochondrial ISC assembly 
machinery, which combines iron and cysteine (source of sulphur) to produce ISCs on 
scaffold proteins, and finally incorporates these clusters into the recipient apoproteins 
(Apo) (Lill and Muhlenhoff, 2008).  Initial assembly of ISCs on the Isu1/2 (scaffold 
proteins) requires that the two elemental components of the machinery are present in 
their reduced state (Zheng and Dean, 1994). These components include the iron-
binding protein Frataxin (putative iron donor) and the cysteine desulfurase complex 
Nfs1 in complex with ISD11 (Lill and Muhlenhoff, 2008). Nfs1 converts cysteine to 
alanine and persulfidic sulphur which in-turn is reduced to sulphur, presumably 
through the electron transport chain comprised of ferredoxin reductase and ferredoxin 
(Fdx), which receive electrons from NADH.  The release, transfer and incorporation of 
ISCs into the recipient apoproteins is mediated by the ISC assembly machinery 
components such as Hsp70 chaperone Ssq1 and the monothiol glutaredoxin GLRX5; 
however, their mode of action remains unclear (Lill and Muhlenhoff, 2008; Sheftel et 
al., 2009; Wingert et al., 2005). Impaired Fe-S cluster biogenesis in GLRX5 RNAi cells 
and GLRX5-deficient patient cells leads to mitochondrial iron overload and cytosolic 
iron depletion (Ye et al., 2010).  
The Fe-S protein biogenesis also occurs outside the mitochondria in the cytoplasm 
and requires the components of the mitochondrial ISC export machinery and the core 
ISC assembly machinery. To date, various components involved in this process have 
been identified, such as the P-loop NTPase Cfd1 (cytosolic Fe–S cluster-deficient 
protein 1), Dre2, Nar1 (nuclear architecture-related protein 1)/IOP1 (iron-only 
hydrogenase-like protein 1), Cia1 and Tah18 (Netz et al., 2007). The ATP binding 
cassette transporter protein ABCB7 also acts as a central component in the biogenesis 




Figure 7: Schematics of Fe-S protein biogenesis.  
Fe-S protein biogenesis involves the crucial function of mitochondria which import iron in 
ferrous (Fe2+) form from the cytoplasm in a membrane potential dependent manner. This 
Import is facilitated by the inner membrane carriers Mfn1/2. Maturation of mitochondrial Fe-S 
holoproteins (Holo) involves two major steps. The synthesis of a transiently bound Fe-S cluster 
on the scaffold protein Isu1 which occurs with the help of the components of the mitochondrial 
iron-sulfur cluster (ISC) assembly machinery. These proteins include the cysteine desulfurase 
complex Nfs1, Fdx-FdxR complex which serves as the sulfur donor for cluster synthesis, and 
receive their electrons (e−) from NADH.  The release of the Fe-S cluster from Isu1 and its 
transfer as well as incorporation into recipient apoproteins (Apo) are facilitated by late 
components of the ISC assembly machinery (dark arrows). Fe-S cluster release from ISU11 
is achieved by interaction of the Hsp70 chaperone. The monothiol glutaredoxin Grx5 is 
involved in this second major step. The extramitochondrial Fe/S protein biogenesis requires 
the core ISC assembly machinery and components of the mitochondrial ISC export machinery. 
The ABC7 transporter of the inner membrane along with ALR exports an unknown compound 
(X, Blue) to the cytoplasm for use in Fe-S protein assembly. In the cytoplasm, the cytoplasmic 
Fe-S protein assembly (CIA) machinery catalyzes Fe/S protein maturation. First, Fe/S clusters 
are assembled on the P-loop NTPases Cfd1 and Nbp35 complex. The Fe-S clusters are bound 
to Cfd1-Nbp35 in a labile fashion and subsequently incorporated with into cytosolic and 
nuclear apoproteins. Fxn = Frataxin; X (blue) = unknown substrate exported by ABCB7. 
Cfd1/Nbp35 are a cytosolic scaffold complex. 
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The expression of key proteins involved in the iron metabolism such as ALAS2, 
Ferritin, and TfR1, is regulated by intracellular iron. TfR1 and ferritin are also regulated 
post-transcriptionally through the binding of iron responsive protein 1 (IRP1) or iron 
responsive protein 2 (IRP2) to iron responsive elements (IREs), therefore maintaining 
cellular iron homoeostasis (Figure 8) (Anderson et al., 2012). IREs are evolutionarily 
conserved hairpin structures of 25–30 nucleotides present within the UTRs of their 
respective mRNAs. The assembly of Fe-S cluster on IRP1 reduces its RNA binding 
affinity while increasing its aconitase activity, therefore providing one of the 
mechanisms for regulating intracellular iron levels. In addition, defects in any of the 
three Fe-S protein biogenesis systems; ISC assembly machinery, ISC export 
machinery, and the cytosolic Fe-S protein assembly (CIA) machinery also effects the 
assembly of Fe-S cluster on IRP1 and alters IRE binding activity. Previous studies 
have shown that the translation of the transcripts is blocked when IRPs bind to IREs 
motifs in 5´-UTR of the respective mRNA (such as ALAS2, DMT1 and HIF-2α). 
However, the stabilization as well as translation of mRNA transcripts (such as MRCKα 
and Cdc14A) proceeds when IRPs bind to IRE motifs in 3´-UTR of the target mRNAs 








Figure 8: Schematics of Fe-S cluster on IRP1 and IREs.  
The presence or absence of a Fe-S cluster on IRP1 serves as a binary switch, determining 
the binding capacity of the protein to IREs. IRP1 binds to IREs in the absence of Fe-S cluster, 
thereby stabilizing mRNAs with 3’-UTR IREs and blocking translation of mRNAs with 5’-UTR 
IREs. Therefore, appropriate regulation of iron handling requires the mitochondrial ISC 
machineries and also a functional cytosolic assembly system (CIA). X (blue) = unknown 
substrate exported by ABCB7, IRE- Iron regulatory elements, IPR- Iron regulatory protein. 
 
Ring sideroblasts are also characteristic of other inherited sideroblastic anaemias such 
as X-linked sideroblastic anaemia (XLSA), sideroblastic anaemia with spinocerebellar 
ataxia (XLSA/A) and Pearson’s syndrome (Cazzola and Invernizzi, 2011). 
Abnormalities of several genes involved in haem biosynthesis, iron-sulfur (Fe-S) 
cluster biogenesis, Fe-S cluster transport, and mitochondrial metabolism have been 
implicated in these disorders. Mutation of ALAS2 (Bergmann et al., 2010; Cotter et al., 
1999), ABCB7 (Maguire et al., 2001), and also mitochondrial DNA deletions (pearson 
syndrome) (Smith et al., 1995) are all associated with bone marrow ring sideroblast.   
Interestingly, none of these candidate genes have been found to be mutated in RARS.  
Increasing evidence suggests mitochondrial dysfunction occurs in early stages of 
erythroid maturation that can lead to abnormal mitochondrial iron deposition and 
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ineffective haemopoiesis. Gene expression profiles of CD34+ cells from RARS patients 
shows significant upregulation of mitochondria-related genes and in particular, genes 
involved to haem synthesis pathway (such as ALAS2) (Pellagatti et al., 2006). 
Defective ALAS2 enzyme activity in bone marrow erythroid cells results in insufficient 
synthesis of protoporphyrin IX, mitochondrial iron overload, and intramedullary death 
of red cell precursors. Moreover, mitochondrial ferritin gene encoded by FTMT has 
also been reported to be highly over-expressed in patients with acquired sideroblastic 
anaemia (Nikpour et al., 2010).  In contrast, Boultwood et al in another study reported 
substantial down-regulation of iron/sulphur cluster transporter ABCB7 gene in patient 
with RARS (acquired) (Boultwood et al., 2008). ABCB7 is required for normal 
hematopoiesis and siRNA knockdown of the gene in HeLa cells results in iron-deficient 
phenotype with mitochondrial iron overload.  
Using in-vitro erythroid differentiation assay, Tehranchi et al showed that the early 
erythroid progenitor cells from low-risk MDS patients (including RARS patients) 
spontaneously release excessive amounts of cytochrome C from mitochondria, 
resulting in activation of caspase-9 and subsequent cell death (Tehranchi et al., 2003). 
Moreover, enhanced sensitivity to Fas ligation was abrogated by inhibiting caspase-9 
activity. Therefore, increased sensitivity of MDS progenitors to death receptor 
stimulation appears to be due to a constitutive activation of the apoptotic signalling 
pathway in the malignant cells. A recent study has reported that Fas-caspase-8 
pathway and Fas-associated protein with death domain (FADD) are involved in 
erythroid apoptosis (Claessens et al., 2005).  In contrast to inherited sideroblastic 
anaemia where ring sideroblasts are found only in the late erythroblasts, in acquired 
RARS erythroblasts accumulate ferritin within the mitochondria during early 
differentiation, before morphological signs of erythroid differentiation are visible 
(Tehranchi et al., 2005). These findings support the notion that acquired sideroblastic 
anaemia’s are unrelated to a defect in haem biosynthesis directly, however, it might 
be due to an iron metabolism alteration that manifests itself in early erythroblasts. 
Thus, the genetic abnormalities present in RARS patients must both give a 
proliferative advantage leading to expansion of the malignant clone as well as 
contribute to the ineffective erythropoiesis and abnormal erythroid iron metabolism, 
leading to accumulation of the iron in the mitochondria of erythroid progenitors. It is 
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likely that this defect involves a gene(s) or a pathway which is responsible for the 
regulation of various cellular process such as erythroid differentiation, mitochondrial 
function, or cellular iron metabolism.  
Abnormal epigenetic profile, such as aberrant DNA methylation and histone 
modification, may also contribute to the altered gene expression and genomic 
instability, suggesting that disease occurs as a result of multiple and cumulative 
alterations to the hematopoietic stem cells. However, whether chromosomal 
aberration, gene mutations or epigenetic changes represent the initiation or secondary 
events, remains unclear.  
1.7 Therapeutic strategies for RARS 
Immunosuppressive regiment’s and thalidomide, which may have proven effective in 
subsets of MDS patients such as RA, are ineffective in patients with RARS (Park et 
al., 2008). Lenalidomide has been demonstrated to abrogate transfusion requirement 
in approximately 25% of the patients with EPO-refractory RARS (median duration of 
response 43 weeks) (Jadersten et al., 2008). The ineffective haemopoiesis in RARS 
responds less well to EPO than other low risk subgroups of MDS such as RA (7.5% 
vs. 21%). However, the combination of EPO and granulocyte colony-stimulating factor 
(G-CSF) induces durable responses (overall response rate of 50%) (Ingram et al., 
2006). Various in-vitro and in-vivo studies have shown that G-CSF strongly inhibits 
apoptosis in differentiating RARS erythroblasts by inhibiting the release of 
mitochondrial cytochrome-C, with a subsequent decrease in caspase-9 and caspase-
3 activity (Schmidt-Mende et al., 2001; Tehranchi et al., 2003; Tehranchi et al., 2005).  
However, G-CSF had no effect on the accumulation of mitochondrial ferritin at any 
time point of stem cell differentiation (Tehranchi et al., 2005). Moreover, EPO has been 
previously demonstrated to inhibit apoptosis (Koury and Bondurant, 1990).  
Interestingly, patients with RARS have significantly better survival and higher 
response rate (survival time - 121+ months, response rate 71%) to EPO/G-CSF as 
compared to RCMD-RS patients (survival time - 31 months, response rate 30%) 
(Howe et al., 2004; Jadersten et al., 2008). This difference correlates well with the 
predictive model for erythroid response, since RCMD-RS patients usually belong to 
intermediate IPSS category, whereas RARS patients belong to a good risk group 
(Hellstrom-Lindberg and Cazzola, 2008).  
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1.8 High throughput molecular technologies 
High-throughput molecular technologies such as second-generation sequencing (SGS) 
and microarrays have accelerated the pace for the identification of novel genetic 
mutations/variations and transcripts associated with various cancers including 
haematological malignancies. 
1.8.1 Second Generation Sequencing  
Since the completion of the human genome project, major changes have occurred in 
the approach to genome sequencing that has moved away from traditional Sanger 
sequencing (first generation sequencing). SGS has allowed highly streamlined and 
multiplex sample preparation prior to DNA sequencing of individual clones in a 
massively parallel fashion. This provides significant time savings and a minimal 
requirement for associated equipment in comparison to automated, multistep pipelines 
necessary for clone-based traditional high-throughput sequencing. The basis of SGS 
is the amplification of hundreds to millions of single DNA molecules separately but in 
the same experiment (in parallel).  The DNA to be sequenced is used to prepare a 
library of fragments that have oligonucleotide adapters (synthetic DNAs) attached to 
each end of the DNA fragment by use of DNA ligase. These universal adapters are 
specific to each sequencing platform that can be used to polymerase-amplify the 
library fragments during specific steps of the protocol. These library fragments are 
then amplified in situ on a solid surface, either a bead or a flat glass microfluidic 
channel with attached adapter sequences that are complementary to the universal 
adaptors on the library fragments. The SGS amplification process allows each 
amplified fragment to yield a single focussed molecule (cluster of amplified DNA 
fragments that originated from a single DNA molecule). SGS is often referred to as 
massively parallel due to its large scale and high throughput of samples, which is an 
appropriate term to describe the technology that follows fragment amplification to yield 
large sequencing data in a limited amount of time. This highly efficient massively 
parallel sequencing technology involves a stepwise reactions that consist of (1) a 
nucleotide addition to the DNA fragment, (2) a detection step to determine the identity 
of the incorporated nucleotides, and (3) a wash step that includes removal of 
fluorescent labels or blocking groups attached to the incorporated nucleotide. 
Therefore, SGS instruments performs sequencing and detection simultaneously which 
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allows thousands to billions of reaction foci to be sequenced at the same time. 
However, the yield of sequence reads from SGS instruments varies from several 
hundred thousand reads (Roche/454, Illumina MiSeq) to tens of millions of reads 
(Illumina HiSeq2000 and Applied Biosystems SOLiD), thus bringing close to the time 
when sequencing an individual’s genome quickly and cheaply is feasible. 
However, there are particular challenges for the detection and diagnosis of cancer 
genome abnormalities. For example, somatic mutation calling is more complex than 
germline mutation calling because some acquired alterations in cancer genome are 
prevalent at a low frequency (<20% of cells) in clinical samples, often owing to 
substantial admixture with normal cells. In addition, a key parameter defined for each 
mutation is its allelic burden (or mutant allele burden) which is defined as the expected 
fraction of reads in the tumour cells that harbour the mutation among all reads that 
map to the same genomic location.  Due to this admixture problems, it is difficult to 
determine the accurate mutant allele burden (MAB) of the acquired genomic 
alternation through the traditional Sanger sequencing. However, SGS technology can 
solve such problems and capture the local complexity of the tumour genome as well 
as the non-tumour contamination levels with high accuracy.  
Sequencing of complete AML genome using SGS technology represented a landmark 
in genetic screening and has since led to the identification of significant disease 
markers such as IDH1/2 and DNMT3A mutations. However, SGS coupled to new 
DNA-enrichment technologies, such as array/bead hybridization-based region 
capture, has enabled highly efficient targeted sequencing of regions of interest, such 
as disease-linked genes, in greatly increasing numbers of samples simultaneously. 
Applying SGS technology to perform ‘whole-exome’ sequencing (WES) allows an 
unbiased investigation of the complete protein-coding fraction of the human genome. 
Recently, comprehensive exome ‘capture arrays’ have become available for 
selectively fractionating approximately 50 Mb or ≈ 200,000 coding exons across the 
human genome. A clear limitation of WES is that it does not identify the noncoding 
variants found by whole-genome sequencing. However, efficiency benefits of 
selectively sequencing the exome in isolation means at least 20 times as many 
samples can be processed at one time compared to whole-genome sequencing, 
Furthermore, data arising from WES is directly attributable to cellular function and thus 
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‘bioinformatically’ less challenging. Various studies involving WES have demonstrated 
that this approach is a cost-effective means of precisely denoting functional variations 
in a large cohort of patient samples. Recent studies involving exome-sequencing 
through capillary-based sequencing in colorectal, breast and pancreatic carcinomas, 
and glioblastoma, led to the discovery of somatic mutations in IDH1 in glioblastoma 
and germline mutations in the gene encoding partner and localizer of BRCA2 (PALB2) 
in patients with pancreatic carcinoma. Studies have also successfully applied targeted 
capture/SGS to identify genetic changes involved in Mendelian diseases such as Miller 
syndrome. Furthermore, in a study of Nephronophthisis-related ciliopathies (NPHP-
RC), 12 different truncating mutations of SDCCAG8 (serologically defined colon 
cancer antigen 8) were identified through WES in 10 families affected by NPHP-RC, 
therefore demonstrating the benefits of targeting sequencing in such diseases.  
1.8.2 Microarray analysis 
Over the past decade, microarray technology has also led the way from studying the 
individual biological function of a gene, protein or, at best, pathways towards more 
global analysis of cellular activity. In addition, this technology has improved our 
understanding of the underlying mechanisms of the malignant process involved in 
various cancers.  
The publication of whole-genome sequencing studies raised an important question 
about the molecular interpretation of the somatic/inherited gene mutation, and not so 
much the number of mutated genes, that are responsible for the variation between 
various cancers. In addition, alternative splicing is another well-established post-
transcriptional modification that plays an essential role in regulating gene expression 
and has been reported to have a role in the pathogenesis of haematological 
malignancies (Oltean and Bates, 2014).  
Gene expression profiling (GEP) provides a detailed image of the transcriptional 
activity of whole genome at a specific time point. Golub and colleagues were the first 
to demonstrate a difference between AML from acute lymphoblastic leukaemia (ALL) 
patients based on their global gene expression (Golub et al., 1999). Furthermore, GEP 
in diffuse large B-cell lymphoma (DLBCL) led to the classification of patients according 
to their expression profiles and as a result DLBCL were divided into two subtypes: 
activated B-cell-like DLBCL and germinal center B-cell-like DLBCL.  These two 
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subtypes differ in the proliferation rate, differentiation level, response to therapy and 
prognosis (Alizadeh et al., 2000). In addition, genome wide gene-expression profiling 
has provided an insight into the molecular pathogenesis of breast cancer which has 
enabled to predict disease recurrence and response to treatments as well as gain 
insights into oncogenic pathways and the process of metastatic progression (Liu et al., 
2007; van 't Veer et al., 2002). 
With recent developments in microarray technology, splicing sensitive microarrays 
that contain probes targeted to individual exons or exon-junctions are becoming 
increasingly popular. By targeting individual exons, exon junctions, and annotated 
isoform variants, such microarrays enable us to profile not only the expression levels 
of the entire transcript, but also detect the transcriptional representation of exons (i.e. 
splice variant). These microarray chips contains a set of unique and distinct 25-mer 
oligonucleotides probes that are immobilised to a solid surface or membrane on the 
chip. These probes are designed such that each probe binds to specific sequence 
corresponding to an exon, splice variant or a gene.  The microarray probes are labelled 
with a detectable fluorochrome molecule.  The level of binding between a specific 
probe and its target sequence is quantified by measuring the fluorescence when 
scanned by the instrument. This signal, in turn, provides a measure of the expression 
of the specific gene or splice variant containing the target sequence. The latest 
generations of microarray chips interrogate 285,000  transcripts as well as analyse 
individual exons of genes separately (GeneChip® Human Transcriptome Arrays 2.0), 
or even more advanced, the entire genome for transcriptional activity without focusing 
on predicted genes (Tiling arrays).   
One of the most frequently utilized methods in studying of the gene expression as well 
as splicing is Affymetrix GeneChip® technology (Santa Clara, CA, USA). Affymetrix’ 
GeneChip® Human Transcriptome high-resolution array contains >6.0 million distinct 
probes covering coding and non-coding transcripts with 70% of the probes on this 
array cover exons for coding transcripts, and the remaining 30% of probes on the array 






Over the last 15 years, there have been significant advances in understanding the 
molecular pathogenesis of MDS. However, establishing the relevance of individual 
gene aberrations found in MDS with a clinical phenotype, particularly RARS, has been 
a major challenge. Applying SGS technology to perform whole-exome sequencing on 
in low-risk MDS with relatively homogenous phenotype such as MDS patients with ring 
sideroblasts will allow a thorough and unbiased investigation of the complete protein-
coding regions. This should enable the unravelling of the genetic make-up and 
elucidate the pathophysiology, refine the prognostic scoring systems, and more 
importantly provide novel therapeutic targets for this subgroup of MDS. This study will 
therefore provide a valuable insight into the potential molecular mechanisms 
associated with this sub group of MDS patients.  
o The main aim is to identify disease specific mutation(s)/variation(s) in a 
phenotypically well-defined MDS subgroup RARS/RCMD-RS with ring sideroblasts 
using DNA-capture (whole-exome) and SGS technology. 
o Validate a relevant candidate(s) variation/mutation profile in a larger cohort of MDS 
patients to understand the clinical/statistical significance within the disease group. 
o To functionally characterize the selected functionally relevant candidates in in-vitro/ 
in-vivo studies using appropriate cell lines and/or mouse model. 
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    Chapter 2 



























2.1 Materials  
2.1.1 Patient Samples 
Twelve patients (MDS patients with >15% ringed sideroblasts, n =11; Congenital 
sideroblastic anaemia, n=1) were initially selected for whole-exome sequencing (Table 
6). 156 MDS patients (Table 7) were selected for follow-up mutation analysis of the 
splicing pathway genes, epigenetic modifiers and other cell signalling/transcription 
regulator genes, followed by validation of the candidate mutations. Patients with MDS 
seen at King’s College Hospital from June 2004 to June 2013 were enrolled in this 
study. All patients had provided written informed consent in accordance to King's 
College London Haemato-Oncology Tissue Bank research ethics protocol 
(08/H0906/94).  Demographic and clinical characteristics of the studied patients are 
detailed in Table 7. All patients were risk stratified according to IPSS categories. The 
clinical variables, FAB, WHO subtype and the prognostic risk of all patients were 
ascertained at the time of sample collection. The median follow-up was 21.4 months 
(range, 1-83 months). The patient cohort was followed up to January 2012 for disease 
progression, and survival. The survival data for patients who underwent allogeneic 


















Table 6: Clinical characteristics of 11 MDS-RS patients and one congenital sideroblastic 
anaemia patient used for whole-exome sequencing.  
BM blasts- Represent bone marrow blasts at the time of sample; M- Male; F- Female; N/A- 









































































































































































































TP1 1 77 M RARS-T Epo/GCSF 2 8.8 9.53 268 >15 Low NORMAL Yes A No No 
MDS 
1 
TP2 2 -  RARS-T Epo/Len 2 
10.
5 
1.9 248 >15 Low NORMAL Yes - No No 
MDS 
2 
TP1 1 75 M RCMD-RS Epo/GCSF 1 8.6 1.87 166 41 Low NORMAL Yes - No Yes 
MDS 
2 
TP2 2 - - RCMD-RS Epo/Len 1 7.1 3.67 137 50 - NORMAL Yes - No Yes 
MDS 
2 







Yes D Yes Yes 
MDS 
3 
N/A N/A 63 M RARS Epo/GCSF 1 9.1 3.15 570 >15 Low NORMAL No A No No 
MDS 
4 
N/A N/A 58 F RARS None 1 
10.
7 
3.21 196 24 Low NORMAL No A No No 
MDS 
5 







4.7 400 32 N/A NORMAL Yes A No No 
MDS 
6 






3.44 151 35 Low NORMAL No A No No 
MDS 
7 
N/A N/A 67 M RARS ATG 0 
10.
4 
4.5 358 50 Low NORMAL Yes A No No 
MDS 
8 
N/A N/A 58 M RARS None 0 7.7 0.9 281 50 Int-I NORMAL Yes A No No 
MDS 
9 
N/A N/A 60 M RARS Epo/GCSF 1 9.8 5.3 334 47 Low NORMAL No A No No 
MDS 
10 
N/A N/A 63 F RARS-T None 1 
10.
5 
6 565 80 Low NORMAL No A No No 
MDS 
11 
N/A N/A 73 M RARS 
Epo/GCSF/
ATO 
0 9.7 2.80 236 78 Low NORMAL Yes A No No 
MDS 
12 
N/A N/A 67 F RARS EPO/GCSF 2 7.1 1.7 389 >35 Int-I NORMAL Yes A No No 
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Table 7: Clinical characteristics and treatments received by all 156 MDS patients 
studied for targeted amplicon sequencing.  
Cytogenetics failed in 4 patients in this cohort. † denotes other treatments which include; 
lenalidomide, thalidomide, cyclosporine   and Antithymocyte globulin (ATG).  * includes 13 
patients who had HSCT after receiving 5-azacitidine. n- Represents number of patients. % -





Total patients 156 
Age, years   
 Median 65.5 
 Range 17-85 
Sex   
  Male [n (%)] 105 (67%) 
  Female [n (%)] 51   (33%) 
WHO category *   
RA/RCMD [n (%)] 40   (26%) 
RARS/RCMD-RS [n (%)] 26   (17%) 
RAEB -1/2 [n (%)] 49   (31%) 
sAML [n (%)] 15   (10%) 
tMDS/AML [n (%)] 12   (8%) 
CMML &MPD/MDS-U [n (%)] 14   (9%) 
Bone marrow blasts   
Median (%) 5 
Range  0-80 
IPSS cytogenetic risk group 151 
 Good  [n] 92 
Intermediate [n] 17 
Poor [n] 44 
Transfusion dependency   
Yes  [n (%)] 80   (51%) 
Progression to AML   
Yes  [n (%)] 45   (29%) 
Treatments    
 5-Azacytidine 68 
Other Treatments† 14 
HSCT* 35 






2.1.2 Commercial Kits 
2.1.2.1 Agilent SureSelect Target Enrichment kit for Illumina paired-end 
sequencing library (v. 2.0.1) 
Agilent’s SureSelect Target Enrichment System is a highly efficient hybrid selection 
technique used for enriching targeted regions of the genome from repetitive 
sequences and non-exonic sequences. It encompasses all exons annotated by the 
GENCODE project as well as Consensus CDS and RefSeq databases. This kit has 
the following components; blocking reagents, hybridization buffers, wash and elution 
buffers, nucleotides, SureSelect biotinylated RNA library “BAITS” and other reagents. 
2.1.2.2 TruSeq PE Cluster Kit v3-cBot-HS for Illumina paired-end sequencing 
The TruSeq PE Cluster Kit v3-cBot-HS provides reagents for the cBot cluster 
amplification system for illumina paired-end sequencing. The cluster generation is 
performed on cBot system (Illumina). This cluster generation kit has the following 
components; primers, blocking reagents, DNA polymerase and other buffers. 
2.1.2.3 TruSeq SBS Kit v3-HS for Illumina paired-end sequencing 
TruSeq SBS v3-HS kits contain ready-to-load reagents for accurately determining the 
DNA sequence on Illumina HiSeq2000 platform. This kit has the following 
components; wash buffer, incorporation mix buffer, high salt buffer, incorporation wash 
buffer, cleavage buffer, cleavage mix reagent, enhanced scanning mix reagent, 
enhanced DNA polymerase (EDP), long read nucleotide mix (FFN) and NAOH. 
2.1.2.4 Genome Sequencer (GS) FLX Titanium Series Kits 
GS FLX Titanium series kit contains all reagents required for emulsion-based clonal 
amplifications of DNA libraries and for subsequent sequencing on a Genome 
sequencer FLX instrument. This kit has the following components: LV emPCR Kit; 
emPCR breaking Kit LV/MV 12pc; picoTiterPlate Kit 70x75; sequencing kit XLR70; 







2.1.3 Buffers  
 
Phosphate Buffered Saline (PBS) 
PBS tablet (Oxoid) 1 tablet; Sterile distilled water 100ml 
Phosphate Buffered Saline with Tween-20 (PBST) 
Sterile PBS 1L; Tween 20 (VWR) 0.02% (v/v) 
1X Tris-Borate-EDTA (TBE) 
800ml of H2O; 200ml of 20X TBE 
1X Tris-EDTA (TE) 
990ml of H2O; 10ml 1MTris-Hcl; 400µl 0.25M EDTA 
Magnetic activated cell sorting (MACS) buffer 
Phosphate-buffered saline (PBS) 500ml (pH 7.2); Bovine serum albumin (BSA) 0.5% 
(w/v); EDTA 2mM 
Fluorescent Activated Cell Sorting (FACS) buffer 
Sterile PBS (pH 7.2) 500ml; Fetal calf serum (Sigma) 2.5% (v/v); Sodium Azide 
(VWR) 0.1% (v/v) 
Freezing Medium 
Foetal calf serum 45ml; Dimethyl Sulfoxide (DMSO, Sigma) 4.5ml 
70% Ethanol 





dH2O 10mls; Ethanol 40mls 
1M NaOH (Melt solution) 























2.2 Methods  
2.2.1 Extraction of Genomic DNA  
DNA was extracted from CD34+ cells (n=12), CD34-CD3+ (n=18), CD34-
CD235+CD71+ (n=3), CD34-CD235- (n=3), CD34-CD3+CD4+ (n=3), CD34-CD19+ 
(n=3), skin (n= 27), buccal swab (n=3) and bone marrow total nucleated cells (n=156) 
using QIAamp DNA extraction kit (Qiagen, UK) according to the manufacturer’s 
protocol. Cells were pelleted by centrifugation at 2000xg for 5 minutes and then the 
supernatant was discarded. Cells were resuspended in 200µl of phosphate buffered 
saline (PBS) and then transferred into the 1.5ml tube.  20µl of Qiagen protease and 
200µl of buffer AL was added to the same 1.5ml tube and mixed by pulse vortexing 
for 15 seconds. The sample was incubated for 1 hour at 56oC. 200µl of 100% (v/v) 
ethanol was added to the sample tube. The sample was mixed on a votex for 15 
seconds and then transferred to the Qiagen spin column. The spin column was 
centrifuged for 1 minute at 8000xg. Then the Qiagen spin column was transferred into 
clean collection tube and 500µl of buffer AW1 was added to it, followed by 
centrifugation for 1 minute at 8000xg. Qiagen spin column was transferred to a clean 
collection tube and 500µl of buffer AW2 was added followed by centrifugation for 3 
minutes at 13000xg. The spin column was then transferred to a clean 1.5ml tube and 
100µl of elution buffer was added followed by centrifugation at 8000xg for 1 minute. 
DNA was stored at +4oC. 
Out of 156 cases, whole genome amplified (WGA) DNA was used in 40 cases for 
targeted amplicon sequencing. 
2.2.2 DNA Quantitation using Quant-iT picoGreen dsDNA Assay kit. 
DNA concentration was determined by using the Rotor-Gene 6000 and Quant-iT pico-
green dsDNA Assay kit. Quant-iT™ PicoGreen® dsDNA reagent (Life Science 
Technologies) is an ultra-sensitive fluorescent nucleic acid stain for quantitating 
double-stranded DNA (dsDNA) in solution. 1µl of DNA was diluted in 10µl of 1x Tris-
EDTA (TE) buffer (Life Science Technologies) and 10µl of 1x florescent dye pico-green 
(Life Science Technologies) was added to the tube containing the DNA. Then the 
tubes containing the sample mixture were run on the Corbett Rotor-gene RG300A 
alongside with the 6 dsDNA standards (Life Science Technologies) with 
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concentrations of 2ng/µl; 1ng/µl 0.5ng/µl; 0.25ng/µl and 0.125ng/µl respectively. The 
data was analysed by using the Rotor-gene software.  
2.2.3 RNA Extraction 
Upto 1 x 107 cells (CD34+ and CD71+CD235+)  were used for RNA extraction using 
RNeasy RNA extraction mini kit (Qiagen, UK) according to the manufacturer’s 
protocol. Cells were lysed using 1ml of Trizol (Thermo Fisher Scientific, UK) and 
incubated for 5 minutes at room temperature. 0.2 ml of chloroform was added to the 
lyzed cells and vortexed for 15 seconds. Cells were centrifuged for 10 minutes at 
15000xg (at 4oC). 200µl of the supernatant was transferred into the fresh 1.5ml 
eppendoff tube. 700µl of Qiagen RLT buffer was added to the mixture. 500µl of 100% 
ethanol was added to the mixture. Samples were vortexed for 15 seconds. Samples 
were transferred to the Qiagen MiniElute spin columns. Spin column tubes were 
centrifuged for 15 seconds at 10000xg.  Spin columns were transferred into a new 
collection tubes. 500µl of RPE was added to the spin column and centrifuged for 15 
seconds at 10000xg. Then, 750µl 70% ethanol (v/v) was added to the spin columns 
and centrifuged for 15 seconds at 10000xg. Spin columns were centrifuged again for 
5 minute at 15000xg. The spin column was then transferred to a clean 1.5ml tube and 
10µl of RNAse free H2O was added to the spin columns followed by centrifugation at 
8000xg for 1 minute. RNA was stored at -20oC. 
2.2.4 Whole-exome Sequencing  
For the generation of standard exome capture libraries, Agilent SureSelect Target 
Enrichment reagent (Agilent Technologies, UK) and protocol (Figure 9) for Illumina 
paired-end sequencing library was used.  
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Figure 9: Schematic representation of the work-flow for whole-exome capture. 
Following the sonication/shearing of the patient genomic DNA, Illumina adapters are ligated 
on the DNA fragments. Agilent’s RNA baits and streptavidin coated magnetic beads are used 
to capture the exonic regions of the DNA. Unbound fraction of the genome which doesn’t bind 
to the RNA baits is washed away using various buffer washes. Illumina sequencing adapters 






2.2.4.1 DNA Sonication  
DNA sonication was performed using Bioruptor (Diagenode, Belgium) or Covaris 
ultrasonicator E220 (Covaris, Inc. USA).  Prior to sonication, patient DNA samples 
were dissolved in a sonication buffer 1x TE with a varying DNA concentration (80ng 
to 1000ng).  DNA sonication was performed according to the optimized conditions as 
shown in Table 8 and Table 9.  
 


















200 to 300 bp 4oC - 8oC 13.25 30 Sec/30 Sec 4/5 Low 100 μl 
 
 
Table 9: Covaris ultrasonicator sonication protocol. 
Sonication protocol for genomic DNA (gDNA) and Whole genome amplified (WGA) DNA. 
Settings Value 
DNA Target Peak 150-200 bp 
Duty Factor 10% 
Peak Incident Power (PIP) 175 
Cycles per Burst 200 
Treatment time 360 Seconds 
Bath Temperature 4oC - 8oC 






2.2.4.2 AMPure Bead purification 
Fragmented DNA was purified using Agencourt AMpure XP beads (Beckman Coulter) 
by following the manufacturer’s protocol. AMpure XP magnetic beads were added to 
fragmented DNA in 1:1.8 ratio (Beads:DNA) and the mixture was incubated at room 
temperature for 20 minutes. Beads were washed twice by using the magnetic particle 
concentrator (MPC) and 500µl of 70% (v/v) ethanol. DNA was eluted by resuspending 
the beads in 35µl of nuclease free H2O.  
2.2.4.3 Pre-Hybridization library preparation 
The purified DNA fragmented library for each patient was end-repaired by adding end-
repair enzyme (Agilent Technologies, UK) cocktail (Appendix Table 1) to the 
fragmented DNA library. Samples were incubated in a thermal cycler for 30 minutes 
at 20oC without heated lid. Following end-repair, samples were purified using 
Agencourt AMpure XP beads as described in section 2.2.4.2. DNA libraries were 
eluted in 32µl of nuclease free H2O.  
End-repaired DNA fragments were tailed with poly dA’s by adding a Klenow exo- 
enzyme (Agilent Technologies, UK) cocktail (Appendix Table 2) to the samples and 
incubated for 30 minutes at 37oC with a heated lid at 50oC. The libraries were purified 
using Agencourt AMpure XP beads as described in section 2.2.4.2.  DNA samples 
were eluted in 29µl of nuclease free H2O. Illumina adapters were ligated to the 
fragmented DNA library using the InPE adapter oligo mix (Illumina), DNA ligase 
(Agilent Technologies, UK) and 5x T4 DNA ligase buffer (Appendix Table 3; Agilent 
Technologies, UK). Samples were incubated in a thermal cycler for 1 hour at 20oC 
without heated lid. Ligated DNA fragmented libraries were purified using Agencourt 
AMpure XP beads as described previously in section 2.2.4.2. The adaptor-ligated 
libraries were eluted in 37µl of nuclease free H2O. 
Adapter ligated DNA libraries were amplified using Herculase II fusion DNA 
polymerase enzyme (Agilent Technologies, UK) cocktail (Appendix Table 4). 
Polymerase chain reaction (PCR) amplification was performed as mentioned in 
appendix table 5. Amplified libraries were purified using Agencourt AMpure XP beads 




2.2.4.4 Hybridization/Exome Capture 
The exomic regions of the genome were enriched using Agilent SureSelect Human All 
Exon Kit (Agilent Technologies, UK) covering approximately 50Mb of the genome and 
Agilent post capture buffer kit (Agilent Technologies, UK). This target enrichment 
process involves using ultra-long 120-mer biotynilated cRNA baits which are used to 
capture the region of interest i.e. exomic regions from the genomic fragmented library. 
500ng of amplified adaptor ligated library from each patient was mixed with 
hybridization buffers (Appendix Table 6), blocking mixes (Appendix Table 7) and 7µl 
of diluted SureSelect all exon capture library (5µl of SureSelect capture library mixed 
with 2µl of diluted RNase block) in a step wise manner, according to the Agilent 
SureSelect Target Enrichment protocol (Agilent Technologies, UK). Samples were 
incubated in a thermocycler for 24 hours at 65°C with heated lid.   
50µl Dynal MyOne streptavidin T1 (Invitrogen) magnetic beads were used for each 
exome capture library. Beads were washed 3 times by using MPC and 200µl 
SureSelect binding buffer (Agilent Technologies, UK). Following on, Dynal MyOne 
streptavidin T1 beads were resuspended in 200µl of SureSelect binding buffer.  
After 24 hours hybridization of the adaptor-ligated DNA libraries, samples were directly 
transferred from the thermal cycler to the tubes containing the washed Dynal MyOne 
streptavidin T1 beads. Hybrid-capture/bead solution was incubated for 30 minutes at 
room temperature. After incubation, hybrid-capture/beads were washed by using MPC 
and 500µl of SureSelect wash buffer 1 (Agilent Technologies, UK). Hybrid-
capture/beads were then washed 3 times by adding 500µl of pre-warmed SureSelect 
wash buffer 2 (Agilent Technologies, UK), incubating for 10 minutes at 65°C, followed 
by MPC separation. Targeted DNA from the exomic regions was recovered by 
resuspending hybrid-capture/beads in 50µl of SureSelect elution buffer (Agilent 
Technologies, UK). Supernatant was transferred into a fresh 1.5ml tubes and 50µl of 
SureSelect neutralization buffer (Agilent Technologies, UK) was added to the captured 
library. Captured DNA libraries were then purified by using Agencourt AMpure XP 
beads as described in section 2.2.4.2. DNA libraries were eluted in 30µl. The captured 
exomic DNA fragments were amplified through PCR by using Herculase 11 fusion 
DNA polymerase (Agilent technologies, UK) cocktail (Appendix Table 8).  Index 
tags/primers were used to barcode each patient in order for them to be sequenced 
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together. PCR amplification was performed as mentioned in appendix table 9. 
Following amplification, samples were purified using Agencourt AMpure XP beads as 
described in section 2.2.4.2. DNA libraries were eluted in 30µl of nuclease free H2O. 
Exomic DNA index-tagged library concentration was determined by 2 separate 
quantification assays inorder to obtain the precise concentration for efficient data 
generation. Initially exomic DNA index-tagged library concentration was determined 
by using the Rotor-Gene 6000 and Quant-iT pico-green dsDNA Assay kit as described 
in section 2.2.2. Later, exomic DNA index-tagged library concentration was 
determined by using Stratagene brilliant-111 Ultra-Fast SYBR Green qPCR assay 
(Agilent Technologies, UK).  Based on the concentration values obtained from Quant-
iT pico-green dsDNA Assay, exomic DNA index-tagged libraries were diluted in 
duplicate using 1x dilution buffer. The qPCR consisted of 10µl of 2X Brilliant master 
mix, 0.4µl of Illumina primer mix, 0.3µl of reference dye, 2µl of diluted DNA index-
tagged library and 7.3µl of dH2O. PCR was performed on 7900HT Fast Real Time 
PCR system using the manufactures conditions (Appendix Table 10). Following on, 
exomic DNA index-tagged library concentrations were calculated by using 7900HT 
Fast Real Time PCR software. Exonic DNA index-tagged libraries were pooled 
together in equal concentrations depending upon the indexes used for the patient 
samples.  
2.2.4.5 Illumina HiSeq2000 Sequencing 
Pooled exomic DNA index-tagged libraries were diluted to 2nM using 1x TE with 0.1% 
(v/v) tween-20. Pooled exomic libraries were denatured by adding 10µl of 0.1N (w/v) 
NAOH to 10µl of pooled exomic libraries and incubated at room temperature for 8 
minutes. Following on, 980µl of pre chilled HT1 buffer (Illumina) was added to the 20µl 
of denatured template pooled exomic libraries. Denatured libraries were further diluted 
to 11pM using HT1 buffer (Illumina) and then mixed on a vortex.  120µl of denatured 
libraries were transferred into an eight-tube strip and placed on ice. 
Cluster generation of the prepared libraries was performed using a TruSeq PE Paired-
End Cluster Generation kit v3 (Illumina) and cBOT cluster generation system 
(Illumina). Cluster generation process involves the hybridization of millions of DNA 
templates to a lawn of oligonucleotides immobilized on the flow cell surface. 
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Immobilized DNA templates are amplified by isothermal bridge amplification. Cluster 
generation reagent plate (Illumina), HiSeq flow cell (Illimina) and tubes containing the 
denatured DNA libraries were loaded on the cBOT cluster generation system. 
Clustered HiSeq flow cell was removed from the cBOT cluster generation system upon 
completion of the cluster generation and stored overnight in the 50ml tube containing 
the storage buffer (Illumina) at 4ºC.  
Paired end sequencing with a read length of 2x 75bp was performed using TruSeq 
SBS reagents v3 kit (Illumina) and Illumina HiSeq2000 system. The Illumina 
HiSeq2000 uses sequencing-by-synthesis technology and produce more than 1 billion 
quality reads or around >350 gigabases (100bp paired-end reads) of data per run. 
TruSeq SBS reagents tray and clustered HiSeq flow cell was loaded on the Illumina 
HiSeq2000 instrument. After performing the required pre-run checks on the Illumina 
HiSeq2000, sequencing read 1 was started using the Illumina HiSeq2000 control 
software.  
After the read 1 sequencing was complete, paired end reagents (HiSeq read 2 cluster 
re-synthesis kit) for read 2 were loaded on the Illumina HiSeq2000. Following on, 
sequencing read 2 was started using the Illumina HiSeq2000 control software.  
2.2.4.6 Data Generation, Alignment Pipeline, SNP detection and 
Structural variation calling 
Whole-exome sequencing data was processed by using an in-house data analysis 
pipeline (Figure 10). Illumina RNASeq 2000 Real Time Analysis (RTA) or the Off-Line 
Basecaller (OLB) software generates the *.bcl files during the sequencing run. *.bcl 
files were de-multiplexed and converted to fastq using CASAVA1.8.2 (Illumina). 
Sequence alignment to the human reference genome (NCBI37/Hg19) and variant 
calling for SNPs and Indels was performed using both CASAVA 1.8 (Illumina) and 
Burrows-Wheelers aligner (BWA) (Li and Durbin, 2009) as well as GATK (McKenna 
et al., 2010) pipelines according to the Broad Institute best practices pipeline. 
Sequence alignment was performed by Dr. Alexander Smith. 
For the illumina pipeline, Annovar software (Wang et al., 2010b) was used to perform 
functional annotation of all variants.  Following on, variants with a quality score of 
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>QSNP 25 and with a tumour read depth of >2 read (total read depth > 6) were passed 
for further analysis.  
For BWA/GATK pipeline, VarScan 1.3.4 (Koboldt et al., 2009; Koboldt et al., 2012) 
was used to call somatic variants on pileup files (Samtools) (Li et al., 2009) for paired 
tumour and normal (skin or CD3+ T-cells) tissue. Reads with alignment score of <10, 
base quality score <15 and fold strand bias >10 were excluded. Pindel (Ye et al., 2009) 
was also used to screen for more computationally challenging large Indel mutations at 
specific loci such as for FLT3 ITD. All resulting variants were passed through 
ANNOVAR (Wang et al., 2010b) using refseq annotation. Genomic duplicated regions 
were also filtered out unless associated with known mutations. Somatic mutations 
were subsequently passed when somatic p-value (VarScan, Fisher’s exact T-test) was 
< 0.01, had ≥3 reads supporting mutation, were present in paired normal tissue at less 
than 20% of the paired tumour tissue and had a allele burden of >5%.   
Candidate variants from both pipelines obtained were passed for validation if the 
variants were deemed to cause protein changes and not found in dbSNP140, esp5400 
and 6500, and 1000 genomes databases at >0.01 population allele frequency.  
A repeat sequencing run was also used to filter out sequencing artefacts where 
candidate mutations supported in both runs were passed. Additionally, variations 
present in available paired skin and CD3+ T-cell samples at >20% (skin) or >50% (T-
cells) the level found in CD34+ tissue were excluded from subsequent analysis. 
Data from both pipelines were largely in agreement for filter passed variants and 
variant depth >2. Any discrepancies between the two pipelines at this level were later 
confirmed to be artefactual calls. Any known myeloid specific variant which didn’t pass 




   
Figure 10: WES data processing pipeline for detecting somatic mutations. 
 
 
2.2.4.7 Data filtration criteria for Xenograft samples 
For isolated human engrafted cells (HEC) CD45+CD33+ from mice, candidate 
mutations were only passed if they were present in more than 1 HEC sample or found 
concurrently in one or more HEC experiment and long-term tissue culture (LTC) 
derived sample or primary CD34+ cells for the same patient. Where only WGA-derived 
data from HEC was available for one engraftment experiment, or a combination of 
WGA and non-WGA data from more than one engraftment experiment, mutations 
were only passed when they were found concurrently in either: (1) WGA HEC and 
non-WGA HEC independent experiments; (2) Repeat WGA DNA samples from the 
same engraftment experiments or; (3) WGA HEC experiments and LTC derived 
sample, CD34+ or HEC experiments derived from non-WGA DNA. For WGA-derived 
HEC, a stand-alone analysis was also performed for individual experiments. For this, 
additional false positive filters were applied to remove additional WGA-derived 
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artefacts with positional and read length distribution bias as well as variant and 
mapping quality biases.  Variants with homopolymer runs of five or more flanking the 
mutation were also filtered out. WGA-derived variants from control WGA experiments 
were also removed. For MDS3, only variants found in at least two of the three animal 
experiments from WGA-derived data were included in final list due to increased 
artefactual events. Stand-alone analysis of non-WGA HEC cells were likewise 
performed but only using filters up to step 7 above. 
2.2.4.8 Mapping Loss of Heterozygozity (LOH) Across Chromosomes by WES 
LOH was mapped from WES data according to the following criteria: Variants were 
called as described above. Variants found in 1000 genome project database with a 
population allele frequency less than 0.001 were selected and filtered out for known 
genomic duplicated regions, read depth <20 and somatic status according to VarScan. 
The filtered set of variants was then plotted graphically for the required chromosome.  
2.2.4.9 Exome Coverage 
Exome coverage was calculated utilizing GATK Depth Of Coverage script against 
intervals that the Agilent V4 Sureselect kit capture probes were based on. For non-
WGA sample, mean base coverage across the targeted region ranged from 77-115X 
and for >98% of the exome base coverage was >10 reads in all cases, based on 9-13 
gigabase of sequence data. For the same amount of sequence data on average, 
WGA-derived exome data yielded average base coverage of 55-75X and 65-83% 
(average 74%) of exome was covered ≥10 reads.  
 
2.2.5 454 Roche Amplicon Sequencing  
2.2.5.1 Gene panel library preparation 3.2.4.1 
Mutation screening for SF3B1, SRSF2, U2AF1, ZRSR2, TP53, FLT3, DNMT3A, 
ASXL1, EZH2, NRAS, KRAS, JAK2, CCBL, RUNX1, CEBPA, BRAF, MPL, NPM1, 
IDH1, IDH2,   C-KIT and TET2 was performed on bone marrow total nucleated cell 
DNA using the Roche GS FLX platform.  All coding exons were selected for 
sequencing for genes including ZRSR2, TP53, DNMT3A, EZH2, RUNX1, CEBPA and 
83 
 
TET2.  Mutation data of TET2 for 142 cases that was available from our previously 
published study (Smith et al., 2010) was included in the analysis. Mutational hotspots 
were specifically sequenced for SF3B1, SRSF2, U2AF1, ASXL1, CCBL, FLT3, NRAS, 
KRAS, JAK2 exon12/14, IDH1, IDH2, BRAF, MPL, C-KIT and NPM1 in all cases. 
Gene hotspot regions were selected based on the previously published data and 
frequency of the mutations shown in COSMIC database (Table 10). In addition, all 
coding exons of SF3B1 were sequenced for all 24 RARS/RCMD-RS patients present 
within our patient cohort. SRSF2, U2AF1 and ZRSR2 genes were amplified by using 
PCR primers published previously (Yoshida et al., 2011b).  Specific PCR primers were 
designed to amplify and sequence coding regions or mutation hotspot regions of 22 
genes (SF3B1, SRSF2, U2AF1, ZRSR2, TP53, FLT3, DNMT3A, ASXL1, EZH2, 
NRAS, KRAS, JAK2, CCBL, RUNX1, CEBPA, BRAF, MPL, NPM1, IDH1, IDH2,   C-
KIT and TET2).  Primer3 program was used to design the PCR primers.  The primers 
were tagged with a universal sequencing primer (aUS1 for forward; aUS2 for reverse). 
PCR primers for all the genes are shown in appendix table 11.  First round PCR 
reaction was performed by using master mixes from Table 11 and using thermal cycler 
protocol as described in Table 12 (see table legends for more details). The amplicons 
were amplified using either Promega GoTaq Hot Start Green (Promega, Madison, WI) 
or Qiagen HotStarTaq DNA Polymerase (Table 12). The product size and specificity 




Table 10: Genes screened for hotspot mutations.  

















SF3B1 30% Exon 12-16 Shows 99% of SF3B1 somatic mutations in haematopoietic neoplasms within this region (344 mutant /2668 sequenced samples) 
SRSF2 15% Exon 1 Shows 100% of SRSF2 somatic mutations in haematopoietic neoplasms within this region (279 mutant /1872 sequenced samples) 
ASXL1 15% Exon 12 Shows 99% of ASXL1 somatic mutations in haematopoietic neoplasms within this region (472 mutant / 3590 sequenced samples) 
U2AF1 12% Exon 2, 6 Shows 99% of U2AF35 somatic mutations in haematopoietic neoplasms within this region (96 mutant /1518  sequenced samples) 
FLT3 6% Exon14, 15 Shows 100% of FLT3 somatic mutations in haematopoietic neoplasms within this region (11816 mutant /51551 sequenced samples) 
NRAS 3.6% Exon 2, 3 Shows 99% of NRAS somatic mutations in haematopoietic neoplasms within this region (676 mutant /6473 sequenced samples) 
JAK2 3% Exon12, 14 Shows 100 % of JAK2 somatic mutations in haematopoietic neoplasms within this region (32218 mutant /76213 sequenced samples) 
CCBL 2.3% Exon 7, 8, 9 Shows 99% of CCBL somatic mutations in haematopoietic neoplasms within this region (163 mutant /3577  sequenced samples) 
IDH2 2.1% Exon 4 Shows 100 % of IDH2 somatic mutations in haematopoietic neoplasms within this region (905 mutant /13777 sequenced samples) 
NPM1 1.8% Exon 12 Shows ≥ 97 % of NPM1 somatic mutations in haematopoietic neoplasms within this region (4181 mutant /14167 sequenced samples) 
IDH1 1.4% Exon 4 Shows 100 % of IDH1 somatic mutations in haematopoietic neoplasms within this region (778 mutant /16301 sequenced samples) 
KRAS 0.9% Exon 2, 3 Shows >97% of KRAS somatic mutations in haematopoietic neoplasms within this region (152 mutant /3716 sequenced samples) 
BRAF 0.5% Exon 11, 15 Shows 100 % of BRAF somatic mutations in haematopoietic neoplasms within this region (6 mutant /581 sequenced samples) 
MPL Rare Exon 10 Shows ≥ 97 % of MPL somatic mutations in haematopoietic neoplasms within this region (534 mutant /14202 sequenced samples) 
C-KIT Rare Exon 17 Shows 40 % of C-KIT somatic mutations in haematopoietic neoplasms within this region (1672 mutant /7734 sequenced samples) 
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Table 11: PCR reagents and concentrations used to make master-mix A and master-
mix B.  
Master-mix A was used to amplify ZRSR2, TP53, DNMT3A, EZH2, TET2, SF3B1, U2AF1, 
ASXL1, CBL, FLT3, NRAS, KRAS, JAK2 exon12/14, IDH1, IDH2, BRAF, MPL, KIT and NPM1.  
Master-mix B was used to amplify SRSF2, RUNX1 and CEBPA. 
Reagent Volume per reaction (µl) 
MASTER MIX A 
Nuclease Free H2O 3   
Hot start Go-taq master mix 5  
DNA (@5ng/µl) 3   
Primer (@ 5 uM) 1   
Total volume 10  
MASTER MIX B 
Nuclease Free H2O 2.55  
Buffer 1  
MgCl2 1  
DMSO 0.75  
dNTP Mix 0.5  
Taq 0.2  
Primer (@ 5 uM) 1  
DNA(@5ng/µl) 3  
Total volume 10  



























Table 12: Thermal cycler conditions used for the PCR. 
Program A was used for ZRSR2, TP53, DNMT3A, EZH2 , TET2, SF3B1, U2AF1, ASXL1, 
CBL, FLT3, NRAS, KRAS, JAK2 exon12/14, IDH1, IDH2, BRAF, MPL, KIT and NPM1. 
Program B was used SRSF2, RUNX1 and CEBPA. 
Steps Temperature Time 
Program A 
Step 1 - Denaturation 95 °C 5 Minutes 
Step 2 - Denaturation 95 °C 35 Seconds 
Step 3 - Annealing 60 °C 40 Seconds 
Step 4 - Extension 72 °C 45 Seconds 
 Repeat Step 2 through step 4 for a total of 35 cycles 
Step 5 - Final Extension 72 °C 15 Minutes 
Step 6 - Hold 4 °C hold 
Program B 
Step 1 - Denaturation  95°C 2   Minutes 
Step 2 - Denaturation  95°C 35 Seconds 
Step 3 - Annealing  60°C 40 Seconds 
Step 4 - Extension  68°C 45 Seconds 
 Repeat Step 2 through step 4 for a total of 35cycles 
Step 5 - Final Extension  68°C 15 Minutes 
Step 6 - Hold 4 °C hold 
 
Second round PCR was then performed on 1 to 1.5µl of the ampliﬁed product obtained 
from the first round PCR (Table 11 & Appendix Table 12). This second round PCR is 
used to incorporate different 20 to 30bp multiple-identifiers (MIDs) within the DNA 
template for the identification of each patient (Figure 11). Patient-specific “barcodes” 




               
Figure 11: Multiple identifier (MID) primer design used in second round PCR.  
Common bi-directional 454 specific primer sequences required for 454 sequencing are 
incorporated within the MIDs (A=forward; B=reverse). “MID-454 A” primers are targeted to 
UaS1 and “MID-454 B” primers are targeted to UaS2 in the second round PCR. 
 
The concentration of all gene amplicons (second round PCR) for 5 randomly selected 
patients was measured by using the Quant-iT pico-green dsDNA assay kit as 
described previously in section 2.2.2. Based on the concentrations obtained from 
picogreen assay, all amplicons for each patient were pooled in one reaction. Following 
on, all patient mixes were measured by using the Quant-iT pico-green dsDNA assay 
kit as described previously in section2.2.2. Subsequently, upto 30 patient mixes were 
pooled together in equal concentrations. All pooled PCR libraries were purified using 
the Agencourt AMpure XP beads as described previously in section 2.2.4.2 and then 
quantitated using the Quant-iT picoGreen dsDNA assay kit as described previously in 
section 2.2.2. Pooled libraries were further processed for sequencing in a batch-wise 
manner. Each pooled PCR library was diluted in nuclease free H2O till the final 
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concentration of 1 x107 molecules/µl was reached. 10µl to 12µl of diluted DNA library 
was subsequently used in the next step (Emulsion PCR). 
2.2.5.2 Emulsion Based Clonal Amplification (emPCR) of DNA Library 
Amplicons 
GSFLX Titanium LV emPCR Kits (Roche 454 Life Sciences) were used to perform the 




Figure 12: Schematic representation of emulsion based clonal amplification. 
 
DNA capture beads-A (with forward primer) and -B (with reverse primer) were washed 
twice with 1ml of 1x capture bead wash buffer TW (Roche 454 Life Sciences). After 
the second wash, beads were resuspended in 100μl 1x capture bead wash buffer TW. 
10µl to 12μl of the pooled DNA library (concentration 1x107 molecules/μl) was added 
to each DNA capture beads-A and -B tubes. 
Two cups containing the emulsion oil/mock amplification mix were placed on the tissue 
lyser (Qiagen) and shaken for 5 minutes at 28 strokes/sec. 4mls of live amplification 
mix A/B (Appendix Table 13), DNA library A/B and DNA capture beads A/B were 
added to each premixed oil/mock amplification mix emulsion cup. The cups were 
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loaded on the tissue lyser and shaken for 5 minutes at 12 strokes/sec. The emulsion 
(containing DNA library and DNA capture beads) from each cup was then dispensed 
into the 96 well PCR plate. Four 96 well PCR plate containing the emulsified 
amplification reactions were loaded on the ABI 9700 and subjected to PCR (Appendix 
Table 14). 
Emulsions containing the DNA beads with amplified DNA were processed using the 
GS FLX Titanium emPCR breaking kit and breaking reagents (Roche 454 Life 
Sciences). 100µl of isoproponol (100%) was added to each PCR plate well containing 
the emulsions and then the assembled vaccum/breaking manifold was used to draw 
the emulsion-isoproponol mix from all 4 plates into four 50ml tubes. 96 well PCR plates 
were washed three times with 100μl of 2-isopropanol (100%, v/v). Amplified DNA 
capture bead-A and -B libraries were mixed at this stage and the 50ml tubes were 
centrifuged at 1000xg for 10 minutes. The supernatant was discarded and the 
amplified DNA capture beads were washed with enhancing fluid (EF), 100% (v/v) 
isopropanol, 100% (v/v) ethanol and then with EF, in a stepwise manner with a 
centrifugation (@ 950xg) step in-between each wash. In order to denature the double 
stranded DNA, 1ml fresh melt solution (19.5mls of molecular grade water + 500μl of 
5M NaOH) was added to the amplified DNA capture beads, followed by vigorous 
vortexing and centrifugation. After repeating it one more time, amplified ssDNA 
capture beads (single stranded DNA capture beads) were washed twice by adding 
1ml of annealing buffer-XT, followed by centrifugation. Following on, amplified ssDNA 
capture beads were resuspended in 45µl of annealing buffer-XT. 12.5µl of enrichment 
primer A and 12.5µl of enrichment primer B were added to each 1.5mls tube, followed 
by incubation at 65°C on a heating block for 7 minutes to enable primer annealing. 
Following on, tubes were placed on ice for 2 minutes. Amplified ssDNA capture beads 
were washed 3 times by adding 1ml of ET, followed by centrifugation. Beads were 
resuspended in 800µl of EF.  80μl of previously washed enrichment beads were added 
to the amplified DNA capture beads, followed by vortexing for 1 minute. The tubes 
were incubated at room temperature on a lab rotator for 30 minutes. After incubation, 
bead mixture was transferred into a 15mls tubes and placed on the MPC for 5 minutes. 
The supernatant was discarded and the beads were washed 10 to 14 times with 1ml 
to 3mls of EF, till a clear supernatant was observed. The beads were resuspended in 
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1ml of melt solution (19.5ml of molecular grade water + 500μl of 5M NaOH) and 
vortexed for 30 seconds. The tubes were placed on the MPC for 5 minutes and the 
supernatant containing the enriched amplified ssDNA capture beads was transferred 
into a fresh 1.5ml eppendoff tube. Enriched amplified ssDNA capture beads were 
washed 3 times by adding 1ml of annealing buffer XT, followed by centrifugation. 200µl 
of annealing buffer, 25μl of sequencing primer A and 25μl of sequencing primer B was 
added to each tube with enriched amplified ssDNA capture beads, followed by 
incubation at 65°C on a heating block for 7 minutes to enable primer annealing. 
Following on, tubes were placed on ice for 2 minutes. ssDNA capture beads were 
washed 3 times by adding 1ml of annealing buffer-XT, followed by centrifugation at 
3000xg for 2 minutes. The bead pellet was resuspended in 1ml of annealing buffer-XT 
and stored at +4°C. 
2.2.5.3 Sequencing/Genome Sequencer 454/FLX setup 
The sequencing was performed on Roche/454 FLX Sequencer and all the reagents 
were supplied by the Roche diagnostics (Roche 454 Life Sciences).  
The picotiter-plate (PTP) was submerged in bead buffer2. Enriched DNA capture 
beads were mixed with DNA bead incubation enzyme mix and incubated for 30 
minutes. DNA capture beads, packing beads, enzyme beads and PPiase beads were 
loaded on the PTP in a step wise manner (Figure 13). The PTP was loaded on the 
Roche/454 FLX sequencer and after performing the required checks on the 








Figure 13: Depositing DNA beads into the PTP device.  
One side of the PTP is polished and the other side of the plate contains wells that are 75 
picoliters in volume and 44µm in diameter. Each PTP comprises 1.6 million wells. The 
diameter of the wells is designed so that only a single capture bead will fit into each well. 
Single DNA capture beads are held within the PTP wells by the packing beads. Enzyme 
containing beads that catalyse the downstream pyrosequencing reaction steps are also added 
to the PTP. 
During the sequencing run, as a result of the nucleotide and other enzyme flow from 
the fluidics system on top of the PTP, hundreds of thousands of beads embedded 
within the PTP apertures with each bead carrying millions of copies of a unique sstDNA 
molecule are sequenced in parallel (Figure 13). The combination of signal intensity 
and positional information generated across the PTP is captured by the charge 
coupled device (CCD) camera device. These raw reads are processed by the 
Roche/454 FLX  analysis software and then filtered by various quality filters to remove 
poor-quality sequences, mixed sequencing reads (generated as a result of more than 
one initial DNA fragment per bead), and sequences without the initiating sequence 





          
Figure 14: Roche/454 FLX Sequencing technology. 
In pyrosequencing, incorporation of a nucleotide by DNA polymerase results in the release of 
pyrophosphate and each incorporation reaction is accompanied by release of pyrophosphate 
(PPi). ATP sulfurylase quantitatively converts PPi to ATP in the presence of adenosine 5/ 
phosphosulfate. This ATP drives the luciferase-mediated conversion of luciferin to oxyluciferin 
that generates visible light proportional to the amount of ATP. The light generated in the 
luciferase-catalysed reaction is detected by a CCD camera and seen as a peak in a pyrogram. 
Each light signal is proportional to the number of nucleotides incorporated. 
 
2.2.5.4 Roche targeted amplicon data analysis 
Data analysis was performed using GS Amplicon variant analyser software (Roche 454 
Life Sciences). An analysis project was generated by importing the reference gene 
sequences (Ensembl), primer sequences of all the sequenced genes and the 
sequences of all the MIDs used in the amplification process into the GS Amplicon 
variant analyser software (Roche, Germany). The data generated by the Roche/454 
FLX sequencer was imported into the analysis project, followed by demultiplexing and 
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subsequently aligning the data to the reference sequence of the genes present on the 
AML gene panel. Following on, a list of variants was generated for further validation.   
2.2.6 MiSeq Amplicon Sequencing  
2.2.6.1 Library Preparation 
PCR amplicon libraries were prepared by using the first round PCR protocol as 
described in section 3.2.4.1. Following on, PCR libraries were purified and quantified 
as described previously in section 2.2.4.2 and section 2.2.2, respectively. The product 
size and specificity for amplicons was also confirmed by gel electrophoresis. Patient 
specific PCR amplicons were normalized and mixed in batches. Following on, all 
patient mixes were measured by using the Quant-iT pico-green dsDNA assay kit as 
described previously in section 2.2.2. Pooled libraries were further processed for 
sequencing in a batch-wise manner. Each pooled patient amplicon libraries was 
diluted in nuclease free H2O till the final concentration of 0.2 ng/µl was reached. Diluted 
patient amplicon libraries were subsequently used in the next step.  
Following on, transposon-based Illumina Nextera technology (Illumina, UK) was used 
to prepare the Illumina sequencing libraries. The Nextera-XT DNA Sample Preparation 
Kit was used to prepare sequencing libraries by following the manufacturer’s protocol 
(with modifications). 1.25µl (0.25ng) of each pooled patient amplicon library (0.2ng/µl) 
was transferred to a new 96 well PCR plate (PCR plate). 2.5µl of tagment DNA (TD) 
buffer and then 1.25µl of amplicon tandem mix (ATM) was added to each PCR well, 
respectively. Library mixtures were mixed by using multichannel pipette, followed by 
centrifugation @ 280xg for 1 minute.  PCR plate was incubated at 55°C (5 minutes) 
and then 4°C (2 minutes). Following on, 1.25µl of neutralize tagment (NT) buffer was 
added to each mixture in the PCR plate. Samples were incubated at room temperature 
for 7 minutes. 3.75µl of nextera PCR master mix (NPM) was added to each well of the 
PCR plate. 1.25µl of index-1 primer and 1.25µl of index-2 primer was added to each 
well in the PCR plate. These dual indexes allow multiplexing of 96 samples 
independent sequencing experiments (patient specific amplicons) utilizing Nextera-
amplicon methodology.  Following on, mixtures were mixed by using multichannel 
pipette, followed by centrifugation @280xg for 1 minute. PCR amplification was 
performed as mentioned in Table 13. Amplified libraries were purified using Agencourt 
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AMpure XP beads as described in section 2.2.4.2. DNA samples were eluted in 50µl 
of nuclease free H2O.  
Following on, all patient mixes (post nextra amplification) were measured by using the 
Quant-iT pico-green dsDNA assay kit as described previously in section 2.2.2. 
Subsequently, patient libraries were pooled together in equal concentrations. Pooled 
patient libraries were purified using the Agencourt AMpure XP beads as described 
previously in section 2.2.4.2 and then quantitated using the Quant-iT picoGreen 
dsDNA assay kit as described previously in section 2.2.2. Libraries were sequenced 
on the Illumina MiSeq platform utilizing version 2 chemistry with 150-250 paired-end 
reads.  
Table 13: Thermal cycler conditions used for the Nextra-PCR. 
Steps Temperature Time 
Step 1  72 °C 3 Minutes 
Step 2  95 °C 30 Seconds 
Step 3  95 °C 10 Seconds 
Step 4  55 °C 30 Seconds 
Step 5 72 °C                                                                 30 Seconds 
 Repeat Step 3 through step 5 for a total of 12 cycles 
Step 5 - Final Extension 72 °C 5 Minutes 
Step 6 - Hold 4 °C hold 
 
2.2.6.2 MiSeq data analysis 
All the data analysis was performed by on-board MiSeq data analysis pipeline. Illumina 
RNASeq 2000 Real Time Analysis (RTA) software generates the *.bcl files during the 
sequencing run. *.bcl files were de-multiplexed and converted to fastqfiles. Sequence 
alignment to the human target reference genes (NCBI37/Hg19) and variant calling for 
SNPs/Indels was performed via Burrows-Wheelers aligner (BWA) (Li and Durbin, 
2009) and GATK (McKenna et al., 2010) pipeline. Processed VCF and BAM files were 
visualized using variant studio (Illimina) and integrated genome viewer (IGV), 
respectively. Candidate variants obtained were passed for validation if the variants 
were deemed to cause protein changes and not found in dbSNP142, esp5400 and 




2.2.7 Sanger Sequencing 
Target genes were amplified (first round PCR) as mentioned in section 2.2.5.1. 
Amplified PCR product was purified using Agencourt AMpure XP beads as described 
previously in section 2.2.4.2. Following on, cycle sequencing PCR was performed  by 
using purified first round PCR product (5ng to 20ng), big dye enzyme master-mix, 5x 
sequencing buffer, (Applied Biosystems) aUS1 (forward) and aUS2 (reverse) 
sequencing primers (Table 14 and Table 15). The PCR product was purified with 
BigDye X-TerminatorTM purification kit (Applied Biosystems). 45ul of SAM solution and 
10µl of X-terminator solution were added to the 10µl PCR product. The plate was 
incubated at room temperature on a shaker for 30 minutes, followed by centrifugation 
at 1000xg for 2 minutes. The plate was then loaded on the ABI 3130xl Genetic 
Analyser and the sequencing program was set up by using the manufacturer’s 
protocol. Data was analysed for mutations by using Applied Biosystems SeqScape® 
software v2.6. 
 Table 14: PCR reagents used to make master-mix. 
Reagent Volume per reaction 
5x Sequencing buffer  2 µl  
Big Dye enzyme 0.5 l 
Primer (5 M)  1 l 
Nuclease free H2O as required 
DNA template 15 ng 
Final Volume  10 l 













  Table 15: Thermal cycler conditions used for the PCR. 
Steps Temperature Time 
Step 1   - Denaturation 96 °C 1 Minutes 
Step 2   - Denaturation 96 °C 10 Seconds 
Step 3   - Annealing 55 °C 5 Seconds 
Step 4   - Extension 60 °C 75 Seconds 
Repeat Step 2 through step 4 for a total of 15 cycles 
Step 5   - Denaturation 96 °C 10 Seconds 
Step 6   - Annealing 55 °C 5 Seconds 
Step 7   - Extension 60 °C 90 Seconds 
Repeat Step 5 through step 7 for a total of 5 cycles 
Step 8   - Denaturation 96 °C 10 Seconds 
Step 9   - Annealing 55 °C 5 Seconds 
Step 10 - Extension 60 °C 120 Seconds 
Repeat Step 8 through step 10 for a total of 5 cycles 
Step  12 Hold 10 °C Infinite 
   
 
2.2.8 Isolation of human haematopoietic stem cells and mature progenitors  
2.2.8.1 Mononuclear cell separation  
Mononuclear cells (MNCs) were separated from patient bone marrow sample by 
density gradient sedimentation with Histopaque-1077 (Sigma).  Briefly, bone marrow 
sample was transferred into a 50ml tube containing the same volume of Histopaque-
1077 (1:1 ratio). Bone marrow cells were centrifuged at 450xg for 20 minutes. MNCs 
were harvested from the histopaque/plasma interface and transferred into a new 5ml 
round-bottom tube. MNCs were washed twice with AutoMACS running buffer (Miltenyl 
Biotec), centrifuged at 300xg for 10 minutes and finally counted. Up to 1x108 MNCs 
were resuspended in 350µl of auto MACS running buffer and subsequently used for 
immunomagnetic enrichment of CD34+ and CD34- cells using magnetic activated cell 
sorting technology (Miltenyl Biotec). 
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2.2.8.2 CD34+ and CD34- cell selection by Magnetic activated cell sorting 
(MACS)   
First, the CD34+ cells were magnetically labelled with CD34 MicroBeads (Miltenyl 
Biotec). 100µl of FcR blocking reagent (Miltenyi Biotec) and 50µl of CD34 micro beads 
(Miltenyi Biotec) were added to MNCs (up to 1 x 108 cells), followed by vortexing. 
MNCs were incubated for 15 minutes at 4ºC. 3ml of AutoMACS running buffer was 
added to CD34 bead cell suspension. The magnetically labelled CD34 cell suspension 
was loaded onto a MACSR column in the MACS separator. Posseld program was 
used to isolate CD34+ cells from MNCs suspension.  The magnetically labelled CD34+ 
cells are retained within the MACS column. The unlabelled cells run through; this cell 
fraction is thus depleted of CD34+ cells and only contained CD34- cells. After removing 
the column from the magnetic field, the magnetically retained CD34+ cells can be 
eluted as the positively selected cell fraction. The Posseld program increases the 
purity of CD34+ cells by enriching the CD34+ cells twice during the separation process. 
Both cell populations (CD34+ and CD34- cells) were washed twice by adding 1ml of 
FACS wash buffer (PBS, 2% FCS) , followed by centrifugation at 300xg for 10 minutes 
and resuspended in 1ml of FACS wash buffer. Cells were counted and then stored on 
ice. CD34+ cells were centrifuged at 300xg for 10 minutes and then supernatant was 
discarded. CD34+ cells were either processed for haematopoietic stem cell separation 
using FACS or stored at -20ºC. Previous studies have reported that a purity of ≥94% 
can be achieved with this isolation method (Bonanno et al., 2009; Giarratana et al., 
2005).  
CD34- cells were divided into two aliquots. One aliquot was processed for FACS 
experiment and another aliquot was used for enrichment of CD235+ and CD235- cells 
using MACS. 10x106 CD34- cells were used for MACS separation. Cells were 
centrifuged at 300xg for 10 minutes and then supernatant was discarded. 20µl of CD3 
micro beads (Miltenyl Biotec)and 80µl of FACS wash buffer was added to CD34- cells 
(up to upto 1 x 107 cells), followed by vortexing and incubating for 15 minutes at 4ºC. 
3ml of AutoMACS running buffer was added to CD3 cell suspension. The magnetically 
labelled CD3+ cell suspension was loaded onto a MACS column in the MACS 
separator. Possel program was used to isolate CD3+ cells from CD34- cell suspension. 
CD34-CD3- cells were centrifuged at 300xg for 10 minutes and then supernatant was 
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discarded. 20µl of CD235a micro beads (Miltenyl Biotec) and 30µl of FACS wash 
buffer was added to the CD34-CD3- cells, followed by vortexing and incubating for 15 
minutes at 4ºC. 1ml of AutoMACS running buffer was added to CD34-CD3- cell 
suspension. The magnetically labelled cell suspension was loaded onto a MACS 
column in the MACS separator. Possel program was used to isolate CD34-CD3-
CD235+ and CD34-CD3-CD235- cells from CD34-CD3- cell suspension. CD34-CD3-
CD235- cells were centrifuged at 300xg for 10 minutes, supernatant was discarded 
and cells were stored as viable cells at -20ºC. 
2.2.8.3 Fluorescent activated cell sorting cell sorting (FACS) - Antibodies, 
Staining and cell sorting  
MACS purified CD34+ and CD34- cells were washed twice by adding 1ml of FACS 
wash buffer, followed by centrifugation at 300xg for 10 minutes. Both cell fractions 
were stained either with antibodies present in antibody panel A (Table 16) or antibody 
panel B (Table 17) or antibody panel C (Table 18). Appropriate amount of PBS was 
added to the tubes to make a final volume of 100µl. Cells and antibodies were 
incubated for 30 minutes in the dark at 4ºC. Cells were then washed twice by adding 
1ml of FACS wash buffer, followed by centrifugation at 300xg for 10 minutes. 
Supernatant was discarded and cells were resuspended in PBS @4ºC at 5x106 
cells/ml. Propidium iodide (PI) was added to the cell suspension prior to sorting to 
exclude dead cells. Cells were then placed on ice and were analysed within 1 hour on 














Table 16: Tables showing antibodies and the flourchromes used for FACS analysis. 
Antibody Panel A 





(up to 108 cells) 
 Anti-Human CD135 (Flt3)  PE 12-1357-41 eBioscience 5µl 
Anti-Human CD45  APC-eF® 780 47-0458-41 eBioscience 5µl 
Anti-Human CD38  APC 17-0389-41 eBioscience 5µl 
Anti-Human CD34  PE-Cy7 25-0349-41 eBioscience 5µl 
Anti-human CD45RA  BV510™ 304141 Biolegend 5µl/106 
Anti-human CD90  AF700 328119 Biolegend 2µl/106 
Anti-Human/Mouse CD49f     
    (Integrin alpha 6) 
FITC 11-0495-80 eBioscience 1µl 
Negative Lineage Antibodies 
Anti-Human CD2 Biotin 13-0029-80 eBioscience 1µl 
Anti-Human CD3 Biotin 13-0037-80 eBioscience 1µl 
Anti-Human CD14 Biotin 13-0149-80 eBioscience 2µl 
Anti-Human CD16 Biotin 13-0168-80 eBioscience 1µl 
Anti-Human CD19 Biotin 13-0199-80 eBioscience 1µl 
Anti-Human CD24 Biotin 13-0247-80 eBioscience 1µl 
Anti-Human CD56 Biotin 13-0567-80 eBioscience 1µl 
Anti-Human CD235a Biotin 13-9987-80 eBioscience 1µl 
 Anti-Human CD66b     V450 561649 BD 5µl 
Streptavidin     EF® 450 48-4317-82 eBioscience 1µl 
 
Table 17: Tables showing antibodies and the flourchromes used for FACS analysis. 
Antibody Panel B  
Cell Surface     
marker  
 
Flourochrome Catalogue  
 number 
Manufacturer Volume 
(up to 108  
cells) 
Anti-Human CD34 APC unknown eBioscience 5µl 
Anti-Human CD71 PE unknown eBioscience 5µl 
Anti-Human CD235 FITC unknown eBioscience 5µl 
Negative Lineage Antibodies 
Anti-Human CD2 Biotin 13-0029-80 eBioscience 1µl 
Anti-Human CD3 Biotin 13-0037-80 eBioscience 1µl 
Anti-Human CD14 Biotin 13-0149-80 eBioscience 2µl 
Anti-Human CD16 Biotin 13-0168-80 eBioscience 1µl 
Anti-Human CD19 Biotin 13-0199-80 eBioscience 1µl 
Anti-Human CD24 Biotin 13-0247-80 eBioscience 1µl 
Anti-Human CD56 Biotin 13-0567-80 eBioscience 1µl 
Anti-Human CD66b V450  561649 BD 5µl 




Table 18: Tables showing antibodies and the flourchromes used for FACS analysis. 
Antibody Panel C 
Cell Surface marker  
 
Flourochrome Manufacturer Volume 
(up to 108 cells) 
Anti-Human CD34 PE-Cy7 eBioscience 5 µl 
Anti-Human CD3 PE BD 5 µl 
Anti-Human CD4 EF450 BD 5 µl 
Anti-Human CD19 APC BD 5 µl 
 
The BD FACS Aria I (San Jose, CA) system is a four-color sorter, with 5 lasers and 15 
detectors capable of both cell analysis and cell sorting. Fluorescently labelled cells 
were then analysed using dot plots measuring forward versus side scatter. Using the 
appropriate flow cytometry values, our cell populations of interest within the stem cell 
compartment were defined by hierarchical gating which was largely similar to the one 
used by Notta et al (Notta et al., 2011); HSCs as Lin-CD45+CD34+CD38-CD45RA-
CD90+CD49f+, MPPs as Lin-CD45+CD34+CD38-CD45RA-CD90-CD49f-, GMPs as Lin-
CD45+CD34+CD38+CD135+ CD45RA+ and MEPs as Lin-CD45+CD34+CD38+CD135-
CD45RA- (Figure 15). In addition, mature erythoid and lymphoid cells were also 
isolated by gating for specific cell surface markers such as Lin-CD34-CD235+CD71+, 
Lin-CD34-CD235+CD71-, Lin-CD34-CD71+, Lin-CD34-CD235+ (Figure 16), CD34-
CD3+, CD34-CD3+4+ and CD34-CD19+ (Figure 17). After sorting, the purity of all the 
cell fractions was checked and a sorting purity of ≥97% was routinely obtained. FACS 
sorted cells were centrifuged at 450xg for 10 minutes and then supernatant was 





Figure 15: Representation of the isolated hematopoietic stem cell subpopulations. 
Viable lineage negative CD34+ cells were defined by hierarchical gating on a combination of 
forward (FSC) and side scatter (SSC), propidium iodide (not shown), CD45 and a lineage 
cocktail. These CD34+ cells were further gated first into CD34+CD38- and CD34+CD38+ 
populations and then subdivided into either HSCs (CD34+CD38-CD90+CD45RA-CD49f+) and 
MPPs (CD34+CD38-CD90-CD45RA-CD49f-) or into GMPs (CD34+CD38+CD135+CD45RA+) 
and MEPs (CD34+CD38+CD135-CD45RA). 
 
 
Figure 16: Representation of the isolated cell populations.  
CD34-CD3-CD235+CD71+ and CD34-CD3-CD235+CD71- cells were defined by gating on a 






Figure 17: Representation of the isolated cell populations.  
CD34-CD3+, CD34-CD3+CD4+ and CD34-CD3-CD4-CD19+ were defined by gating on a 
combination of forward (FSC) and side scatter (SSC), propidium iodide (not shown). 
 
2.2.9 Statistical analysis 
The characteristics of the study population were studied with appropriate statistical 
methods (Mann-Whitney test for continuous variables and Fisher’s exact test for 
categorical variables) comparing patients with specific mutation versus cases without 
mutation. Clinical characteristics, survival and time to progression to AML were 
updated to January 2012 and measured from time of sample collection (N=123) or 
diagnosis (N=31) at Kings College Hospital. The median disease duration prior to 
sample analysis for 123 patients was 11 months (range 1-119 months), during this 
period 29 patients showed disease progression (upstaging of WHO category) of which 
10 were treated with either with intensive chemotherapy or 5-azacitidine. 
The Kaplan-Meier estimate was used to evaluate time to survival and time to 
progression. The log-rank test was used to assess potential differences in outcome 
between subgroups. A p-value of ≤0.05 was considered statistically significant. 
Prism Version 6 software (GraphPad) was also used for statistical analysis. Data is 
presented as the mean ± S.E.M. Statistical analysis was performed using the two-




2.2.10 NSG Xenotransplant Assay 
MNCs were isolated from the bone marrow cells by centrifugation using Ficoll-PaqueTM 
PLUS (GE Healthcare Life Sciences, Buckinghamshire, UK). The cells were 
processed within 24 hours following collection using an Easysep Human CD34 
positive selection kit and Easysep magnet (StemCell Technologies, Vancouver, 
Canada) according to the manufacturer's instructions. 1 ml of RoboSep buffer was 
added to MNCs (up to 5 x 108 cells). Following on, 100µl of EasySep® Positive 
Selection Cocktail was added to the MNCs. Cell mixture was mixed and incubated for 
15 minutes at room temperature. 50µl of EasySep® magnetic nanoparticles was 
added to the MNCs and mixture was incubated for 10 minutes at room temperature.  
After incubation, tube containing the MNC/bead mixture was placed on the magnet for 
5 minutes. The supernatant was discarded and the beads were washed 4 times with 
1ml of buffer. Following on, enriched CD34+ cells were resuspended PBS.   
NSG mice were a kind gift of Dr Leonard Shultz (The Jackson Laboratory). All animal 
experiments were performed in accordance to Home Office and CRUK guidelines. 
Prior to transplantation, mice received a sub-lethal dose of radiation (330-375 cGy) 
from a cesium-137 source. Direct intra–bone marrow injection was performed in the 
mouse tibia with 0.65x105 to 2x105 human bone marrow CD34+ cells from patients and 
healthy donors. 
Engraftment was assessed over time by intra-tibia aspiration under isoflurane 
anaesthesia and the bone marrow was immunophenotyped by the presence of 
mCD45-, hCD45+, CD33+, CD19+ and CD3+ (using anti-mouse and anti-human 
antibodies from BD Biosciences, Oxford, UK) cell populations. After 18-20 weeks, 
mice were terminated and cells were harvested from pooled bone marrow (femurs, 
tibias, pelvis and/or spine). Live cells were stained and sorted on hCD45+ phenotype 
using FACS Aria SORP (BD Biosciences, Oxford, UK). Sorted cells were washed in 
PBS and harvested in order to later perform genomic analysis. All the xenograft 
experiments were performed by Dr Kevin Rouault-Pierre.  
2.2.11 Single cell clonogenic assay 
Five hundred cells from the bone marrow CD34+enriched fraction were plated in 
triplicate in 0.5 mL of MethoCult H4434 (StemCell Technologies, Vancouver, Canada) 
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in 24 wells tissue culture dishes to assess colony-forming units. At day 14 of culture, 
the numbers of colonies were scored. Cells were picked, harvested and washed twice 
with PBS before analysis. Single cell colony images were acquired with a Zeiss 
AxioVert 40 CFL microscope using 5X lens and connected to Canon PowerShot A640 
digital camera. Single colonies were picked using a Zeiss AxioVert 40 CFL 
microscope, 10l tips were used to aspirate the colonies which were then resuspended 
in 10l of PBS in 96 well plate maintain on ice. 
All colonies were subjected to whole-genome amplification (Single cell WGA, Sigma-
Aldrich) as described in section 2.2.13. All colony forming cell (CFC) colonies were 
screened for SF3B1 and additional patient specific point mutations. Amplicon libraries 
were amplified through PCR using the primers specific to gene mutations and 
subjected to Nextra-Illumina sequencing as described in section 2.2.6. Gene mutation 
for each single colony was called when >30% of the sequencing reads were carrying 
a mutant allele.  
2.2.12 Long-term colony Assay 
LTC assays were performed by plating 103 CD34+ bone marrow cells in quadruplets 
on irradiated MS-5 murine stromal cells and cultured in Myelocult H5100 (StemCell 
Technologies, Vancouver, Canada) in the presence of cytokines (20 ng/ml G-CSF, 
20ng/ml IL-3, and 20 ng/ml TPO from PeproTech, London, UK). After 5 weeks, live 
cells were stained and sorted on human CD45+ phenotype using the FACS Aria SORP 
(BD Biosciences, Oxford, UK). Sorted cells were washed in PBS, harvested and stored 
as cell pellet and/or resuspended in Karnoy’s solution in order to later perform FISH 
analysis. These LTC experiments were performed along with Dr Kevin Rouault-Pierre. 
2.2.13 Whole-genome Amplification  
Whole Genome amplification (WGA) of cells was performed with GenomePlex Single 
Cell Whole genome amplification kit (WGA4, Sigma-Aldrich Co, LLC) and/or 
GenomePlex SeqPlex XE kit (SEQXE, Sigma-Aldrich Co, LLC). WGA amplification 
was performed according to the instructions of the manufacturer, along with a no cell 
reaction as a negative control and a reaction of human tissue genomic DNA as positive 
control. For patient samples where only one mouse was used in in-vivo experiments, 
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two independent amplification experiments were performed using two different 
amplification kits (i.e. Sigma WGA4 and Sigma SEQXE). In addition, HSCs and MPPs 
for all patient samples were also amplified by two different amplification kits (Sigma 
WGA4 and Sigma SEQXE) while as GMPs and MEPs were amplified by using Sigma 
SEQXE WGA kit.  
2.2.13.1 Whole genome amplification (WGA4) 
Cells were diluted in 9l of nuclease free H2O. 1x Lysis and fragmentation buffer 
solution was prepared by adding proteinase-K solution and 10x single cell lysis and 
fragmentation buffer (ratio 1:8). 1µl of the freshly prepared proteinase-K solution-10x 
single cell lysis and fragmentation buffer was added to the cells. Samples were mixed 
and incubated in a thermal cycler at 50°C for 1 hour, then heated to 99°C for four 
minutes. Following on, cells were kept on ice for 5 minutes and then subjected to 
centrifugation at 300xg for 1 minute. 2µl of 1x single cell library preparation buffer and 
1µl of library stabilization solution was added to each well containing the cells. 
Samples were mixed thoroughly, centrifuged (300xg for 1 minute) and place in thermal 
cycler at 95°C for 2 minutes, then cooled to 4°C for 2 minutes. 1µl of library preparation 
enzyme was added to the cells. Cells were incubated in the thermal cycler at the 
following temperature; 16°C for 20 minutes, 24°C for 20 minutes, 37°C for 20 minutes, 
75°C for 5 minutes and then cooled to 4°C  for 5 minutes. Following on, amplification 
master mix (7.5µl of 10x amplification master mix, 48.5µl of nuclease free H2O and 
5.0µl of WGA DNA polymerase) was added to each well containing the cells. Samples 
were mixed thoroughly, centrifuged briefly, and incubated in thermos cycler (Table 19). 
After cycling was complete, WGA samples were purified as described in section 








Table 19 : Thermocycler conditions used for PCR amplification 
Steps Temperature Time 
Step 1 - Denaturation 95 °C 3 Minutes 
Step 2 - Denaturation 94 °C 30 Seconds 
Step 3 – Annealing/ Extension 65 °C 5 minutes 
 Repeat Step 2 through step 3    
for a total of 25 cycles 
 
Step 4 – Hold  4 °C α 
 
2.2.13.2 Whole genome amplification (SEQXE) 
Cells were diluted in 9l of nuclease free H2O. 1x lysis and fragmentation buffer 
solution was prepared by adding proteinase-K solution (WGA4) and 10x single cell 
lysis and fragmentation buffer (WGA4, ratio 1:8). 1µl of the freshly prepared 
proteinase-K solution-10x single cell lysis and fragmentation buffer was added to the 
cells. Samples were mixed and incubated in a thermal cycler at 50°C for 1 hour, then 
heated to 99°C for four minutes. Following on, cells were kept on ice for 5 minutes and 
then subjected to centrifugation at 300xg for 1 minute. 2µl of 1x library preparation 
buffer and 1µl of nuclease free H2O was added to each well containing the cells. 
Samples were mixed thoroughly, centrifuged (300xg for 1 minute) and place in thermal 
cycler at 95°C for 2 minutes, then cooled to 4°C for 2 minutes. 1µl of library preparation 
enzyme was added to the cells. Cells were incubated in the thermal cycler at the 
following temperature; 16°C for 20 minutes, 24°C for 20 minutes, 37°C for 20 minutes, 
75°C for 5 minutes and then cooled to 4°C  for 5 minutes. Following on, amplification 
master mix (15µl of 10x Amplification Master Mix, 42.5µl of nuclease free H2O and 
1.5µl of WGA DNA Polymerase) was added to each well containing the cells. Samples 
were mixed thoroughly, centrifuged briefly, and incubated in thermos cycler (Table 20). 
After cycling was complete, WGA samples were purified as described in section 






Table 20: Thermocycler conditions used for PCR amplification. 
Steps Temperature Time 
Step 1 - Denaturation 94 °C 2 Minutes 
Step 2 - Denaturation 94 °C 15 Seconds 
Step 3 – Annealing/Extension 70 °C 5 minutes 
 
Repeat Step 2 through step 3  for a total of 20 cycles 
Step4 -  Extension 70 °C 30 minutes 
Step 5 – Hold  4 °C α 
 
2.2.14 Fluorescence in situ Hybridization (FISH) 
Human cells were pelleted, washed twice in PBS and then resuspended in 0.5ml to 
1ml of Karnoy's solution (3:1 Methanol/Acetic Acid Glacial, purchased from Sigma-
Aldrich and Fisher Chemical respectively) and then stored at 4ºC prior to hybridisation. 
For interphase FISH, fixed cells were centrifuged and appropriate amount of 
supernatant was removed. Pelleted cells were then transferred onto the slides and 
hybridized with a XL 7q22/7q36 (Metasystems) locus-specific probe which detects 
deletions in the long arm of chromosome 7 (Figure 18). The orange labelled probe 
targets a specific region at 7q22 and the green labelled probe binds specifically to 
7q36. In addition, a blue (aqua) labelled probe which hybridizes to the centromere of 
chromosome 7 functions as a reference probe. Fluorescence images were obtained 





Figure 18: Detailed map of locus specific probe targeting q arm of chromosome 7. 
XL 7q22/7q36 probe detects a specific region at 7q22 (orange) including the MLL5 gene while 
as the green labelled probe hybridizes specifically to 7q36 (green) and includes the EZH2 
gene. In addition, a blue (aqua) labeled probe which hybridizes to the centromeric region of 
chromosome 7 acts as a reference probe. 
 
2.2.15 Affymetrix Human Transcriptome 2.0 gene expression profiling 
Total RNA was extracted from FACS purified cells as described in section 2.2.3. 
Purified RNA was quantified using ND-8000 (Nanodrop) spectrophotometer. Patient 
libraries were prepared by following manufacturer’s protocol. In-between 50ng to 
150ng of RNA was used for library preparation as recommended by the manufacturer. 
The workflow for the library preparation is depicted in Figure 19. 
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Figure 19: Work-flow for library preparation of Affymetrix HTA 2.0 array.  
All reagents for library preparation are supplied by Affymetrix. cDNA, followed by cRNA is 
synthesized using 50ng to 150ng of purified RNA. Following on, cRNA is purified and then 
used to generate ss-cDNA. Ss-cDNA is purified, labelled and then hybridized to the Affymetrix 
chip.  
2.2.15.1 Reverse transcription to synthesise first-strand cDNA 
All reagents were included in the WT amplification kit. First-Strand master mix 
containing the 4µl of first-Strand Buffer and 1µl first-Strand Enzyme (per reaction) was 
prepared on ice. 5μl of the first-strand master mix was then added to 5μl of total RNA 
(upto 150ng). Poly-A controls at this step was not included in the reaction in order to 
increase the volume of patient total RNA (5μl instead of 3μl, as recommended by the 
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manufacturer). The reaction mixtures were mixed well and incubated in a thermocycler 
by using the recommended PCR program (25°C for 60 minutes, 42°C for 60 minutes 
and 4°C for 2 min; heated lid at 42°C).  
2.2.15.2 Second-strand cDNA synthesis 
Amplified libraries were immediately processed for second strand cDNA synthesis. 
Second-strand master mix containing the 18µl of second-strand buffer and 2µl second-
strand enzyme (per reaction) was prepared on ice.  20µl of the second-strand master 
mix was added to the 10µl of the amplified first-strand reaction (final reaction volume 
30 µl). After mixing and brief centrifugation, the samples were incubated in a 
thermocycler using the recommended program (16oC for 60 minutes, 65oC for 10 
minutes and 4°C for 2 minutes).  
2.2.15.3 In-Vitro Transcription (IVT) to synthesise cRNA 
Amplified libraries were left at room temperature for 5 minutes and then immediately 
prepared for in vitro transcription. IVT master mix containing the 24µl of IVT buffer and 
6µl IVT enzyme (per reaction) was prepared on ice. 30µl of the IVT master mix was 
added to 30µl amplified second-strand cDNA libraries (final reaction volume 60 µl). 
Reactions were vortexed briefly and incubated for 40°C for 16 hours with a heated lid 
at 40oC. The samples were placed on ice and immediately prepared for purification. 
2.2.15.4 cRNA Purification 
The cRNA elution buffer (Nuclease-free dH20) was pre-heated to 65o C for at least 10 
minutes. The purification beads were mixed thoroughly by vortexing. 100µl of the 
beads were added to each 60µl of the cRNA reaction and transferred to a 96 well 
plate. The reactions were mixed and incubated at room temperature for 10 min. The 
cRNA samples bind to the beads during the incubation. The plate was transferred to 
a 96 well magnetic stand (Agentcourt, Bioscience) to capture the beads. Following on, 
the supernatant was aspirated and discarded. Beads (with attached cRNA) were 
washed three times with 200µl of 80% (v/v) ethanol. The beads were air-dried on the 
magnetic stand for up to 10min and the cRNA was eluted in 27µl of preheated (at 
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65oC) nuclease-free water. Purified cRNA libraries were quantified by ND-8000 
(Nanodrop) spectrophotometer. 
2.2.15.5 2nd Cycle single-strand cDNA synthesis 
24µl of cRNA library for each patient with a concentration of 625ng/µl (total 15µg 
cRNA) was transferred to a 96 well place kept on ice. 4µl of 2nd cycle primers were 
added to each patient library and mixed thoroughly. Libraries were incubated in a 
thermocycler using the recommended program (70o C for 5 minutes, 25o C for 5 
minutes and 4oC for 2 minutes) with heated lid (at 70oC). After annealing the primers, 
the reactions were mixed briefly and centrifuged.  
Mastermix containing the 8µl of ss-cDNA buffer and 4µl ss-cDNA enzyme (per 
reaction) was prepared on ice. 12µl of the master mix was added to each cRNA/2nd-
Cycle primer reaction (final volume 40µl). After mixing briefly and centrifugation, 
libraries were incubated in a thermocycler using the recommended program (25oC for 
10 minutes, 42oC then 90 minutes, 70oC for 10 minutes and 4oC for 2 minutes) with a 
heated lid (@70oC).The samples were placed immediately on ice and prepared for 
next step. 
2.2.15.6 Hydrolyse RNA by RNase H 
4µl of RNase H was added to each 2nd-cycle ss-cDNA library (final reaction volume 
44µl). The reactions were incubated in a thermocycler using the recommended 
program (37oC for 45 minutes, 95oC for 5 minutes and 4oC for 2 minutes) with heated 
lid (@70oC). Following on, 11µl of nuclease-free water was added to each reaction, 
mixed briefly and immediately prepared for purification. 
2.2.15.7 Purification of 2nd- Cycle single-strand cDNA 
Purification beads were mixed thoroughly. 100µl of the beads were added to 55µl of 
the 2nd-cycle ss-cDNA sample and transferred to a 96 well plate. The samples were 
mixed with 150µl of 100% ethanol by pipetting and incubated for 20 minutes at room 
temperature. The plate was placed on a magnetic stand for 5 minutes to capture the 
beads. The supernatant was carefully aspirated and discarded. Beads were washed 
three times with 200µl of 80% (v/v) ethanol. The beads were air-dried on the magnetic 
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stand for 5 minutes. cRNA libraries were eluted in 30µl of preheated nuclease-free 
water (@ 65oC). Purified libraries were quantified by ND-8000 (Nanodrop) 
spectrophotometer. 
2.2.15.8 Fragmentation and labelling of single-strand cDNA 
31.2µl of the ss-cDNA library for each patient with a concentration of 176 ng/µl (total 
5.5µg) was mixed with 16.8µl of fragmentation master mix which was prepared on 
ice (Table 21) 
Table 21: Reagents used to make master-mix. 
Reagent Volume/reaction 
Nuclease-free dH20                                  10µl 
10X cDNA fragmentation buffer                                  4.8µl 
UDG,10 U/µl                                  1µl 
APE 1, 1,000 U/µl                                  1µl 
Total Volume                                  16.8µl 
 
The samples were mixed gently and incubated in a thermocycler using the 
recommended program (37oC for 60 minutes, 93oC for 2 minutes and 4oC for 2 
minutes) with heated lid (@100oC). Following on, 45µl of the fragmented ss-cDNA was 
transferred to new 96 well plate. 15µl of the labelling master mix (Table 22) was added 
to each fragmented ss-cDNA library. 
Reactions were mixed, briefly centrifuged and incubated in a thermocycler using the 
recommended program (37oC for 60 minutes, 70oC for 10 minutes and 4oC for 2 
minutes). Following on, samples were briefly centrifuged and stored at -20oC. 
Table 22: Reagents used to make the labelling master mix. 
Reagent Volume/reaction 
5X TdT Buffer 12µl 
DNA labelling reagent, 5mM 1 µl 
TdT, 30 U/µl 2µl 
Total Volume 15µl 
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2.2.15.9 WT Array Hybridization 
Dimethyl sulfoxide (DMSO) was thawed prior to use. Pre-prepared 20x hybridization 
controls were denatured by heating for 5 min at 65oC. Hybridization master mix was 
prepared at room temperate (Table 23). 
 
Table 23: Reagents used to make the labelling master mix. 
Reagent Volume/reaction 
Control Oligo B2 (3 nM) 3.7 µl 
20x Hybridization Controls 
(bioB, bioC, bioD,cre) 
11 µl 
2x Hybridization Mix 110 µl 
DMSO 15.4 µl 
Nuclease-free water 19.9 µl 
Total Volume 160 µl 
 
The master mix was thoroughly homogenised and 160µl of the master mix was added 
to 60µl (5.2 µg) of the fragmented and biotin-labelled ss-cDNA libraries. Reactions 
were mixed and brief centrifuged. Libraries were incubated in a thermocycler using the 
recommended program (99oC for 5 minutes and 45oC for 5 minutes) with heated lid 
(@ 99oC). After incubation, 200µl of the each library was injected and hybridized to 
HT 2.0 expression array using GeneChipR Hybridization Oven 645 (Figure 20). A 
pipette tip was inserted into upper right septum for venting while the samples were 
loaded from the bottom left septum on the array. After loading the libraries, both septa 
were covered with tough spot stickers to minimize evaporation and to prevent leaks. 
The arrays were loaded on the hybridization trays in a rotating incubator (rotation 





Figure 20: Components of the HTA 2.0 array chip.  
The square in the centre indicates the probe arrays where libraries are loaded. 
 
After 16 hours of incubation, HTA 2.0 arrays were removed and the hybridization 
cocktail was aspirated through the septum using a pipette. 250µl of wash solution-A 
was loaded into each array and the arrays were placed into the GeneChipR Fluidics 
Station 450. Following instructions on the LCD of the fluidics station, 1.5ml of 
Eppendoff tube containing a master mix (600μl Stain Cocktail 1, 600μl Stain Cocktail 
2 and 800μl of array holding buffer) was placed on each holder. Following on, arrays 
were washed and stained in the fluidics station for 90 minutes. This Human 
Transcriptome 2.0 gene expression profiling was performed under the supervision of 
Dr. Azim Mohamedali. 
2.2.15.10 Expression microarray data analysis 
Data analysis was performed using Affymetrix expression console and Affymetrix 
transcriptome console software (Figure 21). The HT 2.0 arrays were scanned using a 
GeneChipR 3000 Scanner (7G upgrade) to capture images (DAT files). The raw 
images from the DAT file generated from Affymetrix array probes were converted to 
CEL files. Using the Affymetrix expression Console software (build 1.3.1.187), probe 
cell intensity files (*.CEL) were converted to probe level summarization files (*.CHP) 
for all 12 samples (CD34+ samples, n=4; Erythroid CD71+CD235+ samples, n=4). 
Following on, initial data analysis (including annotation, data normalization and data 
QCs) was performed using Affymetrix expression console with default settings.   
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All the CHP files were imported into the Affymetrix transcriptome analysis console 
(TAC) 2.0 (build 2.0.0.9) using Gene Level and Exon Level differential analysis option. 
Within the TAC, the genome assembly hg19 was used with the gene-level and exon-
level library annotation file supplied by Affymetrix.  
TAC  was further  used to perform both "gene" level (one-way ANOVA analysis) and 
"splicing" level (1-way ANOVA analysis) differential expression analysis between the 
SF3B1 mutant vs SF3B1 wildtype patient samples (CD34+ cells and CD71+CD235+ 
cells). The data was filtered further using a FDR <0.1 (unadjusted P value) and a fold-
change cut-off of ≥±2 (or Splicing Index ±2)  to create a list of significantly up or down 
regulated genes and differentially splicing gene transcripts.  
 
                      
Figure 21: Data processing pipeline for Affymetrix HTA2 array data analysis.  
DAT files were converted to CHP files using Affymetrix expression console. Normalized and 
annotated CEL files were then imported into the Affymetrix transcriptome analysis console 
(TAC). Gene level and alternative splicing analysis was performed using TAC. Filtration 
threshold were applied and then data was visualized manually.   
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3.1 Whole- exome sequencing of Eleven MDS-RS patients 
RARS is a low-risk MDS subtype that is characterized by isolated anaemia, erythroid 
dysplasia and less than 5% myeloblasts. Furthermore, 15% or more ring sideroblasts 
are characteristically observed in the differentiating bone marrow erythroid precursors. 
However, ringed sideroblasts are also characteristic of other inherited sideroblastic 
anaemias (Cazzola and Invernizzi, 2011). Aberrations of various genes involved in 
haem biosynthesis, iron-sulfur (Fe-S) cluster biogenesis, or Fe-S cluster transport, and 
mitochondrial metabolism have been implicated in these inherited disorders 
(Bergmann et al., 2010; Cotter et al., 1999; Maguire et al., 2001; Smith et al., 1995).   
Interestingly, none of these candidate genes have been found to be mutated in RARS, 
although various authors have proposed the role of mitochondrial dysfunction. 
Furthermore, DNA methylation and histone modification abnormalities are frequently 
observed in the bone marrow cells in these patients that can itself lead to altered gene 
expression and genomic instability (Issa, 2010), therefore suggesting that RARS 
disease occurs as a result of multiple and cumulative alterations to the hematopoietic 
stem cells.  Additionally, stem cells in RARS patients have also been shown to be 
clonal, therefore providing the evidence for the clonal nature of this disorder. 
Therefore, the initiating events (genetic or/and epigenetic) responsible for the disease 
not only provides proliferative advantage to the abnormal clone, but also leads to 
ineffective erythropoiesis and dysfunctional erythroid iron metabolism causing 
accumulation of the metal in the mitochondria. Since the abnormal phenotype i.e. bone 
marrow dysplasia observed in RARS is in the erythoid lineage only, suggesting a 
genetic homogeneity in this disease group and hence presents a strong likelihood of 
having a common genetic cause although this has not however been determined yet. 
Therefore, RARS provides an ideal disease sub-group for further mutation screening 
of the protein coding part (whole-exome) of the genome.  
Sequencing of complete genome of an individual with AML using ‘second-generation’ 
sequencing (SGS) technology represented a landmark in genetic screening of the 
leukaemia genome. This SGS technology along with the new DNA-enrichment 
technologies, such as array/bead hybridization-based region capture, has enabled 
highly efficient targeted sequencing of regions of interest, hence increasing numbers 
of samples that can be processed simultaneously. This focussed way of sequencing 
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the smaller fraction of the genome such as protein coding exons (the ‘exome’) enables 
us to sequence the targeted region at a higher depth (reads per base) with no extra 
cost. The haploid human exome roughly constitutes ≈1% of the human genome 
spanning across ≈180,000 exons. One of the challenges for focusing on the exonic 
regions has been how to define the set of targets that constitute the exomic regions 
within the whole-genome. In addition, there has been considerable uncertainty 
regarding which genomic sequences of the human genome are truly protein coding 
regions. Initial commercial whole-exome capture kits used the CCDS (Consensus 
Coding Sequence Project) definition of the exome, which is subset of genes 
determined to be coding with high confidence. However, recently available commercial 
kits now target all of the genes present in the Refseq database (Pruitt et al., 2007) and 
an increasingly large number of hypothetical proteins. In at least one example, 
identification of a novel disease gene MLL2 shown to be the causal marker in Kabuki 
syndrome (Ng et al., 2010) would have been missed, if the CCDS definition was not 
expanded to the Refseq database (Pruitt et al., 2007). Reflecting this, more recent 
whole-exome kits now target up to ~62Mb region, rather ~30Mb.  
With this approach, genomic DNA is fragmented and then hybridized to capture RNA 
probes that are specific to the exonic regions of the genome. Following on, capture 
genomic region is isolated and purified by magnetic beads or other purification 
strategies. There are other methods which are used for targeted enrichment and these 
include amplicon/targeted PCR or capture by circularization. Sequencing this region 
substantially reduces the amount of sequencing necessary to ascertain protein coding 
variants with higher confidence. In addition, by focussing only on the exonic regions 
of the genome we avoid sequencing the majority of the repetitive regions within the 
genome, which are difficult to map, assemble and call variants from. WES studies 
have demonstrated that this approach is a cost-effective means of precisely denoting 
functional variations in a large cohort of samples (Meyerson et al., 2010; Otto et al., 
2010). Furthermore, previous studies have demonstrated that some genomic 
alterations in MDS are present at low frequencies (<20% mutant allele burden) in 
clinical samples, hence making it difficult to detect these gene mutations. This is 
largely due to the substantial admixture of MDS dysplastic haematopoietic cells within 
the different types of myeloid cells and normal lymphoid cell populations (such as T-
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cells and B-cells) in the bone marrow compartment, thus making it difficult to 
molecularly characterize and model the disease.  Sequencing only the exonic regions 
at higher depth (reads per base) will also help us to detect mutation present at lower 
frequencies (<20% mutant allele burden). Therefore, applying SGS technology to 
perform WES on MDS-RS will allow a comprehensive and unbiased investigation of 
the complete protein-coding regions, and will therefore help to identify novel disease 
specific acquired and/or inherited mutations. This will enable us to unravel the potential 
molecular mechanism of the phenotypic abnormalities which in-turn will help to 
elucidate the pathophysiology, refine the prognostic scoring systems, and more 
importantly provide novel therapeutic targets for this subgroup of MDS. 
Since MDS in-general is specific to myeloid lineage of the haematopoiesis, therefore 
DNA isolated from patient’s CD34+ cells is the ideal source of material for whole-
exome screening. Eleven MDS-RS patients all of whom had >25% ringed sideroblasts 
patients, comprising 7 RARS, 2 RARS-T and 2 RCMD-RS (Table 24) were selected 
for the initial whole-exome sequencing.  One patient with congenital sideroblastic 
anaemia was also included in the WES analysis.  CD34+ cells were isolated from bone 
marrow cells of these patients using MACS isolation protocol (see methods section 
2.2.8 for more details). Previous studies have reported that a purity of ≥94% can be 
achieved with this isolation method (Bonanno et al., 2009; Giarratana et al., 2005).   
Analysis of constitutional DNA in patients with haematological malignancies is 
essential to delineate the origin of a particular genetic lesion. This will enable us to 
distinguish the somatic alterations from germline mutations or polymorphisms. 
Furthermore, possible sources of constitutional DNA which can be used are skin 
biopsies, cultured skin fibroblasts, CD3+ T-cells bone marrow or peripheral blood cells 
and buccal epithelial cells. However, DNA obtained from patient’s buccal epithelial 
cells can be contaminated with leukemic DNA, hence suggesting that this DNA source 
is not an ideal source of constitutional DNA (Endler et al., 1999; Zebisch and Sill, 
2008). Therefore, paired skin biopsy or bone marrow CD3+ T-cells from patients were 
used as constitutional source of DNA in this study.  CD3+ T cells were isolated from 
patient’s bone marrow cells by MACS and following the same protocol which was used 
for CD34+ isolation (see methods section 2.2.8 for more details).  
120 
 
WES was performed on CD34+ cells (primary bone marrow sample) as described in 
methods section 2.2.4. Paired constitutional DNA from skin (6 patients) or CD3+ T-
cells (4 patients) was similarly sequenced in parallel. An average of 8-13 gigabase of 
sequence data was generated per patient exome and processed using the Burrows-
Wheelers aligner (BWA)/GATK pipeline (Broad Institute ‘Best practise’ pipelines). 
Additional software tools were also used for downstream data analysis as detailed in 
methods section 2.2.4.6 (See methods section for full details). The mean base 
coverage across the targeted region ranged from 162 reads to 325 reads, with >98% 
of the exome base coverage of >10X in all cases (Figure 22). Functional variants not 
found in dbSNP140, esp5400 (<0.01%) and 6500 (<0.01%) or 1000 genomes 
























Table 24:Total variant (SNVs and Indels) with ≥3 tumour mutant reads observed for each 
individual patient were subjected to our filtration criteria as discussed in methods chapter. 
Candidate filtered somatic variants generated were selectively subjected to confirmation using 
Sanger sequencing. For patient with no constitutional source of DNA, only known myeloid 
related gene mutations were passed for further confirmation. No somatic variants were 
observed for one patient with congenital sideroblastic anaemia. Only candidate missense, 
nonsense, splice-site and indel variants were subjected to confirmation. †Congential 
Sideroblastic anaemia, *Patient sample with no paired constitutional DNA source.  
Patients SNVs Indels 





























































































MDS1 123,914 21,891 23 11 0 0 13,474 421 4 0 
MDS2 115,277 21,044 1 14 0 1 25,571 867 0 0 
MDS3 103,812 23,415 6 5 0 0 14,807 686 1 1 
MDS4 93,110 22,115 2 4 0 0 12,321 572 0 0 
MDS5† 93,435 22,877 0 0 0 0 11,897 661 0 0 
MDS6 131,607 22,777 0 10 1 0 16,481 430 0 0 
MDS7 155,482 23,769 3 11 2 0 18,678 491 0 3 
MDS8 146,862 23,026 4 12 1 0 18,186 442 2 1 
MDS9 121,353 22,372 0 8 0 0 15,207 409 1 1 
MDS10 128,628 22,809 2 4 0 0 15,913 440 1 2 
MDS11* 132,578 25,462 N/A N/A N/A N/A 16,212 463 N/A N/A 






Figure 22: Data coverage of the WES data. 
The percentage of targeted bases that were covered by sequencing reads. More than 65% of 
the exome was covered with at-least 100 sequencing reads and 98% of the exome was 
covered with ≥20 sequencing reads.  
 
Due to the late onset of the phenotypic as well as clinical presentation of the patients 
with MDS (median age of diagnosis 70-75 years), we hypothesised that any genetic 
aberration which leads to the disease must be a somatic lesion acquired during the 
lifetime of the patient. In addition, none of the inherited mutations present in congenital 
sideroblastic anaemia patients have reported in patients with acquired sideroblastic 
anaemia. Therefore, we decided to concentrate only on the acquired mutations 
present in the patients CD34+ cells. Following on, somatic mutations were 
subsequently passed when somatic p-value (VarScan, Fisher’s exact t-test) was 
<0.01, had ≥3 reads supporting mutation, were present in paired normal tissue at less 
than 20% of the paired tumour tissue skin (or <50% for T-cells) and had a mutant allele 
burden (MAB) of >5%.  The reason for selecting this mutation ratio between 
normal/tumour tissues for initial analysis was to avoid false negative results which 
could be due to the fact that skin biopsies and CD3+ T-cells from patients might have 
background tumour cell contamination.  
Following on from initial whole-exome data analysis, acquired candidate mutations 
were identified for 10 patients with paired constitutional DNA samples. These 
mutations were selectively validated by Sanger sequencing (Table 25). For 1 patient 
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where paired constitutional DNA was not available, only known myeloid-related genes 
mutations were included for further analysis.  The total number of confirmed somatic 
mutations were 54, ranging from 2 to 10 per patient. This mutation rate was 
comparable to that in AML (7.3 – 13) (Ley et al., 2010) and chronic lymphocytic 
leukaemia (≈12) (Puente et al., 2011), however, it is lower than multiple myeloma 
(≈33)(Chapman et al., 2011) and solid tumours (32-500) (Lee et al., 2010b; Shah et 
al., 2009). Of the mutations detected in our patient cohort, 4 were frameshift insertion-
deletions (indels) and 50 were non-synonymous; 49 were found in coding sequences 
and one in intron splice-junction (within 3 bp from the exon junction).  The mutation 
spectrum observed in our cohort showed a predominance of transitions, especially 
C→T and G→A. This mutational spectrum is similar overall to those observed in 
haematological, colorectal, pancreatic, and brain cancers (Greenman et al., 2007; 












Table 25: Detailed information for somatic mutations identified by whole-exome sequencing in 11/12 patients.  
Complete list of somatic mutation detected in patients with a paired constitutional DNA are shown in table. However, patient where no 
constitutional DNA was available (n=1), only known myeloid specific somatic mutations are shown in table. Gene names in bold black font and 



















































































































































































T C Lys700Glu  43% Skin yes 0 Damaging Probably 
damaging 
Subunit of the splicing factor SF3B 
required for 'A' complex assembly 
formed by the stable binding of U2 
snRNP to the branch-point sequence 
(BPS) in pre-mRNA 




G T Lys120Asn  31% Skin no 0.01 * Damaging Benign Core component of nucleosome 




G A Ala45Thr  27% Skin no 0.35 Tolerated Benign Implicated in cell shape modulation 
(spreading) and motility 




C T Gly70Arg  28% Skin no 0.03 Damaging Probably 
damaging 
Probable hormone 




G T Val617Phe  36% Skin yes 0 Damaging Probably 
damaging 
Non-receptor tyrosine kinase involved in 
various processes such as cell growth, 
development, differentiation or histone 
modifications 




C T Ala159Thr  15% Skin no 0.02 Damaging Benign Plays an important role in the physiology 
of adrenergic neurons 




G C His662Gln  42% CD3+  
T-cells 
yes 0.01 Damaging Probably 
damaging 
Subunit of the splicing factor SF3B 
required for 'A' complex assembly 
















































































































































































snRNP to the branch-point sequence 
(BPS) in pre-mRNA 




G C SS Exon 6 
G>C 
40% CD3+  
T-cells 
no N/A N/A N/A DNA-unwinding enzyme 




C G  Trp581Ser 41% CD3+  
T-cells 
no 1 Tolerated Probably 
damaging 
Required for genome-wide de novo 
methylation 




A G Val647Ala  7% CD3+  
T-cells 
no 0.15 Tolerated Probably 
damaging 
Protease which specifically processes 
pro-lysyl oxidase. Required for the 
embryonic development 




C T Val224Met  41% CD3+  
T-cells 
no 0.02 Damaging Probably 
damaging 
Catalyses the formation of NAD(+) from 
nicotinamide mononucleotide (NMN) 
and ATP 




T A Tyr74Phe  35% CD3+  
T-cells 
no 0.05 Damaging Possibly 
damaging 
Required for the breakdown of 
glycolipids 




C T  Gly410Ser  38% CD3+  
T-cells 
no 0 Damaging Probably 
damaging 
Involved in the ATP-dependent 
secretion of bile salts into the 
canaliculus of hepatocytes 




C T Gly189Arg  29% CD3+  
T-cells 
no 0.03 Damaging Benign Acts as a transcriptional regulator 




G A Arg268Gln  41% CD3+ 
 T-cells 
no 0.73 Tolerated N/A Acts as guanine nucleotide exchange 
factor (GEF) for RHOA, RAC1 and 
CDC42 GTPases 




A G Leu213Pro 17% CD3+  
T-cells 
no 0.29 Tolerated Benign Unknown 




G T His662Gln  28% Skin yes 0.01 Damaging Probably 
damaging 
Subunit of the splicing factor SF3B 
required for 'A' complex assembly 
formed by the stable binding of U2 
snRNP to the branch-point sequence 




















































































































































































A G Try72His  31% Skin no 0.32 Tolerated Probably 
damaging 
Unknown 




G T Cys923Phe 33% Skin no 0.02 Damaging Possibly 
damaging 
Transcriptional activator. May act as a 
tumour suppressor 




A T Pro357Leu 21% Skin no 0.1 Tolerated Benign May play roles in cilia formation and/or 
maintenance 




T C Lys700Glu  40% Skin yes 0 Damaging Probably 
damaging 
Subunit of the splicing factor SF3B 
required for 'A' complex assembly 
formed by the stable binding of U2 
snRNP to the branch-point sequence 
(BPS) in pre-mRNA 




C G Pro251Ala  44% Skin no 0 *Damaging Probably 
damaging 
Cellular myosin that appears to play a 
role in cytokinesis, cell shape, and 
specialized functions such as secretion 
and capping 




G A Arg476Trp  23 Skin no 0 Damaging Probably 
damaging 
Activates CDC42, a member of the Ras-
like family of Rho- and Rac proteins. 
Plays a role in regulating the actin 
cytoskeleton and cell shape. 




G A Pro148Ser  25 Skin no 0.19 Tolerated Probably 
damaging 
Functions as an integral cofactor in cell 
pH regulation, cell maturation, cellular 
transport and cell surface stability. 




C G Glu622Asp 40 Skin yes 0.05 Damaging Possibly 
damaging 
Subunit of the splicing factor SF3B 
required for 'A' complex assembly 
formed by the stable binding of U2 
snRNP to the branch-point sequence 
(BPS) in pre-mRNA 




C T Arg736His  8 CD3+ 
 T-cells 
yes 0.39 Tolerated Probably 
damaging 
Required for genome-wide de novo 
methylation 




C A His691Asn  24 CD3+  
T-cells 
no 0 * Damaging Possibly 
damaging 
Part of ion pump responsible for 























































































































































































G A Gln1447X 23 CD3+  
T-cells 
no N/A Tolerated N/A Involved in the nuclear localization 
pathway of MCM3 




G C His662Gln  45 CD3+  
T-cells 
yes 0.01 Damaging Probably 
damaging 
Subunit of the splicing factor SF3B 
required for 'A' complex assembly 
formed by the stable binding of U2 
snRNP to the branch-point sequence 
(BPS) in pre-mRNA 




T C Met2578Thr  25 CD3+  
T-cells 
no 0.34 Tolerated Benign Orphan receptor 




C A Leu58Phe  37 Skin no 0.27 Tolerated Probably 
damaging 
May be required for correct bipolar cell 
division through the regulation of 
centrosome duplication and mitotic 
spindle assembly 




G A Ala15Val  63 Skin no 0.05 Damaging Benign Member of the five-member G-protein 
associated melanocortin receptor family 




A G Ile2147Val  40 Skin no 1 Tolerated Benign Integral component of the filamentous 
matrix of the centrosome involved in the 
initial establishment of organized 
microtubule arrays in both mitosis and 
meiosis 




G C His662Gln  37 Skin yes 0.01 Damaging Probably 
damaging 
Subunit of the splicing factor SF3B 
required for 'A' complex assembly 
formed by the stable binding of U2 
snRNP to the branch-point sequence 
(BPS) in pre-mRNA 




C T Gly23Arg  44 Skin no N/A N/A Benign Plays a role in the regulation of 
autophagy 




C T Ala163Thr  48 Skin yes 0.8 Tolerated Benign Plays an important role in lipid droplet 
accumulation. Plays a role in the 
regulation of cell morphology and 
cytoskeletal organization 




G T Pro747His  19 Skin no 0.09 Tolerated Brobably 
damaging 
Putative transcription activator that may 
















































































































































































oncogenesis. Binds, in vitro, to double-
stranded DNA 
 
MDS    







45 Skin no 0.03 Damaging N/A Dioxygenase that catalyses the 
conversion of the modified genomic 
base 5mC into 5hmC and plays a key 
role in active DNA demethylation 




A G Ser249Gly  25 Skin no 0.33 Tolerated Probably 
damaging 
Required for centrosome duplication at 
different stages of procentriole 
formation. 




G A Thr103Ile 37 Skin no 0.08 Tolerated benign Catalyses the pyridoxal-phosphate-
dependent breakdown of 
phosphoethanolamine 




A G Ser394Gly  29 Skin no 0.41 Tolerated Benign Phosphorylates inhibitor of NF-kappa-B 




C T Arg128His  40 Skin yes 0 Damaging Probably 
damaging 
Unknown 




C T Ala434Thr 37 Skin no 0.77 Tolerated Benign Unknown 




T C Asp781Gly  45 Skin yes 0 Damaging Probably 
damaging 
Subunit of the splicing factor SF3B 
required for 'A' complex assembly 
formed by the stable binding of U2 
snRNP to the branch-point sequence 







C - Thr259fs 26 CD3+  
T-cells 
no 0 Damaging N/A Calcium/phospholipid-binding protein 
which promotes membrane fusion and 







T C  Lys700Glu  40 CD3+  
T-cells 
yes 0 Damaging Probably 
damaging 
Subunit of the splicing factor SF3B 
required for 'A' complex assembly 
formed by the stable binding of U2 
snRNP to the branch-point sequence 







C T Arg882His  50 CD3+ 
 T-cells 
yes 0.03 Damaging Possibly 
damaging 








C T Ser494Leu 39 CD3+  
T-cells 























































































































































































C A Glu622Asp 60 N/A yes 0.05 Damaging Possibly 
damaging 
Subunit of the splicing factor SF3B 
required for 'A' complex assembly 
formed by the stable binding of U2 
snRNP to the branch-point sequence 







C T Arg882His  75 N/A yes 0.03 Damaging Possibly 
damaging 








G A Gly 210Arg  40 CD3+ 
 T-cells 









T C Lys 700Glu 43 CD3+  
T-cells 
yes 0 Damaging Probably 
damaging 
Subunit of the splicing factor SF3B 
required for 'A' complex assembly 
formed by the stable binding of U2 
snRNP to the branch-point sequence 









- 730_730del 42 CD3+  
T-cells 
no 0.02 Damaging N/A Dioxygenase that catalyses the 
conversion of the modified genomic 
base 5mC into 5hmC and plays a key 







A - Gln510fs 42 CD3+  
T-cells 
no 0.04 Damaging N/A Required for the relief of p53-dependent 







G A Arg635 Trp  50 CD3+  
T-cells 
yes 0 Damaging Probably 
damaging 




3.1.1 Whole-exome sequencing reveals SF3B1 mutations in MDS-RS 
The molecular pathogenesis and the cause of the accumulation of mitochondrial iron 
that gives rise to ringed sideroblasts in MDS-RS patients is unknown. We evaluated 
whether WES could be applied to identify directly the causative gene underlying the 
ring sideroblastic phenotype. Even in this scenario for ‘whole exome data set’, the key 
challenge that arises immediately is that the large number of mutations present by 
chance in any single ‘diseased genome’ makes it difficult to identify which variant is 
causal, even when only considering somatic functional variants. Because of the 
genetically homogenous phenotype observed in the MDS-RS patients, we 
hypothesized that any genetic defect leading to ring sideroblatic phenotype would 
involve a common gene(s) or a pathway.  
Among the genes found to be recurrently mutated in our cohort of patients, splicing 
factor 3b subunit 1 (SF3B1), a component of the major and minor spliceosomes, 
initially stood out due to its high mutation frequency. SF3B1 mutation was present in 
the 11/12 patients sequenced in this study (Table 25). Four patients carried Lys700Glu 
mutation, three patients His662Gln mutation, two patients Glu622Asp mutation and 
one patient had Asp781Gly mutation in the SF3B1 gene. On the basis of the proportion 
of reads reporting the mutant allele burden (MAB), all the mutations were 
heterozygous and present as a dominant clones. Validation of these mutations in 
available paired skin biopsy by Sanger sequencing allowed me to confirm acquired 
nature of these mutations (Figure 23).  No acquired mutation was detected in one 
patient (MDS5) with congenial sideroblastic anaemia, however, a constitutional 
ALAS2 (R425C) gene mutation which has been previously (Camaschella, 2009; Cotter 







Figure 23: Somatic SF3B1 mutations in MDS patients with ring sideroblasts.  
Sanger sequence electropherogram (top panel) from 5 patients demonstrates the most 
common mutation identified in this study. The absence of these mutation in a sequence 
electropherogram from matched constitutional DNA (bottom panel) obtained from skin biopsy 
confirms the somatic nature of these mutations. 
To characterize the spectrum and frequency of SF3B1 mutations in greater detail, 
targeted mutational sequencing of the SF3B1 gene was performed in 18 additional 
MDS-RS patients (RARS, n=7; RARS-T, n=1; RCMD-RS, n=9 and MDS/AML, n=1). 
All the patients had >15% ring sideroblast at the time of sample collection. SF3B1 
mutations were identified in 86% (6/7) RARS, 100% (1/1) RARS-T, 44% (4/9) RCMD-
RS and 100% (1/1) MDS/AML with a preceding RARS (Data was presented as a 
poster at 53rd American Society of Haematology Conference, 2011, San Diego, 
California). At the same time, similar data was published by two other groups showing 
the presence of SF3B1 mutations in MDS-RS patients (Papaemmanuil et al., 2011; 




3.1.2 SF3B1 mutations- Type, allele burden and sites  
The distribution of observed mutations across the SF3B1 gene was striking. All SF3B1 
mutations were non-synonymous amino-acid substitutions. MAB ranged from 28% to 
60% with an average mutant allele burden of 45% (n=29), indicative of a heterozygous 
state. No frameshift, indels, splice-site mutations, or nonsense substitutions were 
observed. All the mutations clustered in exons 14 to 16 of the gene, and one variant 
in particular, Lys700Glu, accounted for 12 of the 23 variants observed (Figure 24). 
Several other mutated amino acid residues were also observed, these include His662 
(n=5), Glu622 (n=2), Arg625 (n=1), Lys666 (n=2), and Asp781 (n=1). All SF3B1 
mutations clustered in the protein c-terminal HEAT motifs implicated in snRNP 












Figure 24: Somatic SF3B1 mutations in MDS patients with ring sideroblasts. 
(A) SF3B1 gene with all known exons and protein sequence alignments of the SF3B1 C-
terminal domain around the mutated residues (Red arrows) in evolutionarily diverse species. 
(B) Distribution of somatic mutations across the SF3B1 protein. Top panel represents the 
mutated HEAT motifs and the mutated codons of the protein. NTD, N-terminal domain.  
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3.1.3 In-silico analysis of SF3B1 mutations 
To investigate the impact of mutations, an in-silico 3-D model of the C-terminal part of 
the SF3B1 protein (Figure 25) was constructed using SWISS-MODEL (Biasini et al., 
2014). In this model, most of the aberrations clustered in the fifth, sixth, seventh, eighth 
and ninth HEAT motifs on the inner surface of the protein and may define a binding 
interface, consistent with the suggestion that the helical motifs form the outer shell of 
the U2 complex. Interestingly, the sixth motif which contains the frequent Lys700Glu 
mutations is at the hinge (Figure 24 and Figure 25) of the S-shape shell like structure. 
Similarly, Asp781Gly also affects the external loop at the hinge. As this part of the 
protein is highly conserved among various species, therefore it is highly likely that 
these mutation are deleterious.  
 
Figure 25: 3D structure of C-terminal domain of the Sf3b1 protein (left) and detailed 
view of the mutated codons (right).  
Each loop represent a heat domain present within the N-terminal of the Sf3b1. Mutated codons 


















3.1.3.1 SF3B1 – Transversion mutations  
The 1866 G→C mutation leads to the replacement of Glutamic acid (Molar mass, Mm-
147.12926 g/mol) with Aspartic acid (Mm-133.10268 g/mol) at codon 622 while 1986 
C→G mutation results in Histidine (Mm-155.15456 g/mol) to Glutamine (Mm-
155.15456 g/mol) replacement at codon 662. The wild-type and mutant amino acids 
in both the mutations differ in size (Figure 26). Mutant residues appear to be smaller 
in mass which might lead to loss of interactions with other interacting proteins. 
The 1996 A→G mutation results in Lysine (Mm- 146.18756 g/mol) to Arginine (Mm-
174.20096 g/mol) substitution at codon 666. Both the wildtype and mutant residues 
share the same backbone (Figure 26), however the side chain is different. The mutant 
residue is larger than the wild-type residue which might lead to irregularities in the 
protein structure. However, 1996 A→C mutation results in the Lysine (Mm- 146.18756 
g/mol) to Glutamine (Mm-146.1445 g/mol) substitution at codon 666. In this case, there 
is a difference in charge with the wild-type residue being positively charged while the 
mutant residue is neutral. The loss of charge can cause changes in the interactions 
with other molecules or residues. The wild-type and mutant amino acids also differ in 
size. The mutant residue is smaller which could lead to loss of interaction with other 
interacting proteins.  
3.1.3.2 SF3B1 - Transition mutations  
The 2009 A→G mutation leads to Lysine to Glutamic acid substitution at codon 700 
and both residues (wildtype and mutant) have the same backbone (Figure 26). The 
mutant residue is small and negatively charged while as the wildtype residue is larger 
with a positive charge. This change in the charge and size can cause repulsion with 
other residues in the protein or ligands.  
The 2342 A→G mutation changes Aspartic acid to Glycine at codon 781. The wild-
type residue is negatively charged while as the mutant residue is neutral. However, 
1873 C→T mutation results in the substitution of Arginine into Cysteine at codon 625 
with a positive charge of the wildtype residue and a neutral charge for mutant residue. 
The backbone of the wildtype and mutant in both cases is same, however, the side 
chain is absent or small in the mutant residue. Both mutant residues (Glycines and 
Cysteine) are hydrophobic as well as very flexible, and can disturb the required rigidity 
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of the protein at this position. This can result in loss of hydrogen bonds and/or disturb 
correct folding. Furthermore, the wild-type and mutant amino acids in both cases also 
differ in size and therefore can lead to loss of interactions with other proteins. 
 
 
Figure 26: Chemical structure of the amino acids. 
Each panel shows a structure of the respective wildtype and substituted amino acids observed 
in SF3B1 mutant patients. Each amino acid has a backbone shown in red and a side chain 




3.1.4 In-Silico prediction for SF3B1 mutations 
Missense mutations that are disease-associated tend to alter residues that are 
evolutionary conserved.  To explore the functional consequences of the observed 
amino acid substitutions in in-silico, we studied the potential degree to which the 
missense mutations can affect the function of the protein by using various algorithms 
such as Align-GVGD, SIFT and PolyPhen-2. These algorithms predict the impact of 
missense mutations on protein structure and function using algorithm-generated 
sequence alignments or manually curated alignments.  
3.1.4.1 SIFT: Prediction of tolerated and deleterious SF3B1 mutations  
SIFT (Sorts Intolerant From Tolerant) algorithm predicts the consequences of an 
amino acid substitution on the function of the protein by considering the sequence 
homology and physical properties of amino acids. SIFT classifies mutations as 
“deleterious” or “neutral” using normalized probabilities calculated from the input 
multiple sequence alignment.  Genomic variants at a position with normalized 
probabilities <0.05 are predicted deleterious while as a probability score of ≥0.05 is 
predicted as neutral or tolerated. 
SIFT analysis revealed that bulk of the SF3B1 mutations are likely to alter the function 
of the protein (Table 26). Of the 7 SF3B1 mutations, majority of the mutations including 
the commonest amino acid change Lys700Glu were predicted to be deleterious with 
SIFT score of <0.05. Interestingly, Lys666Gln was shown to have a damaging effect 
(SIFT score 0), whereas Lys666Arg was predicted to have no effect on the protein 









Table 26 : In-Silico prediction for SF3B1 mutations. 
 SIFT PolyPhen-2 Align-GVGD 
Substitution Score Prediction Score Prediction GV GD Prediction 
Arg625Cys 0 Damaging 1 Probably 
damaging 
0 179.53 Class C65 
Asp781Gly 0 Damaging 0.999 Probably 
damaging 
0 93.77 Class C65 
Lys700Glu 0 Damaging 1 Probably 
damaging 
0 56.87 Class C55 
Lys666Gln 0 Damaging 1 Probably 
damaging 
0 53.23 Class C45 
Glu622Asp 0.05 Damaging 0.877 Possibly 
damaging 
0 44.6 Class C35 
His662Gln 0.01 Damaging 1 Probably 
damaging 
0 24.08 Class C15 
Lys666Arg 0.17 Tolerated 0.93 Possibly 
damaging 
0 26 Class C25 
 
 
3.1.4.2 PolyPhen-2: Prediction of SF3B1 mutant protein structural and 
functional modifications 
PolyPhen-2 algorithm is the latest tool created by the developers of the PolyPhen. Its 
novel elements include the set of predictive features, the alignment pipeline, and the 
probabilistic classifier based on machine-learning methods. PolyPhen-2 prediction is 
based on eight sequence-based and three structure-based predictive features that are 
selected automatically by an iterative algorithm. These include comparison of the 
features of the wild-type allele and the mutant allele. Essentially, PolyPhen-2 
characterizes protein structural modifications caused as a result of amino acid 
substitutions which effect protein structure and function. PolyPhen-2 provides both 
qualitative prediction such as ‘probably damaging’, ‘possibly damaging’, ‘benign’ or 
‘unknown’ and a score. Another useful feature is that the algorithm calculates a Bayes 
posterior probability that a given mutation is deleterious.  
PolyPhen-2 analysis revealed that SF3B1 mutations such as Lys700Glu, His662Gln, 
Lys666Gln and Arg625Cys were likely to have a damaging effect (probably damaging, 
PolyPhen-2 score 1) on the protein (Table 26). Likewise, Asp781Gly was predicted to 
be ‘probably damaging’ with a PolyPhen-2 score of 0.999.  However, Glu622Asp and 




Another algorithm program namely Align-GVGD predicts consequences of variants 
based on a combination of Grantham Variation (GV), which measures the biochemical 
evolutionary variation at a particular position in the sequence alignment, and 
Grantham Deviation (GD), which measures the biochemical difference between the 
reference and variant amino acid. Align-GVGD uses a set of five criteria based on GV 
and GD, which groups variants ranging from the most pathogenic to least likely 
pathogenic. The program provides a series of ordered classifications ranging from the 
most likely deleterious ‘C65’ to the least likely deleterious ‘C0’ [deleterious 1 (GV = 0 
and GD > 0), deleterious 2 (0 < GV ≤ 61.3 and GD > 0), neutral 1 (GD = 0), neutral 2 
(GV > 61.3 and 0 < GD ≤ 61.3) and unclassified]. This algorithm has previously been 
used for developing in-silico models for a few clinically relevant tumour suppressor 
genes such as BRCA1 (Tavtigian et al., 2006) and TP53 (Mathe et al., 2006). 
              
Figure 27: Align-GVGD algorithm prediction for SF3B1 mutations.  
Align-GVGD uses a set of five criteria based on GV and GD, which groups variants ranging 
from the most pathogenic to least likely pathogenic (deleterious ‘C65’ to the least likely 
deleterious ‘C0’). Figure shows all the SF3B1 variants including the most frequent variant 
Lys700Glu fall between the deleterious regions C15 to C65.  
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Among the SF3B1 mutations, Arg625Cys and Asp781Gly had the highest align-GVGD 
score (Class C65) and therefore likely to have deleterious effect on the protein (Table 
26 and Figure 27). The most frequent SF3B1 mutation Lys700Glu was also found to 
be highly deleterious (align-GVGD Class C55). Furthermore Glu622Asp, His662Gln 
and Lys666Arg had an align-GVGD score of C35, C15 and C25, respectively. These 
mutations were less likely to have any effect on the protein function.   
Together, this data suggest that mutated SF3B1 may affect the structure and functions 
of protein, in the form of mis-folding and intermolecular interactions, and play an 
important role in the disease susceptibility.  
 
3.1.5 Exome sequencing reveals additional gene mutations in MDS-RS 
patients   
Next, we sought to identify if there are additional somatic mutations affecting any 
specific pathway(s) in these SF3B1 mutated patients. To investigate this, we selected 
our candidate mutations which passed out “mutation filtration” criteria (see methods 
section 2.2.4.6 and Figure 10 for more details). Between 4 to 16 well-supported 
candidate mutations were identified per individual exome and subjected to validation 
using targeted mutation approach and Sanger sequencing (see methods section 
2.2.5, 2.2.6 and/or 2.2.7 for more details). Following the validation of the candidate 
mutations, our data revealed other somatic mutations (Table 25) in MDS-RS patients 
which included the known myeloid-related gene targets in myelodysplasia with similar 
mutation frequencies as previously reported, therefore indicating an acceptable 
sensitivity of the current study. The mutations of the known myeloid gene targets, 
however, accounted for only 16% of all detected mutations (n=56), and the remaining 
confirmed novel 36 mutations in the previously unreported genes.  
Among the known myeloid-related genes, epigenetic modifier gene mutations were 
present in 8/12 MDS-RS patients (DNMT3A, n=6; TET2, n=2). Interestingly, single 
epigenetic modifier gene mutations were observed coinciding with SF3B1 aberrations. 
Moreover, mutual exclusivity could exist among genes of the same functional 
categories, because no concurrent presence of gene mutations of splicing complex or 
epigenetic modifiers were detected in the same patient. Like SF3B1 mutations, all the 
epigenetic modifier mutation were heterozygous (MAB 41% to 50%). However, one 
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patient had a DNMT3A R882H mutation with an MAB of 75%, indicating a 
homozygous state or loss of heterozygosity (LOH) at chromosome 2p23.3. JAK2 
which is a cell signalling protein was mutated (V617F, MAB 43%) in one patient 
(MDS1).  Of particular note, none of the ‘oncogenic’ gene mutations such as cell 
signalling proteins (KRAS/NRAS, C-Kit, and PTPN11) or tumour suppressor proteins 
(TP53) appear to be mutated in MDS-RS patients, therefore indicating a possible 
mutual exclusivity.  
WES revealed additional 36 patient specific novel mutations in CD34+ cells (Table 25). 
These mutations include ones in previously uncharacterized zinc finger proteins, and 
mutations in factors which suggest defects in metabolic pathways (SLC7A2, ANXA7, 
IKBKE, AGXT2L1, MC2R, ATP1A4, TESC, SPATA13, ABCB11, NAGA, NMNAT2, 
TLL2, RETNLB), cell proliferation (PPM1D), DNA maintenance (CEP110, AFF3, 
G3BP1, HIST1H2AC), transcription regulation (MCM3AP, CAMTA1, NR0B2) and 
cytoskeletal organization (FITM2, ATG9B, PCNT, PKHD1, GPR112, FGD1,  
MYH14, PTPDC1, TH, FBLIM1 ; Table25). However, mutations in the haem 
biosynthesis pathway enzymes (for example, ALAS2, ALAD, FECH and UROD) and 
globin genes (for example, HBQ1, HBA2, HBB and HBA1) were not detected in our 
patient cohort. Furthermore, in-silico analysis of all the gene mutations demonstrated 
that some of the gene aberrations disrupt the function of the respective protein while 
others are benign (Table 25). However, more analysis is needed to unravel the role of 
these mutations in SF3B1 mutant patients.  
3.1.6 Architecture of Clonality in MDS-RS patients 
Previous studies have established MDS as clonal diseases by using X-linked 
polymorphic markers and molecular cytogenetics (Boultwood and Wainscoat, 2001; 
Janssen et al., 1989; Mongkonsritragoon et al., 1998). However, recently the use SGS 
and various bioinformatics software’s have led the researchers to infer the clonal 
architecture in the total bone marrow samples through the identification of clusters of 
co-existing mutations with similar MABs. Therefore, based on the MAB of the mutated 
genes obtained from the genome sequences (WES data) of confirmed SNVs, we 
sought to identify the clonal architecture of the bone marrow compartment in these 
patients. We hypothesized that MAB should be 50% for heterozygous mutations or 
100% for homozygous mutations, if mutations exist in all tumour cells, but it is often 
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lower because of the admixture of non-tumour elements in clinical samples. With the 
sensitivity of this approach, the peak of greater MAB value should represent the 
founding clone, whereas the peak(s) with smaller MAB may represent subclone(s), 
although very small subclone(s) could be under the limit of detection with this 
sequencing approach. Another major problem with using this approach is that we won’t 
be able to determine confidently whether a mutation is present in homozygous or 
heterozygous state.  
Based on this approach, in our patient cohort SF3B1 mutations are present in-between 
45% to 50% MAB, indicating that these mutations are present in all the bone marrow 
cells in a heterozygous state. Similarly, majority of the other gene mutations including 
the cell signalling proteins (such as JAK2, MDS1 36% MAB) and patient specific 
mutations (such as TLL2, MDS2 7% MAB; ANAX7, MDS10 26% MAB) are present at 
<50% MAB, and likely to be heterozygous mutations (Figure 28). In contrast, some of 
the gene mutations such as DNMT3A (MDS11, 75% MAB), MC2R (MDS8, 63% MAB) 
are present at a MAB of >50%, indicating that these aberrations are homozygous 
mutations (Figure 28 and Table 25) or the presence of LOH at the genomic locus, and 
these mutations are present in a fraction of the bone marrow cells. Therefore, it is 
difficult to conclude the clonal composition of the bone marrow compartment in some 
patients where gene mutations are present at different frequencies. However, in 
majority of our patients SF3B1 mutation appears to be the initiating mutant clone due 
to its higher abundance in the bone marrow cells while as other gene mutation are 
likely to be the subclone(s). Given that our data suggests that SF3B1 mutations are 
present in all the bone marrow CD34+ cells, therefore they should reflect the aberrant 
cellular activities at very high levels of disease involvement along with the 







          
              
Figure 28: Prediction of order of genetic lesions in MDS-RS patients. 
Patients with one or more candidate driver mutation were identified by whole-exome 
sequencing (followed by confirmation by target mutational sequencing). Vertical lines 
represent MDS-RS patients. SF3B1 and known myeloid related gene mutations are shown by 
labelled coloured circles. Other coloured circles represent patient specific mutations detected 
through whole-exome sequencing (see table 25 for more details).  
3.1.7 SF3B1 mutation persists throughout the disease progression 
Leukemic transformation in patients with RARS is a very rare event. One of the patient 
(MDS54) from our cohort with RARS and SF3B1 mutation evolved to AML at 4 months 
after diagnosis. To investigate whether SF3B1 mutation persists throughout the 
disease evolution, relevant sequential samples were screened using SGS platform. 
454-Roche sequencing analysis of the samples taken from patient at the time of 
diagnosis revealed SF3B1 mutation with a mutant allele burden of 39% (Figure 29). 
At the time of transformation to AML, SF3B1 mutation was maintained at the similar 
level (Figure 29). Following intensive chemotherapy (Fludarabine, Cytarabine and 
Filgrastim, FLAG), patient attained a transient morphological remission but relapsed 
rapidly with the SF3B1 MAB remaining constant (MAB 41%) throughout the disease 
duration, which as a heterozygous mutation would occur in a majority of sample cells. 
Therefore, our data suggests that SF3B1 mutation in this patient originates from the 
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early haematopoietic stem cells which is not eradicated by the intensive chemotherapy 




Figure 29: SF3B1 mutation persists during the disease progression. 
Samples were obtained at diagnosis, transformation and progression. Distribution of 
generated amplicon sequence reads per patient. For an exemplary patient, the read length (x-
axis) and number of generated sequence reads (y-axis) is represented. Mutation burden is on 
the (y axis). SF3B1 mutation burden was maintained at the same level from diagnosis, at 
progression to AML and at time of remission following intensive chemotherapy. 
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3.1.8 SF3B1 mutations have no impact on the clinical outcome of MDS 
patients with ring sideroblasts 
Patients with an SF3B1 mutation had a higher platelet count as compared to patients 
who did not have an SF3B1 mutation (mean, mutant 335x109/L vs wildtype 85x109/L; 
P=0.003) as well as high neutrophil count (mean, mutant 3.1x109/L vs wildtype  
1.5x109/L; P=0.059; Figure 30). There was no significant difference in haemoglobin 
levels (mean, mutant 9.148g/dl vs wildtype 9.533g/dl; P=0.059; Figure 30) and ferritin 
levels (mean, mutant 1308μg/L vs wildtype 1312μg/L; P=0.61) between SF3B1 mutant 
vs wildtype patients. Univariate analysis revealed that there was no difference in 
overall survival (OS) or leukaemic transformation when comparing patients with or 




    
Figure 30: Relationship between SF3B1 mutation status and blood/bone marrow 
findings.  
Panel A-D shows the box-and-whisker plots for haemoglobin levels, neutrophil counts, platelet 
counts and ferritin levels. The circles above and below the box-and-wisker plots indicate outlier 
data for individual patients. Panel E shows the box-and-wisker plot for SF3B1 MAB and 
percentage of ring sideroblasts. Values for percentage of MAB are grouped here in 3 arbitrary 
categories: SF3B1 WT (n=5), SF3B1 MAB 1-40% (n=9), and SF3B1 MAB >40% (n = 11). 
MAB- Mutant allele burden. 








Figure 31: SF3B1 mutations have no impact on the overall survival of the patients.  
No significant difference in overall survival or leukemic transformation when comparing 
patients with or without SF3B1 mutation. The P values are derived from Kaplan-Meier analysis 
with a log-rank test and median survival times with 95% confidence intervals. 
 
Data for the estimation of the ring sideroblasts using consensus criteria (Mufti et al., 
2008) was available for 25 of the 29 MDS patients.  Ring sideroblasts were identified 
at variable percentages with a mean of 53.16% (range, 15%-90%). Among the patients 
with SF3B1 mutations, there was no significant difference in the percentage of ring 
sideroblasts and the SF3B1 MAB (Figure 30). However, patients with MAB of >40% 
had higher percentage of ring sideroblasts as compared to patients with wildtype 
SF3B1 (Figure 30). Of 23 patients with SF3B1 mutations, 2 patients had 15-29% ring 
sideroblasts, 9 patients had 30-50% ring sideroblasts and 9 patients had 61-90% ring 
sideroblasts (percentage of ring sideroblasts was not available for 3 patients). There 
was no significant difference between the percentage of ring sideroblasts vs the MAB 
within the SF3B1 mutant group (Figure 31).  
3.2 Transcriptome analysis of progenitor cells from SF3B1 mutant patients 
To date, question remains as how SF3B1 mutations can give rise to the phenotypic 
changes observed only in the erythroid progenitor cells in MDS-RS patients. 
Therefore, we set out to identify the downstream effects of SF3B1 mutations in 









pathway(s) or gene(s) responsible for ‘SF3B1 specific’ sideroblastic phenotype. Bone 
marrow CD34+ progenitor cells and CD71+CD235+ erythroid progenitor cells were 
isolated using BD FACS Aria SORP (San Jose, CA; See methods section 2.2.8 for full 
details). Three MDS-RS patients in whom SF3B1 mutations were detected in total 
bone marrow cells were used for this analysis (Table 27). In addition, one acquired 
sideroblastic anaemia patient with wildtype spliceosome genes was used as a control 
(Table 27). The cells of interest were isolated by the cell surface markers (CD34, CD71 
and CD235) as described in the methods section 2.2.8. After sorting, the purity of all 
the cell fractions was checked and a sorting purity of ≥97% was routinely obtained.  

















































































































MDS1 MDS-RS M RCMD-
RS 
46,XY 50% K700E (43%) JAK2                   
(V617F, 36%) 
MDS4 MDS-RS F RARS 46,XX 24% K700E (40%) None 
MDS6 MDS-RS M RCMD-
RS 
46,XY 65% E622D (40%) DNMT3A                
(R736H, 8%) 
MDS28 MDS-RS F RARS 46,XX Unknown WT ASXL1                 
(G643V, 32%) 
 
Following the cell separation, gene expression/Splicing array analysis was perform 
using Affymetrix GeneChip Human Transcriptome Arrays (version 2.0; HTA2). These 
high-resolution arrays contain >6.0 million distinct probes for coding and non-coding 
transcripts. Furthermore, 70% of the probes cover exons for coding transcripts while 
as the remaining 30% of probes target exon-exon splice junctions and non-coding 
transcripts. This Affymetrix array is the only commercially available microarray for 
expression profiling at both gene as well as exon levels; although it provides accurate 
assessments of gene expression.  
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The raw images from the DAT file generated from Affymetrix array probes were 
converted to CEL files. Initial data analysis (including normalization) was performed 
using Affymetrix expression console (Figure 21). The quality of the data was checked 
manually by looking the QC matrix generated by the Affymetrix expression console 
(Figure 32). Principle component analysis (PCA) divided the samples into two groups 
(CD34+ and CD71+CD234+ groups) as shown in Figure 33.  
Affymetrix TAC v2.0 was used to perform one-way ANOVA analysis to detect 
differentially expressed gene as well as differential splicing index between the SF3B1 
mutant vs SF3B1 wildtype patient samples (CD34+ cells and CD71+CD235+ cells, 
Table 28, Appendix Table 15 and Appendix Table 16). The data was filtered further 
using a FDR <0.1 (unadjusted P value) and a fold-change cut-off of ≥2 (or Splicing 
Index ±2) to create a list of significantly up or down regulated genes and differentially 
splicing gene transcripts.  
 
Figure 32: QC plots produced for normalized arrays for each sample.  
(A)Shows the data probes intensities for each array. (B) Shows the relative expression signals 
for each array after the RMA-gene and RMA alternative splicing analysis. Both figures 
demonstrates that the intensity signals generated by all (with SF3B1 Wildtype and SF3B1 




Figure 33: Principle component analysis (PCA) preformed using Affymetrix Console 
Software. 
The PCA graphs of the global gene expression data (A) and alternative splicing data (B) were 
computed using Affymetrix console software. Bone marrow cells were grouped into two groups 
i.e. CD34+ and CD71+CD235+.  
 
A list of genes was generated (Table 28) after the preliminary analysis i.e. 
normalization and annotation. However, no significant difference in the gene 
expression profile was observed between the SF3B1 mutant vs SF3B1 wildtype 
groups (Appendix Table 15 and Appendix Table 16) after applying the filtration criteria.  
In addition, we did not observe any significant difference in the splicing index’s 











Table 28: Details of the data generated following HTA 2.0 array. 
Data analysis by Affymetrix transcriptome analysis console. ** Applying data filtration as 
described in methods chapter.  
Gene Level analysis 
 CD34+ CD71+CD235+ 
Total no of Genes 
Coding Genes 


































Genes after data filtration* 0 0 
Alternative Splicing Analysis 
 CD34+ CD235+ 
Total no of Genes 
Coding Genes 








Genes expressed in both conditions 
Genes expressed genes to indicate alternative splicing 
Genes expressed in SF3B1 WT but not in Mutant 
Genes expressed in SF3B1 Mutant but not in WT 














genes expressed in both conditions 
Genes expressed genes to indicate alternative splicing 
Genes expressed in SF3B1 WT but not in Mutant 
Genes expressed in SF3B1 Mutant but not in WT 

















RARS is an acquired form of MDS mainly characterized by an initial phase of erythroid 
hyperplasia with an excess iron accumulation in the mitochondria of erythroblasts 
which subsequently leads to ineffective erythropoiesis (Cazzola and Invernizzi, 2011). 
In a significant proportion of patients, this is followed by a phase of marrow failure, 
with or without the emergence of leukemic blasts. Over the past few years, various 
genetic factors have being associated with RARS (Boultwood et al., 2008; Cazzola 
and Invernizzi, 2011; Malcovati et al., 2009; Nikpour et al., 2010). However, the 
mechanisms underlying the pathogenesis of RARS and the cause of the unusual 
pattern of iron deposition within the erythroid cells remains yet to be determined.  
In order to understand the mechanism underlying the pathogenesis of RARS, WES 
was performed on CD34+ cells from 11 MDS patients with ring sideroblasts (MDS-RS) 
as such progenitors are likely to provide the reservoir of myeloid mutations, as has 
been previously reported (Anand et al., 2011; Smith et al., 2010).  Our WES data 
revealed recurrent mutations of the SF3B1 gene in 11/11 cases, which as such, 
demonstrated the unquestionable power of second-generation sequencing (SGS) 
technologies in cancer research. No SF3B1 mutation was detected in one patients 
with congenital sideroblastic anaemia. However, a constitutional mutation in ALAS2 
gene which has been previously (Camaschella, 2009; Cotter et al., 1999; Kaneko et 
al., 2013) linked with sideroblast phenotype was detected in this patient.  Follow-up 
targeted sequencing in additional 18 MDS patients with ringed sideroblasts identified 
acquired SF3B1 mutations in 86% (6/7) RARS, 100% (1/1) RARS-T, 44% (4/9) 
RCMD-RS and 100% (1/1) AML with a preceding RARS. All the mutations were 
confirmed as acquired somatic mutations by their absence in DNA isolated from paired 
skin biopsy or CD3+ T-cells. Two studies published at the same time reported similar 
data showing the presence of SF3B1 mutations in MDS patients with ring sideroblasts 
(Papaemmanuil et al., 2011; Yoshida et al., 2011b). In fact, Yoshida et al unmasked a 
complexity of novel mutations affecting multiple but distinctive components of the 
splicing machinery in approximately 45% to 85% of MDS patients depending on the 
disease subtypes.  
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Precise removal of pre-mRNA introns, a critical aspect of gene expression is catalysed 
by a highly dynamic protein complex, the spliceosome (Kuwasako et al., 2008). SF3B1 
located on chromosome 2q33.1, is an essential component of the U2 snRNP which 
along with other snRNPs forms the main building block of the major spliceosome, 
responsible for removing the vast majority of pre-mRNA introns (Kuwasako et al., 
2008). Sf3b1 lies within the U2-snRNP spliceosome catalytic site, and has an 
important role in the pre-spliceosome assembly and splicing catalysis. Sf3b1 is 
composed of two regions: the N-terminal domain (Sf3b155 NTD) and the C-terminus. 
The N-terminal of Sf3b1 is unstructured; less conserved and contains the binding sites 
for splicing associated factors U2AF65, p14, Cyclin E, and Nipp 1 (Wahl et al., 2009). 
However, the C-terminus of Sf3b1 is highly conserved among different species, 
including human, mouse, schizosaccharomyces pombe, caenorhabditis elegans and 
Xenopus (Isono et al., 2001). All the SF3B1 mutations detected in our patient cohort 
were present in this highly-conserved protein c-terminal. This part of the protein 
contains 22 tandem helical repeats (HEAT motifs) that form rod–like, helical structure 
and wrap around the U2 snRNP, therefore providing the stability to the whole U2 
snRNP complex of the major spliceosome. It is worth to note that majority of the 
mutations were present in the sixth HEAT motif while as some were also present in 
the fourth and fifth HEAT motif. Each of the HEAT motif contains repeats of ≈47 amino 
acid residues. The structural studies of Sf3b have revealed that these HEAT motifs 
wrap round the U2 snRNP and are thought to stabilize the structure of the U2 snRNP. 
The conformation of Sf3b bound to the U11/ U12 di-snRNP differs from that of isolated 
Sf3b and upon integration into the di-snRNP, Sf3b rearranges itself into a more open 
form (Golas et al., 2005; Stark and Luhrmann, 2006). The candidate domain within the 
whole SF3b complex that drives this rearrangement is likely to be Sf3b1 HEAT motifs 
itself. This observation is based on the similar reports of the changes in the curvature 
of the proteins with HEAT repeats which have been previously reported in protein 
complexes such as importin-β. Importin-β HEAT motifs upon binding to one of its 
interaction partners importin-α or Ran changes its conformation (Cingolani et al., 
1999). The sixth HEAT motif in which majority of the mutations are present, lies at the 
hinge of the shell-like structure which plays a major role in this rearrangement process 
of Sf3b1 (Golas et al., 2005). There is an increasing evidence suggesting that initial 
splicing occurs as the nascent RNA molecule is being transcribed, an integrated 
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process in which a continuous cross-talk exists between the spliceosome and the 
proteins involved in the initiation, elongation, and termination stages of the 
transcription machinery (Chen and Manley, 2009). Therefore, knowing the critical 
function of the Sf3b, the likely consequence of these mutations would be the 
impairment of the switching mechanism by which Sf3b1 changes its conformation and 
interacts with other spliceosome components, therefore leading to the disruption of the 
splicing itself. On the other hand, it might have a direct effect on the interaction of 
Sf3b1 or spliceosome with the active transcriptional machinery.             
Functional characterization of SF3B1 mutations and their contribution to 
myelodysplasia is still unclear. Sf3b1-/- homozygous null mutant mice have been 
shown to die very early, around the 16- to 32- cell stage (Isono et al., 2005), therefore 
reinforcing the importance of SF3B1. It is worth to note that all the SF3B1 mutations 
are heterozygous substitutions and none of aberrations shown in this study or reported 
elsewhere are homozygous substitutions or frameshift and splice-site aberrations. 
Therefore these aberrations are likely to produce a structurally intact but functionally 
impaired Sf3b1 protein with perhaps an altered gain-of-function protein. This is also 
reflected from our in-silico mutational analysis which suggests that SF3B1 mutations 
will likely have an effect on the function of the protein as has also been suggested by 
others (Papaemmanuil et al., 2011).  
A connection between pre-mRNA processing and cell cycle progression has been 
implicated by various studies including a study by our group (Orr et al., 2012). In a 
transient experiment, Steve and colleagues showed reducing the expression of SF3B2 
or SF3B4 prevented T cells entering the cell cycle (Orr et al., 2012). Furthermore, in-
vitro knockdown experiments have linked loss of Sf3b1 function with the aberrant cell 
cycle characteristics, cell cycle arrest and increased apoptosis, where aberrant 
splicing of cell-cycle genes has been noted (Kaida et al., 2007; Yoshida et al., 2011a). 
In support of this, a study by Jonathan et al reported that 5 novel splicing isoforms of 
CDC25C were found in MDS patients, and the splicing patterns were generally distinct 
in patient samples compared with healthy controls. One of the novel isoforms 
CDC25C-6 was found to be present in 58% of the patients. The highly conserved 
CDC25 phosphatases is a critical component of cyclin/CDK regulation. CDC25A, is 
involved in initiation of the S phase of cell division, while the other two, CDC25B and 
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CDC25C, regulate the G2/M transition (Caudill et al., 2008). This study provides a 
possible link between the aberrant splicing of cell cycle gene and the MDS 
pathophysiology.   
Somatic SF3B1 mutations are found almost (up to 85%) in all MDS patients with ring 
sideroblasts (RARS, RCMD-RS and RARS-T), therefore suggesting a causal 
relationship between mutation and its downstream effects resulting in the formation of 
ring sideroblast. Although, the majority of the SF3B1 aberrations are dominant 
heterozygous mutations, however, the percentage of ring sideroblasts in these 
patients ranges considerably from 20% to 95%. Interestingly, various studies (Cazzola 
et al., 2012; Damm et al., 2012c; Papaemmanuil et al., 2011) including ours have 
found a relationship between the SF3B1 mutations and the percentage of ring 
sideroblasts, however, this does not explain the huge phenotypic (i.e. ring sideroblasts 
percentage) variability in these patients. A recent study by Visconte et al has 
implicated the role of SF3B1 aberrations in the formation of ring sideroblasts in MDS 
(Visconte et al., 2012b). The author found that meayamycin which is a pharmacologic 
inhibitor of the Sf3b complex induces the formation of ring sideroblasts in the healthy 
bone marrow cells (Visconte et al., 2012b). In agreement with this, transient siRNA-
mediated silencing of SF3B1 elsewhere (Nikpour et al., 2012) resulted in reduced 
expression of ABCB7 in K562 cells. Down regulation of ABCB7 led to markedly 
reduced erythoid growth in in-vitro with accumulation of mitochondrial ferritin in 
immature RBCs. Furthermore, normalization of ABCB7 expression in these cells 
rescued the RARS phenotype. In the same study, 11/13 studied RARS patients with 
SF3B1 mutation had aberrant ABCB7 exon usage as compared to normal bone 
marrow cells (Nikpour et al., 2012), therefore suggesting a link between the two genes 
and the RARS disease phenotype. On the other hand, recently mitochondrial 
transporters SLC25 (SLC25A37 and SLC25A38) and ALAD genes were implicated in 
the pathogenesis of ring sideroblast phenotype in RARS (Del Rey et al., 2015). In 
contrary to this, our gene expression data did not reveal any obvious downstream 
target genes (such as mitochondrial pathway genes or haem biosynthesis genes) 
specific to SF3B1 mutations. This could be due to the fact that the net downstream 
effect of SF3B1 mutations is very subtle. Due to the high turn-over of the erythroid 
cells in the body and hence higher requirement of the Sf3b1 protein, this subtle effect 
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on the downstream “gene(s) or pathway(s)” is enough to cause the phenotypic 
changes in erythroid cells but are not detectable with the current available technology. 
However, the difference in the results between our study and other published studies 
could be due to the fact that we were trying to identify the ‘SF3B1 mutation’ specific 
effect (by comparing SF3B1 mutated vs SF3B1 wildtype patients, both groups with 
ring sideroblasts) while as other published studies were focussing on the ring 
sideroblastic phenotype (by comparing SF3B1 mutated patients with ring sideroblasts 
vs SF3B1 wildtype non-sideroblastic anaemia MDS subgroups). In addition, different 
coexisting mutations present alongside SF3B1 mutations might also be influencing the 
outcome of gene expression data coming from different studies. However, whether 
‘SF3B1-ABCB7’ relationship forms basis of the pathophysiology of RARS remains to 
be determined and will require detailed biochemical studies of the mutant protein. 
Fundamentally however, the influence of such SF3B1 mutations is not just in myeloid 
tissue and RARS, but has also been observed in chronic lymphocytic leukaemia (CLL) 
and lymphoid tissue (Greco et al., 2012; Wang et al., 2011), suggesting that genetic 
background plays an important role in the functional manifestation of these 
aberrations. 
RARS patients generally have a relatively benign clinical course with a small fraction 
of patients progressing to AML. All the patients with SF3B1 mutations had normal 
cytogenetics except one patient with trisomy 8. There was no difference in overall 
survival or leukemic transformation when comparing patients with or without SF3B1 
mutation. We also have found that MDS-RS patients with SF3B1 mutations have 
higher platelet counts and fewer bone marrow blasts.  
MDS has long been considered an oligoclonal disorder with the abnormal clones 
originating from the early hematopoietic stem cells. Analysis of the clonal spectrum by 
means of the MAB analysis of the coexisting mutations can shed new light into the 
order (or sequence) of these mutations in the bone marrow stem cell compartment. 
The fact that SF3B1 mutations were detected in the CD34+ progenitor bone marrow 
cells in all the screened patients suggests that these mutations occur in the early 
haematopoietic stem cells. This is also evident from the bioinformatics clonal analysis 
performed on these patients where in majority of the cases, SF3B1 mutations are 
detected in majority of the cells as suggested by the highest MABs. Additional mutation 
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(such as ASXL1, DNMT3A) detected in these patients are acquired downstream of the 
SF3B1 mutant clones. Furthermore, mutation analyses performed on serial samples 
in one patient who was initially diagnosed with RARS and subsequently transformed 
to AML, also provides us with evidence that SF3B1 mutations are an early ancestral 
events initiating from the stem cells. In this case, the SF3B1 mutant clone survives 
various treatments during the course of the disease and is detected at the time of 
remission as well as progression. The contribution of SF3B1 mutations in disease 
transformation or progression to AML may be limited, but they may instead provide a 
favourable environment or sufficient pressure for other more destabilizing mutations 
to occur. 
Our WES data revealed additional novel patient specific mutations along with SF3B1 
mutations. These include mutations in genes involved in epigenetic machinery, cell 
proliferation, DNA maintenance and cytoskeletal organization. However, we did not 
find any mutation in genes involved in haem synthesis pathway and mitochondrial ion 
transport which is consistent with the previous findings (Papaemmanuil et al., 2011; 
Yoshida et al., 2011b). Among the known myeloid gene mutations, DNMT3A was 
frequently present alongside with SF3B1 mutations, perhaps suggesting a possible 
link between the two genomic abnormalities. Interestingly, only single epigenetic 
modifier mutations (either DNMT3A, ASXL1 or TET2) seemed to co-occur with SF3B1 
mutations, therefore highlighting the importance of genetic background and how 
particular mutation combinations may attain an acceptable biochemical equilibrium 
and stable disease. The phenotypic and/or genotypic variations between patients with 
SF3B1 mutations may either be a function of the different SF3B1 mutation, or reflect 
additional mutation(s) present in the MDS clone in these cases.  
In summary, the newly identified mutation in SF3B1, found in a significantly high 
proportion of MDS patients with ring sideroblasts, provides a possible causative link 
to the typical phenotypic ring sideroblasts observed in this disease subtype. However, 
questions therefore arise similar to the one raised by ribosomal defects in MDS 
(particularly in relationship to the 5q- syndrome) - does an SF3B1 mutation confer a 
clonal advantage to the mutant clone in the bone marrow compartment, and if so, 
how? What are the initiating mutational events? What is the origin of these mutations 
within the haematopoietic compartment? How SF3B1 mutations may interact with 
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other coexisting spliceosome or known myeloid specific mutations? What is their 
prognostic significance in isolation or in combination with other mutations in MDS? 
Future analyses of SF3B1 gene and known myeloid specific gene mutations in a larger 
diverse MDS patients will help to build a complete picture of the diseased genome and 
an understanding of the interactions and/or mutual exclusivities between genetic 








4 SF3B1 and other spliceosome mutations exhibit specific associations 
























4.1 Somatic mutations in MDS 
Developments in genomics utilizing highly sensitive and scalable array-based and 
second-generation sequencing-based technologies have led to the identification of 
genes that are often mutated in MDS. Recent studies have reported mutations 
involving multiple components of the mRNA splicing machinery including SRSF2, 
U2AF1, ZRSR2, PRPF40B, U2AF65 and SF1 in patients with MDS, myeloproliferative 
disorder (MPN) and AML (Abu Kar et al., 2012; Damm et al., 2012a; Damm et al., 
2011; Graubert et al., 2012; Makishima et al., 2012; Malcovati et al., 2011; 
Papaemmanuil et al., 2011; Patnaik et al., 2012; Thol et al., 2012b; Visconte et al., 
2012a; Wu et al., 2012; Yoshida et al., 2011a). In addition, we and other have also 
reported mutations in splicing factor SF3B1 gene in MDS patients with ring 
sideroblasts (Papaemmanuil et al., 2011; Smith et al., 2011; Yoshida et al., 2011b). 
SF3B1, the most frequently mutated spliceosome component in MDS (30% of cases), 
is mutated in 70-85% of RARS/RCMD-RS patients and correlate with the presence of 
ring sideroblasts (Papaemmanuil et al., 2011; Patnaik et al., 2012).  
Over the past decade a number of novel gene mutations have been identified that are 
associated with MDS including genes involved in epigenetic regulation  (TET2, 
DNMT3A, IDH1/2, ASXL1, EZH2) (Boultwood et al., 2010; Kosmider et al., 2010; 
Nikoloski et al., 2010; Smith et al., 2010; Walter et al., 2011) and cell 
signalling/transcription regulation (TP53, NRAS/KRAS, RUNX1, FLT3, CCBL and 
ETV6) (Bains et al., 2011; Bejar et al., 2011; Jadersten et al., 2011; Shih et al., 2004). 
In fact, around 50% of MDS patients have defects in one or more of these ‘epigenetic’ 
or ‘oncogenic’ factors, therefore suggesting an underlying genomic instability and 
aberrant transcriptional regulation in the evolution of this disease. However, 
establishing the relevance of these individual alterations with the pathogenesis of the 
disease has been a major challenge primarily because the molecular basis of MDS is 
phenotypically multifaceted and likely contributors are epigenetic changes, altered 
response to cytokines, the immune response to evolving clone(s), and the bone 
marrow stroma.  
To gain a better understanding of SF3B1 and other spliceosome aberrations, and how 
they may interact with other known myeloid specific gene mutations, and to determine 
their prognostic significance in isolation or in combination, a comprehensive mutational 
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screening was performed in a cohort of 154 MDS patients of various WHO subtypes 
(Table 29). Sequential samples were available from two patients in whom disease 
transformation (i.e. AML) was observed.  
Patients with MDS seen at King’s College Hospital from June 2004 to June 2014 were 
enrolled in this study. All patients had provided written informed consent in accordance 
to National Research Ethics Protocol (08/H0906/94).  Demographic and clinical 
characteristics of the studied patients are detailed in Table 29. All patients were risk 
stratified according to IPSS categories. The clinical variables, FAB, WHO subtype and 
the prognostic risk of all patients were ascertained at the time of sample collection. 
The median follow-up was 21.4 months (Range, 1-83 months). The patient cohort was 
followed up to January 2012 for disease progression, and survival. The survival data 
for patients who underwent allogeneic haematopoietic stem cell transplant (HSCT) 
(n=35, 22%) were censored on the day of transplant. 
A panel of 22 genes consisting of splicing factor genes SF3B1, SRSF2, U2AF1 and 
ZRSR2; genes implicated in epigenetic regulation TET2, IDH1/2, ASXL1, EZH2 and 
DNMT3A; and known oncogenes/genes involved in cell signalling/transcription 
regulation TP53, FLT3, NRAS, KRAS, RUNX1, CCBL, C-KIT, JAK2, MPL, CEBPA, 
BRAF and NPM was selected and optimized for the mutational screening. These 
genes were selected based on the previously published reports showing the 
commonly mutated genes in myeloid malignancies. PCR primers specific to coding 
exons of all genes were designed using Primer 3 program.  These primers were tagged 
with a universal sequencing primer (aUS1 for forward; aUS2 for reverse) which was 
subsequently used alongside Roche multiple-identifiers (MIDs) to barcode each 
patient (see methods section 2.2.5 for more details).   
DNA isolated from 154 patient bone marrow total nucleated cells (TNCs) or CD34+ 
cells was used for gene amplicon library preparation. Constitutional DNA (skin, n=27; 
CD34-CD3+ cells, n=18) was available from 45 patients. Following the PCR 
amplification of the exonic regions of the target genes, all amplicons (exonic regions) 
for each patient were pooled in one reaction. PCR amplified gene amplicons (after 
second round PCR) for randomly selected patients were loaded on an agarose gel 
and visualized under the UV-illuminator. In addition, the concentration of all gene 
amplicons (second round PCR) for 5 randomly selected patients was measured by 
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using the Quant-iT pico-green dsDNA assay kit as described in methods section 3.2.2. 
Pooled libraries were further processed for sequencing in a batch-wise manner (see 
methods section 2.2.2 for more details). 
The sequencing was performed on Roche/454 FLX Sequencer. The average 
sequencing coverage across all genes was 200X and >90% of the coding regions had 
a coverage of >100X. This coverage enabled a reliable detection of mutant clones 
down to ≥5-10% MAB (defined as the proportion of sequence reads containing the 
mutation). Mutations in any one or more of these genes were detected in 76% 
(n=117/154) of the patients, with 38% (n=59) of the patients having splicing factor 
mutations and 49% (n=75) of patients harbouring more than one mutation (Figure34 
and appendix table 15). Known single nucleotide polymorphisms (SNPs) and 
insertion/deletion variants listed in national Center for Biotechnology informations SNP 
database (dbSNP, build 140) and previously reported as germ line were excluded from 
further analysis. All mutations were confirmed through independent PCR and GS-FLX 
sequencing/Sanger sequencing experiments. For data relating to samples at/prior to 
transformation to AML, where 454-amplicon sequencing data was not available, 
relative peak intensity from Sanger sequencing was used to estimate MAB. Novel 
mutations which had not been previously reported were confirmed as acquired by their 
absence in 48/54 cases for whom constitutional source of DNA was available: skin 
biopsy (n=27), CD3+ T-cells (n=18) and buccal swab (n=3) paired constitutional DNA. 
The remaining 7 novel variants (3 stop codons, 1 frame-shift mutation, 1 in-frame-shift 
deletion and 2 splice-site mutation) detected in  6 patients were also included in the 
analysis although constitutional source of DNA was not available (Appendix Table 19).  
The nature of these mutations makes them unlikely to be benign inherited variants. 
The reminder of the mutations identified in this study had previously been reported in 








Table 29: Clinical characteristics of patients studied. 
Patients were stratified by presence or absence of splicing factor mutations SF3B1, SRSF2 
and U2AF1.  Cytogenetics failed in 4 patients in this cohort. P values with statistical 
significance are highlighted in bold. n- Represents number of patients; % - Represents 































































































































Age, years    0.42   0.16   0.8 
Median 65.5 65.2 63.1  66.9 63.1  62.8 63.5  
Range 17-85 35-83 17-85  51-82 17-85  48-75 17-85  
Sex    0.98   0.5   0.38 















WHO category *    <0.001   <0.001   0.2 
































































































Bone marrow blasts    0.19   0.39   0.27 
Median (%) 5 1 6  8.5 4  9 4  
Range 0-80 0-19 0-72  0-19 0-80  0-59 0-80  
IPSS cytogenetic risk group 151   <0.001   0.15   0.46 
























































































Figure 34: Gene Mutations detected in our MDS patient cohort.  
(A) Frequency of gene mutations in our cohort of patients. (B)Top row represents distribution 
of mutations in 117 cases; where the shade of the bar indicates the cytogenetic risk groups 
according to the inset key. Underlying rows represent individual gene mutations denoted by 
coloured bars and specified on the left hand side. Bars with white strips indicate nonsense 
mutations, including splice-site mutations, while bars without stripes represent missense 






















































































































































































































4.1.1 Spliceosome gene mutations - frequency and clinical correlates 
Sequencing of the splicing factor genes revealed 61 somatic mutations in 38% (59 of 
154) of MDS patients (Table 29 and Appendix Table 19), comprising SF3B1 16% 
(n=24), SRSF2 13% (n=20), U2AF1 10% (n=15) and ZRSR2 1% (n=2).  WHO 
subgroups for mutations of splicing factor genes included, RARS/RCMD-RS (20/24, 
83%), CMML or MDS/MPN (9/14, 64%), sAML (6/15, 40%), RAEB-1/2 (13/49, 27%), 
RA/RCMD (10/40, 25%), but were uncommon in tMDS (1 of 12).  Splicing factor 
mutations were common in low/int-1 IPSS (36/68, 53%) compared to int-2/high risk 
IPSS categories (12/63, 19%, p<0.002). Furthermore, with the exception of one case, 
all patients with isolated splicing gene mutations and no additional coexisting 
mutations (n=21) belonged to low/int-1 IPSS subgroup. Patients with complex 
karyotypes were less likely to harbour any splicing factor mutations as compared with 
good and intermediate risk IPSS cytogenetic groups (13 % vs 47% and 44%, p<0.002). 
Overall, 24 of 154 (16%) MDS patients had a somatic mutation of SF3B1, however the 
frequency of SF3B1 mutation was significantly higher in the RARS/RCMD-RS (20/24, 
83%) as compared to other WHO categories (4/130, 3%, p<0.001). Although there 
were no significant differences in patients between the groups with respect to age, 
sex, blast percentage and neutrophil count, SF3B1 mutations correlated strongly with 
lower haemoglobin (median-8.9 vs 10.1 g/dl, p<0.006), higher platelet count (median-
296 vs 102 x 109/l, p<0.001), low/int-1 risk IPSS score (31% vs 0%, p<0.001), normal 
cytogenetics (24% vs 0%, p<0.002), transfusion dependency (21% vs 9%, p<0.03) 
and a decreased likelihood of leukaemic progression (4% vs 15%, p<0.02) when 
compared with wild type SF3B1. 
Among the 154 MDS patients, 20 had SRSF2 mutations (13%) and showed a 
significantly high neutrophil count (median-11 vs 2.8 x 109/l, p<0.001) and higher 
haemoglobin levels (median 10.9 vs 9.8 g/dl, p<0.03) compared to patients with wild 
type SRSF2. There was no difference in platelet count or transfusion dependency rate 
between the groups. SRSF2 mutations were more frequently seen in patients with 
MDS/MPN or CMML (50%) and RAEB-1/2 (14%), but was absent in low risk IPSS 
including patients with ringed sideroblasts. Interestingly, both patients with 
isochromosome17q (n=2) had mutations of the SRSF2 gene which maps to 17q25.1. 
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There was significant difference in rates of leukaemic progression in patients with 
mutant SRSF2 compared with wild type (50% vs 24%, p<0.02), with two thirds of 
patients with co-existing SRSF2 and cell signalling/transcription regulator mutations 
progressing to AML. U2AF1 mutations were detected in 15 (10%) patients with 
clustering in male patients (12/15, 80%) and was also associated with lower 
haemoglobin (median-9 vs 10 g/dl, p<0.05) when compared to wild type U2AF1, but 
no significant differences in age, platelets, neutrophils, transfusion dependence, IPSS 
score or WHO subtype, were observed between the two groups. ZRSF2 mutations 
were detected in only two (1%) MDS patients. 
Interestingly, splicing factor mutations were largely mutually exclusive to each other, 
with only 2 patients having two separate spliceosome gene mutations, one with 
mutations in SF3B1 and U2AF1 whilst the other patient had mutations in SF3B1 and 
ZRSR2 genes. 
4.1.2 Splicing factor mutations- Type, site and allele burden 
Majority of SRSF2 mutations were heterozygous non-synonymous amino acid 
substitutions, with an average MAB of 37.5% (n=20), comprising Pro95His/Leu/Arg 
(n=16) (Figure 35) changes as previously reported (Yoshida et al., 2011a).  A novel 
24 base pair deletion in SRSF2 causing the frameshift mutation Tyr93fsX121 was 
detected in 4 patients, which  would be predicted to cause  loss of protein function 
(Figure 36).  
However, U2AF1 mutations exclusively present within the amino- and the carboxyl-
terminal zinc finger motifs had a lower average MAB of 27% (n=15). These mutations 
targeted codon S34F (n=4) and Gln157Pro/Arg/His (n=11) of the protein (Figure 35). 
On the other hand, ZRSR2 mutations had a much higher average MAB of 60.5% (n=2), 
were distinct in nature and did not cluster in the same protein domain (Figure 35), 







          
          
 
       
Figure 35: Distribution of SRSF2, U2AF1 and ZRSR2 mutations.  
Each panel represents the known protein functional domains and 3D protein structure for SRSF2, 
U2AF1 and ZRSR2. Distribution of somatic mutations are shown across all the protein domains for 






Figure 36: Patients with novel SRSF2 mutations.  
Top half of each panel shows the 454-Roche sequencing data output for patients with 24 
basepair SRSF2 deletion. Grey lines within the graph represents deleted nucleotides. Bottom 
half of each panel shows the clinical characteristics (Age, WHO, Blast count, Haemoglobin, 
Neutrophils, Platelets) as well as additional mutations (if present) for each patient. MAB- 




4.1.3 Prevalence of mutations in Epigenetic modifiers and Cell Signalling 
/Transcription regulators 
The overall frequency of mutations of genes involved in epigenetic regulation (TET2, 
ASXL1, DNMT3A, IDH2, EZH2 and IDH1), cell signalling/transcription regulators 
(FLT3, RUNX1, NRAS, C-KIT, CCBL, JAK2 and MPL) and mutations in tumour 
suppressor gene TP53 were 52% (n=80), 18% (n=28) and 12 % (n=19), respectively 
(Table 29 and Appendix table 19). Interestingly, mutations predicted to effect 
epigenetic regulation were detected in nearly half the patients, with TET2 mutations 
being the most frequent in 22% (n=34) of the cohort. The frequency of other mutations 
was ASXL1 (17%, n=26), DNMT3A (10%, n=16), IDH2 (8%, n=13), EZH2 (7%, n=11) 
and IDH1 (1%, n=2). Although mutations in epigenetic modifiers clustered in female 
patients (64% vs 25%, p<0.05), there was no differences in the WHO subtypes, IPSS 
score, transfusion dependency or leukemic transformation rate when compared with 
cases wild type for genes involved in epigenetic regulation. Furthermore, mutations in 
genes involved in cell signalling/transcription regulation were detected in 18% of MDS 
patients with mutations of NRAS and RUNX1 each present in 6% (n=9 each), CCBL 
(4%, n=6), FLT3 (3%, n=4) and JAK2 (2%, n=3). C-KIT and MPL mutations were 
detected in one patient each. Overall patients with these mutations, with the exception 
of JAK2 and MPL, were associated with high risk MDS, increased blast count, 
transfusion dependency and increased likelihood of leukemic transformation when 
compared to their wild type counterparts (p<0.01).  No BRAF, NPM and KRAS 
mutations were detected.  
4.1.4 Mutual exclusivity of TP53 with spliceosome mutations 
TP53 mutations were detected in 12% (19/154) of cases (Table 29 and Appendix table 
19). TP53 mutations were infrequent in patients with splicing factor mutations (5%, 
3/59) compared to patients with wild type splicing factor genes (17%, 16/99, p<0.04).  
However, among patients with splicing factor mutations, all three TP53 mutations were 
observed exclusively in those who had mutations in spliceosome component U2AF1 
(20% vs 0%, p<0.01). Among the patients with concurrent TP53 and U2AF1 mutations, 




4.1.5 Coexistence and exclusivity of splicing factor mutations with commonly 
mutated epigenetic modifiers and Cell signalling/transcription regulating 
genes   
Of the 59 patients with spliceosome mutations, 15 (25%) had isolated splicing factor 
mutations, whilst 29 (49%) and 15 (25%)  had mutations in epigenetic modifiers  and 
cell signalling/transcription regulator mutations  respectively, including 8 patients with 
coexisting mutations from all 3 mutation classes (Figure 34, Figure 37 and Table 30). 
Regardless of disease subtypes, MDS cases with non-SF3B1 splicing factor mutations 
had significantly more mutations in other genes screened here (mean 2.4 
mutations/case), than in patients with SF3B1 mutations (mean 1.9 mutation/ case, 
p<0.03). 
Furthermore, mutations of epigenetic modifiers were associated with mutant SRSF2 
compared to wild type (70% vs 50%, p<0.07), which was predominantly due to the 
presence of more TET2 mutations with mutant SRSF2 than wild type (40% vs 25%, 
p<0.04). Patients with splicing factor mutations were less likely to have multiple 
epigenetic modifier mutations (14%, n=5) compared to patients with wild type splicing 
factors (33%, n=15) (p<0.03), although if present, multiple mutations of epigenetic 
modifiers more often coexisted with U2AF1 (n=4) rather than SF3B1 or SRSF2 (n=1) 
mutations. DNMT3A mutations were less likely to be seen with SRSF2 mutations 
compared with other spliceosome mutations (0% vs 15%, p<0.08), whilst ASXL1 
mutations were more likely to co-occur with SF3B1 than other splicing factor mutations 
(23% vs 4%, p<0.07), indicating non-random mutation associations and tolerances. A 
trend towards an association between IDH2 and U2AF1 was observed, when 
compared with other splicing mutations (p<0.06). 
Mutations of genes involved in cell signalling/transcription regulation (FLT3, NRAS, 
CCBL, RUNX1, JAK2, MPL and C-KIT) clustered with splicing factor mutations (27% 
vs 13%, P<0.02). When splicing factor mutations were examined individually, these 
non-TP53 mutations co-existed frequently with SRSF2 mutations (50% vs 13%, 
p<0.003), compared to MDS patients with wild-type SRSF2. Furthermore, when 
considering  all 59 cases of splicing factor mutants alone, mutations of FLT3, NRAS, 
CCBL, RUNX1, JAK2, MPL, C-KIT and TP53 were significantly less often associated 
with SF3B1 mutations compared with other splicing factor alteration cases (8% vs 
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34%, p<0.009). SRSF2 mutations co-existed with mutations of cell 
signalling/transcription regulation genes, especially with alterations of NRAS (p<0.04) 
and FLT3 (p<0.03), compared with non-SRSF2 splicing factor mutations (40% vs 13%, 
p<0.02).  Furthermore, NRAS mutations (n=9) were mutually exclusive to epigenetic 
modifier mutations IDH2 (n=13) and EZH2 (n=11). CEBPA mutations co-existed with 
SF3B1 mutations than with other splicing factor mutations (21% vs 0%, p<0.008).  
The average MAB for SF3B1 and SRSF2 mutations was 41% (24 cases) and 37.5% 
(20 cases), respectively.  Coexisting point mutations present alongside with these 
splicing factor mutations had an average MAB of 35% and 37.5%, respectively, where 
the MAB of epigenetic modifiers  (38% and 39%) was higher than cell 
signalling/transcription regulator mutations (27.5% and 28.75) for SF3B1 and SRSF2, 
respectively.  U2AF1 mutations had a lower average allele burden of 27% (15 cases) 
with 39% average MAB of other coexisting mutations where the burden of the cell 
signalling/transcription regulator mutations (45%) was higher than epigenetic modifier 
mutations (33%). This seemed to be due to the U2AF1/TP53 mutant cases which had 
a relatively higher TP53 than U2AF1 MAB in 2/3 cases. ZRSR2 mutation allele burden 






              
Figure 37: Frequency and distribution of various gene mutations in MDS patients as depicted by Circos diagram.  
The arc length corresponds to the frequency of mutations in relevant gene and the ribbon width corresponds to the percentage of the patients 
that have other coexisting mutations. (A) Coexistent mutations between 22 individual genes in 119 patients. (B) Coexistent mutations between 





Table 30: Summary of mutations coexisting with mutant and wildtype spliceosome 
components in 154 patients.  
Mutations were grouped according to their functional relevance; splicing factor, SF3B1, 
SRSF2, U2AF1 and ZRSR2; epigenetic modifier, TET2, IDH1/2, ASXL1, EZH2, and 
DNMT3A; Cell signalling/transcription regulator, FLT3, NRAS, C-KIT, RUNX1, CCBL, JAK2 
and MPL; tumour suppressor TP53. Table 2A compares mutations in the grouped genes. 
Table 2B shows co-existing gene mutations and individual gene mutations coexisting with 
splicing factor mutations. 37 patients were wildtype for all screened genes. Table cells 
indicate number of patients within mutant or non-mutant spliceosome groups followed by the 
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4.1.6 Sequential acquisition of cell signalling/transcription regulating gene 
mutations in SF3B1 mutant clones with disease transformation 
Only 2 of 24 patients with RARS/RCMD-RS and SF3B1 mutations evolved to AML at 
variable time points after diagnosis (Patient MDS54, 4 months; patient UPN MDS105, 
36 months). To investigate the contributions of SF3B1 and coexisting mutations in 
disease evolution, relevant sequential samples were screened for both these cases. 
Sequencing analysis of the samples taken from patient MDS54  and  MDS105  at the 
time of diagnosis  and at presentation to our institute ( 24 months after diagnosis) 
revealed SF3B1 mutation with a MAB  of  39% and 42%, respectively (See exampled 
for MDS54 in Figure 38). A TET2 mutation was detected at diagnosis, with a MAB of 
60%, in MDS54 (Figure 38) and a RUNX1 mutation in MDS105.  However, MDS105 
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transformed to AML and underwent allogeneic HSCT in morphological remission, 
following induction chemotherapy. He relapsed with AML and lost his donor 
chimerism, shortly after HSCT. The SF3B1 and RUNX1 mutation burden was 
maintained at the same level as at the RARS stage and at AML relapse after HSCT in 
MDS105.  Similarly, SF3B1 and TET2 mutations were maintained at the same mutant 
allele burden at transformation in MDS54. At the time of transformation to AML, 
MDS54 also acquired a mutation in RUNX1 (Phe163Tyr) with a MAB of ≈30%, and a 
FLT3-ITD (Phe590_Trp603dupInsPro) with a MAB of ≈50% (Figure 38). Following 
intensive chemotherapy, MDS54 attained a transient morphological remission but 
relapsed rapidly with FLT3-ITD and RUNX1 MAB increasing to ≈80% and ≈45% 
respectively. The MAB of SF3B1 and TET2 genes remained constant at 40% to 50% 
throughout the disease duration, which as a heterozygous mutation would occur in a 
majority of sample cells. As such, RUNX1 and FLT3 mutations seemed to have 









          
Figure 38: Clonal evolution and disease progression in RARS patient.  
Sequencing analysis of sequential samples in MDS54 with an SF3B1 mutation. Three 
horizontal rows represent samples collected at different time points: diagnosis, transformation 
to AML and disease progression after a short duration of remission, respectively.  
Accumulation of the oncogenic mutations and changes in mutant allele burden levels are seen 
through disease progression along with increase in the blast count. Sanger sequencing was 
used to confirm/ determine the mutation status throughout the experiment. 454 sequencing 




4.1.7 Prognostic significance of mutations 
The median overall survival (OS) of the entire cohort was 34.4 months (95% 
confidence interval (CI), 16.9 to 51.9 months). Univariate analysis revealed that 
patients with SF3B1 mutations had a better OS [Not Reached (NR) vs 24.2 months, 
p<0.003] and progression free survival (PFS) (NR vs 40.3, p<0.02) than wild type 
SF3B1 (Figure 39A and Figure 39B), whilst none of the other splicing factor gene 
mutations had an impact on either outcome measure. The median OS of patients with 
either of splicing factor mutations was significantly better than wild type spliceosome 
(NR vs 24.2 months, p<0.03), but no difference in PFS was seen between the groups 
(Figure 39C and Figure 39D).  
 
     
Figure 39: Statistical analysis for SF3B1 and Splicing factor gene mutations. 
Overall survival (A) and progression free survival (B) for patients with SF3B1 mutations (n=24) 
compared with wild type SF3B1 (n=130). Overall survival (C) and progression free survival (D) 




On a univariate model, there was no significant difference in either OS or PFS in 
patients with other individual mutations compared to wild type, except for TP53 and 
NRAS (Figure 40). Among patients with epigenetic modifier mutations (n=81), a 
proportion also had coexisting splicing factor mutations (n= 37) and 44 patients had 
epigenetic modifier mutations alone. A trend towards a better survival was seen in the 
group of patients with epigenetic modifier mutations with splicing gene mutations 
compared with the rest (p<0.06), although the distribution of mutations of genes 
involved in cell signaling /transcription regulation and TP53 mutations were evenly 
distributed in both groups (Figure 41). 
 
 
Figure 40: Statistical analysis for TP53 and NRAS gene mutations. 
Overall survival (A) and progression free survival (C) for patients with TP53 mutations (n=19) 
compared with wild type TP53 (n=135). Overall survival (B) and progression free survival (D) 





Figure 41: Statistical analysis for Epigenetic modifying and splicing factor gene 
mutations. 
Overall survival (A) and progression free survival (B) for patients with  epigenetic modifier (EM) 
mutations  stratified according to coexistence of splicing factor (SF) mutations with epigenetic  
modifier mutations (n=37) or epigenetic modifier mutations alone (n=41). 
 
Patients with mutations of splicing factor and of genes involved in cell 
signalling/transcription regulation or TP53 (n=15) had an extremely poor OS (15.8 
months vs NR, p<0.009) and PFS (12.5 months vs NR, P<0.001) when compared with 
spliceosome mutations without mutations of genes involved in cell 
signalling/transcription regulation (n=44), (Figure 42) although this group had only 3 
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Figure 42: Overall survival (A) and progression free survival (B) for patients with 
spliceosome mutations (n=59). 
Patients were stratified according to patients with splicing factor mutations (SF) co-existing 
with mutations of genes involved in cell signalling/transcription regulation (CS/TR) or TP53 
mutations versus splicing factor mutations co-existing with epigenetic modifier (EM) mutations 
versus patients with splicing factor mutations alone. 
 
 
Table 31: Multivariable analysis of overall survival.  
The variables included are age, WHO category, medullary blasts, IPSS cytogenetic risk 
groups, transfusion dependency, SF3B1 mutations, NRAS mutations and TP53 mutations. 
 
SF                         
EM                 
CS/TR or TP53
P<0.009
SF vs CS/TR or TP53  p<0.001
SF vs EM                      p=0.14




S vs CS/TR or TP53      p<0.001
S vs EM                          p=0.445
EM vs CS/TR or TP53  p<0.003
P<0.001
A B
   
OS 
Variable Hazard Ratio 95% CI p value 
Age 1.0 1-1.1 0.05 
WHO category 1.1 0.9-1.3 0.12 
IPSS Cytogenetic 1.9  1.3-2.6 0.001 
Medullary blast count 1 0.9-1 0.2 
Transfusion dependency 1.7 0.9-3 0.08 
SF3B1 0.2 0.1-0.8 0.03 




Multivariant analysis using variables: age at the sample collection, WHO category, 
medullary blast count, IPSS cytogenetic groups, transfusion dependency status, and 
SF3B1, NRAS, TP53 mutations, revealed that NRAS mutations did not have impact 
on OS or PFS. Patients with SF3B1 and TP53 mutations had varying impacts on OS 
with hazard ratios (HR) of 0.2 (p<0.03, 95% CI, 0.1-0.8) and 2.1 (p<0.04, 95% CI, 1.1-
4.4), respectively. None of the analyzed genotypes, including SF3B1 and TP53, 
impacted on PFS in multivariable model (Table 31). The results this chapter will be 




























Our initial findings and also other concurrent reports (Goldstein et al., 2010; Makishima 
et al., 2012; Papaemmanuil et al., 2011; Visconte et al., 2011; Yoshida et al., 2011a) 
of frequent spliceosome pathway mutations in MDS in-general, prompted us to 
perform a comprehensive study of mutant spliceosomal genes including SF3B1 in 154 
MDS patients. To gain further understanding into the genetic and biochemical 
pathways driving this disease, and the interaction of the various known myeloid related 
gene mutations, we also investigated other genes commonly mutated in MDS. In this 
study, 76% of MDS patients had mutations of the genes screened, with nearly 50% of 
patients having more than one mutation. Two large sequencing studies using an 
111gene panel (Papaemmanuil et al., 2013) and 104 gene panel (Haferlach et al., 
2014) published subsequently reported a mutation rate of 78% and 89.5% in MDS 
patients, respectively. The mutation rate reported by Haferlach and colleagues is 
higher which can be due to the variability in the MDS subtypes between published 
studies including ours. For examples, 40% of the patients sequenced in the Haferlach 
study were RAEB1/RAEB11 patients which are known to have higher mutation 
frequency.   
Splicing factor genes, SF3B1, SRSF2, U2AF1 and ZRSR2 were mutated in 38% of 
patients. Although collectively these mutations were found in a wide spectrum of MDS 
subtypes, some were strongly associated with specific disease features. SF3B1 
mutations for example were strongly correlated with high levels of ringed sideroblasts 
and were therefore found in 80% of RARS/RCMD-RS patients, as also reported in 
other studies (Haferlach et al., 2014; Papaemmanuil et al., 2011; Papaemmanuil et 
al., 2013). Conversely, SRSF2 and U2AF1 mutations were often seen in advanced 
forms of MDS such as RAEB1/RAEB11 and CMML respectively, which fitted well with 
a higher number of coexistent mutations in genes involved in cell 
signalling/transcription regulation (e.g. NRAS, FLT3 and RUNX1) with known 
oncogenic functions. 
Occurrence of SF3B1 mutations has been linked to significantly better OS and in some 
instances longer, leukaemia-free and event-free survival in RARS (Papaemmanuil et 
al., 2011). Similarly a beneficial independent prognostic impact for SF3B1 mutations 
182 
 
on outcome, especially OS was seen in this study. In accordance with this observation 
is an absence of coexistent TP53 aberrations, which is a strong predicator of poor OS, 
according to data presented both here and elsewhere (Bejar et al., 2011). 
Furthermore, data from a cohort of 317 MDS patients indicated no influence of SF3B1 
mutations on OS or time to leukemic progression (Damm et al., 2012c). In addition to 
this, previous studies have also linked mutations of U2AF1 (Damm et al., 2012b; 
Makishima et al., 2012) and SRSF2 (Makishima et al., 2012) with an increased risk to 
AML progression and/or shorter OS. However, another study by Thol et al 
demonstrated only SRSF2 mutations were associated with shorter OS as well as time 
to AML progression and not mutations in U2AF1 (Thol et al., 2012a). We could only 
demonstrate a correlation of SRSF2 mutations with progression to AML, but no impact 
on OS. U2AF1 mutations similarly did not have any impact on the outcome in this 
study. Although NRAS and TP53 mutations had impact on outcome, only TP53 
retained significance in a multivariate model.  
Within the spliceosome mutant group, SF3B1 seemed to be the strongest driver of a 
beneficial effect and the only spliceosome factor independently attributed with better 
OS and PFS. Such a model possibly suggests that splicing factor mutations are early 
disease events and define a ‘founder’ disease clone that subsequently develops 
additional, increasingly deleterious mutations during the natural course of the disease, 
clonal evolution and disease progression. Furthermore, as particular splicing factor 
mutations differ in their patterns of association with other mutations, this suggests a 
hierarchy of tolerated mutational load and limitation to particular paths of disease 
evolution. For example, a dearth of co-existent TP53 mutations throughout 
spliceosome mutant cases and mutual exclusivity of TP53 mutations with SF3B1 and 
SRSF2 mutants at the time of diagnosis and disease transformation further supports 
a restrictive pattern of genetic insults. Furthermore, a restrictive pattern of additional 
coexisting mutations previously linked with disease transformation, such as FLT3 and 
RUNX1, are seen alongside SF3B1 mutations, although this might be expected in low 
risk disease such as RARS/RCMD-RS, which make up the majority of SF3B1 mutants. 
However, it is important to note that SF3B1 mutant cases which gained such 
oncogenic mutations during transformation maintained a constant SF3B1 MAB, 
indicating evolution within the same disease clone population. 
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Interestingly, SRSF2 mutants, which are present both in low and high risk disease 
cases, similarly did not coexist with TP53 mutations here, but rather FLT3, NRAS or 
RUNX1 mutant oncogenes, as was the case for transformed SF3B1 mutants. 
Conversely, U2AF1 mutations were found to coexist with TP53 mutations here, 
although the U2AF1 mutation burden was significantly lower than that of TP53 in 2/3 
of these cases, where TP53 mutation burden was high and consistent with LOH on 
chromosome 17p confirmed by metaphase cytogenetics in one of these cases. 
Furthermore, FLT3 and NRAS mutations were independently more likely to occur with 
SRSF2 mutations, accentuating the leukemic transformation rate in these patients, but 
were less likely to occur with SF3B1 mutant cases. The questions therefore remains, 
are such mutual exclusivities driven at a molecular level and due to a lethal 
combination of genetic lesions and do mutations in different spliceosome components 
carry different weights in terms of biological importance and different thresholds of 
additional insults that a particular mutant clone can endure?  
Significantly, mutations of epigenetic modifiers also seemed to fall in with particular 
splicing factor mutations. For example, ASXL1 mutation was less likely to coexist with 
SF3B1 mutations compared to SRSF2 and U2AF1 mutations cases, whilst DNMT3A 
mutations were not found with SRSF2 but coexisted with SF3B1 mutants (4/24). 
Similar results were reported by Bejar and colleagues showing the molecular synergy 
between SF3B1 and DNMT3A genetic lesions (Bejar et al., 2012). Again this highlights 
the importance of genetic background and how particular mutation combinations may 
attain an acceptable biochemical equilibrium and stable disease. It is of particular 
interest that only single epigenetic modifier mutations seemed to co-occur with SF3B1 
and SRSF2 mutations, which would fit the theory that such mutations represent early 
events in disease where numerous clonal genetic lesions or separate disease clones 
have not yet evolved. This is again highlighted in the case of TET2 mutations, 
reasoned as early disease events and which do not add a prognostic value in MDS 
(Delhommeau et al., 2009; Smith et al., 2010), which were more likely to be found in 
MDS cases with mutant spliceosome in our patient cohort, especially SRSF2 
mutations.  
Mutation analyses performed on serial samples in patients who were initially 
diagnosed with RARS and subsequently transformed to AML, also provides us with 
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clear evidence that SF3B1 mutations are an early ancestral event. In these cases, the 
SF3B1 mutant clone survives various treatments during the course of the disease, 
acquiring additional oncogenic mutations such as FLT3 and/or RUNX1, enabling the 
disease to evolve. Supporting this theory, splicing factor mutants in isolation have a 
better OS in MDS cases generally, which seemingly worsens as additional mutant 
genes are added to the genetic makeup. Bejar and colleagues in a previous study 
reported that mutations in 5 genes (TP53, RUNX1, EZH2, ASXL1 and ETV6) are 
independent predictors of poor OS in patients with MDS (Bejar et al., 2011) which 
tends to support our data. It is worth to note that splicing factor gene mutations were 
not studied in this study. Therefore, the contribution of SF3B1 mutations in disease 
transformation or progression to AML may be limited, but they may instead provide a 
favourable environment or sufficient pressure for other more destabilizing mutations 
to occur. Furthermore, the fact that SF3B1 mutations are present in CD34+ but not in 
T-cells in MDS, further reinforces their importance and link to a clonal advantage 
through the course of myeloid disease, particularly in RARS. 
Tumour heterogeneity observed in the bone marrow is quite common in MDS, 
especially in advanced WHO subtypes and high-risk prognostic subgroups. This also 
seems to be associated with increasing number of particular gene mutations and 
intratumoral subpopulations (low level mutations) observed in these patients as 
reported here and elsewhere (Haferlach et al., 2014; Papaemmanuil et al., 2013). 
Taken together, accumulation of increasing number of gene mutations especially 
‘oncogenic’ mutations and growing intra-tumoral heterogeneity characterize the clonal 
evolution as well as advancement of the MDS disease which is associated with a 
worse prognosis.  
It is noteworthy that functional studies to date have not as yet arrived at a consensus 
in identifying definitive functional pathways affected by splicing factor mutations, even 
in RARS where SF3B1 mutation dominate. The variation between RARS samples with 
SF3B1 mutations may either be a function of the different SF3B1 mutations, or reflect 
additional mutations present in the MDS clone in these cases. Although, the majority 
of the SF3B1 mutant cases have a dominant heterozygous mutation clone, however, 
the percentage of ring sideroblasts in these patients ranges considerably from 20% to 
95%. Interestingly, various studies (Cazzola et al., 2012; Damm et al., 2012c; 
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Papaemmanuil et al., 2011) including ours have found a relationship between the 
SF3B1 MAB and the percentage of ring sideroblasts, however, this does not explain 
the huge phenotypic (i.e. ring sideroblasts percentage) variability in these patients. 
Therefore,  this again implies the interplay of several factors driving the MDS clone, 
where spliceosome mutations are perhaps fuelling subtle biochemical changes which 
can be built upon in the course of disease evolution by the emergence of other 
changes (i.e. genetic or epigenetic) within the diseased genome.  
Recent findings including ours have shown that multiple mutations are present in 
clonally evolving diseases such as MDS, brings forth a series of important questions: 
What are the initiating mutational events? What is the origin of these mutations within 
the haematopoietic compartment? Which of the mutation subsets are “driver 
mutations” and hence contribute to the tumour progression? Spliceosome mutations 
are largely mutually exclusively to each other and are less likely to have multiple 
epigenetic modifier mutations as compared to cases with wild-type spliceosome. Does 
this infer that mutations of multiple genes that have different functions or participate in 
independent pathways may be additive or even synergistic in providing an advantage 
to the tumour clone as compared to the mutations of two genes participating in the 
same pathway or process?  Is there a “cross talk” between the processes or 
pathways?   The relationship between the founding mutant clone to the “leukaemia 
initiating cell” and also the other emerging low-level mutant clones is not yet clear; 
therefore separation of individual diseased clonal populations and functional testing is 
essential to determine this partnership. Hence, identifying the combinatorial patterns 
of “driver mutations” in individual diseased clones would help us to identify the 
functional relationships between the mutated genes and aberrant pathways in MDS 








5 MDS initiating-cells originate from the haematopoietic stem cell 



















5.1.1 Haematopoiesis and Xenotransplantation 
Since the pioneering work of Till and McCulloch in the early 1960s, the science of bone 
marrow-derived haematopoietic stem cells (HSCs) has progressed enormously from 
observational to functional studies. The regenerative potential of HSCs was further 
established with clonal in-vivo repopulation assays in two independent studies, thus 
confirming the existence of multipotential HSCs and their progeny (Becker et al., 1963; 
Till and Mc, 1961). This finding prompted others to develop clonal in-vitro assays that 
have been combined with recent developments of genomic technologies, stem cell 
isolation as well as xenotransplantation models in various studies. This has started to 
lead to a better understanding of the complex clonal architecture and mutational 
hierarchy of phenotypically and functionally defined ‘malignant stem cells’ detected in 
haematological malignancies. Furthermore, the successful establishment of murine 
xenograft NSG models, particularly for acute myeloid leukaemia (AML) has yielded 
empirical evidence for the existence of so-called ‘cancer stem cells’, a minor 
subpopulation of cells responsible for maintenance of neoplastic proliferation (Horton 
and Huntly, 2012). In addition, recent studies have demonstrated that chemotherapy-
resistant leukemic stem cells reside in the endosteal region of bone marrow (Ishikawa 
et al., 2007). The findings from these studies have helped to clarify how leukemic cells 
are maintained and propagated in-vivo.  
5.1.2 Haematopoietic stem cells  
HSCs are undifferentiated multipotent stem cells with the ability to perpetuate 
themselves for indefinite periods through self-renewal. HSCs reside as rare cells (1 in 
106 bone marrow cells) in the bone marrow.  
To be defined as a “true stem cell”, a cell must demonstrate durable self-renewal 
capacity as well as differentiation potential into all the downstream cell lineages within 
the haematopoietic hierarchy (Figure 43). It should also be do so at a clonal or single-
cell level to exclude the possibility that a population that is homogeneous in terms of 
cell surface antigen expression is still functionally heterogeneous and composed of 
multiple single-lineage precursors. Functional in-vitro clonogenic assays (long term 
culture-initiating cells, LTC-ICs and CFC) as well as quantitative in-vivo transplantation 
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methods when combined with the FACS, has provided increasingly detailed insight 












       
      
Figure 43: Current models of hematopoietic differentiation in humans (top) and mouse 
(bottom).  
In humans (top), haematopoietic stem cells (HSCs) defined by CD49f marker have long-term 
reconstituting and self-renewing capacity; multipotent progenitors (MPPs) have limited self-
renewal leading to transient but multilineage reconstitution; common myeloid progenitors (CMPs); 
common lymphoid progenitors (CLPs). In mice (bottom), HSCs can be divided into long-term (LT), 
intermediate-term (IT), and short-term (ST) classes based on the duration of repopulation capacity. 
In mice, differentiation of HSCs gives rise to transiently engrafting MPPs, and a series of immature 
lymphoid-biased progenitors (such as LMPPs) that undergo gradual lymphoid specification. Both 
human and mice have well-defined populations of myelo-erythroid progenitors: CMPs, GMPs and 




 Over the past few decades, our ability to prospectively characterize mouse HSCs has 
improved but our understanding of the human HSCs lags far behind, especially in 
haematological malignancies. Like in the mouse, characterization and purification of 
human HSCs requires simultaneous detection of several independent cell specific 
markers.  Cell surface antigen CD34, a ligand for L-selectin that is expressed on upto 
3% of the human bone marrow cells was the first antigen found to enrich human HSCs 
as well as progenitors (Civin et al., 1984). Subsequent clinical studies have confirmed 
that it is a HSC specific marker (Kang et al., 2008; Vogel et al., 2000). In-vivo studies 
later demonstrated that the most primitive human HSCs express CD34 but lack CD38 
cell surface antigens (Bhatia et al., 1997; Cashman et al., 1997; Hogan et al., 2002). 
However, cells expressing CD90+ (thy1) within the CD34+CD38- population have been 
shown to have the highest capacity to reconstitute the bone marrow of a sublethally 
irradiated NOD/SCID host (Baum et al., 1992; Murray et al., 1995). In addition, the 
human trials demonstrating the HSC function was performed using autologous 
mobilized peripheral blood in clinical transplantation, where long-term engraftment 
was observed by transplantation of purified CD34+CD38-CD90+ cells (Michallet et al., 
2000; Negrin et al., 2000; Vose et al., 2001). Further studies introduced CD45RA as 
marker of more differentiated progenitors that negatively enrich for HSCs (Majeti et 
al., 2007). Together, these studies support the idea that human HSCs are present 
within the CD34+CD38-CD90+CD45RA- fraction of the haematopoietic compartment 
and they constitutes <0.5% of the total adult bone marrow cells.  
Immediately downstream of HSCs are MPP that are not capable of long-term self-
renewal. Until recently, little was known about these cells; however, the distinction 
between MPPs and HSCs is based on mouse studies. These studies have showed 
that a number of intermediate cell types with varying degrees of self-renewal capacity 
exist between long-term HSCs and the first lineage-committed progenitor. The first 
study to provide evidence for MPPs in humans came from an in-vivo experiment where 
transplantation of CD34+CD38lo cord blood cells generated transient myelo-erythroid 
engraftment (Mazurier et al., 2003). Subsequently, Majeti and colleagues proposed 
that the loss of CD90 expression by CD34+CD38-CD45RA- cells distinguishes CD90+ 
HSCs from transiently-engrafting CD90- MPPs. However, cells lacking CD90 antigen 
still engrafted after serial transplantation in NOD/SCID mice, suggesting that this 
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population was not completely resolved from HSCs (Majeti et al., 2007). Notta et al in 
a recent study reported that CD49f (integrin alpha 6) is also expressed on ≈50% of 
human CD90+ and ≈25% of CD90- cells. In the same study, cells expressing CD49f 
marker within CD34+CD38−CD45RA−CD90 cell population was shown to efficiently 
generate long-term multilineage grafts in-vivo and the loss of CD49f marker identified 
transiently engrafting MPPs (Notta et al., 2011).  
The hierarchical progression from HSCs to mature progenitors within the bone marrow 
compartment involves gradual loss of self-renewal ability, proliferation capacity, and 
lineage potentials. However, the loss of self-renewal capacity by progenitors during 
differentiation precedes lineage commitment. Furthermore, the earliest commitment 
decision (downstream of MPPs) segregates myelo-lymphoid lineages which give rise 
to common myeloid progenitors (CMPs) and lymphoid progenitors, and each of these 
undergo further commitment steps. This also forms the basis of the first 
comprehensive “classical” model of the haematopoiesis in defining committed mouse 
myeloid and lymphoid lineages (Akashi et al., 2000; Kondo et al., 1997; Reya et al., 
2001). The mouse mature progenitors have an extensive proliferative potential and 
generate large numbers of mature cells. More recently, efforts at defining human 
myeloid progenitor cell populations by cell surface markers have been attempted using 
data from mouse studies. Human myeloid progenitors (CMPs, GMPs, and MEPs) were 
isolated using IL-3 receptor a chain (CD123) or FLT3 (CD135), and CD45RA cell 
surface antigens. GMPs, but not MEPs, express CD123 and CD135 antigens 
(Doulatov et al., 2010). In addition, the human CMP→GMP transition is marked by 
acquisition of CD45RA antigen (an isoform of CD45 that negatively regulates some 
select classes of cytokine signalling), and CD135+CD45RA– CMPs produced 
myeloerythroid cells, but not lymphoid compartment in-vitro as well as in-vivo (Manz 
et al., 2002).  However, the main question over the years has been whether CMPs 
always give rise to GMPs and MEPs, or whether there are other possible branch points 
that give rise to MEPs—for example, from an HSC or MPP. Using lineage tracing data 
with FLK2-Cre mice, it has been shown that the majority of mouse erythrocytes and 
megakaryocytes are derived from Flk2-positive multipotent progenitors. In mice, Flk2 
is expressed by CMPs, but not in adult HSCs, MPPs and MEPs, therefore it seems 
that most of the MEPs and GMPs transition through a CMP stage of the differentiation. 
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Thus, human myeloid cell development seems to be consistent with the mouse 
haematopoietic classical model.  
Unlike the myeloid progenitors CMPs/GMPs/MEPs, which follow the classical model 
of differentiation, lymphoid progenitors have been more controversial with some in-
vivo studies suggesting an alternative “myeloid-based” model. According to this model, 
lymphoid and myeloid progenitor fates remain coupled, instead of splitting early in 
differentiation process (Kawamoto et al., 2010). This model predicts the existence of 
progenitors with myelo-lymphoid, but not E-MK, potential. In mouse, this hypothesis 
was validated with the isolation of LSK CD34+ Flt3hi lymphoid-primed multipotent 
progenitors (LMPPs) which display priming of lymphoid transcripts and mediate 
transient lympho-myeloid repopulation with lymphoid bias, but have a very low E-MK 
potential. Therefore, the available evidence suggests that lymphoid differentiation is 
not a single lineage bifurcation, but perhaps a gradual and parallel differentiation 
process with many intermediate states. As a result of the uncertainties in determining 
the precise potential for any given progenitor population, particularly for human bone 
marrow progenitors, studies have proposed a broader term, namely MLP (Doulatov et 
al., 2010). MLPs are used to describe any progenitor that can give rise to all the 
lymphoid lineages (B-, T-, and NK- cells), but that may or may not have other lineage 
potentials (for example, GMPs).   
The search for the cell surface antigens present on the early lymphoid progenitors 
MLPs in human bone marrow has been focused on the earliest T cell marker i.e. CD7 
antigen and B cell marker i.e. CD10. Study by Galy et al demonstrated that 
CD34+CD10+ cells derived from human bone marrow were able to give rise to B-, T- 
and Nk cells, but not myelo-erythoid cells (Galy et al., 1995). However, Hao and 
colleagues used in-vitro single cell assay to show that rare CD7+ cells present within 
the primitive CD34+CD38- population were found to differentiate to B and NK cells, but 
not myelo-erythoid cells (Hao et al., 2001). Likewise, another recent study also 
reported robust T cell potential of this progenitor population in mice (Hoebeke et al., 
2007).  In a recent study, single-cell assay revealed that the multilymphoid (B, T, and 
NK) potential in humans was restricted to the CD34+CD38–CD90-/loCD45RA+ (CD90–
CD45RA+) compartment. Human myeloid cells predominantly monocytes, 
macrophages, and dendritic cells were also present in the lymphoid colonies 
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generated from single CD90-CD45RA+ cells. In addition, human CD90-CD45RA+ cells 
transiently engrafted in NSG mice and gave rise to both myelomonocytic and B cells, 
arguing that their myeloid potential is not an artefact of in vitro assay (Doulatov et al., 
2010). Another study reported similar observation using human CD90-CD45RA+ cells. 
MLPs gave rise to B, T, and NK cells, as well as myeloid lineages in-vitro as well as in 
in-vivo assays. Engrafted human myeloid cells consisted of granulocytes and 
monocytes, suggesting these human MLPs have lineage potential similar to that of 
mouse LMPPs (Goardon et al., 2011). Therefore, it is clear that human MLPs are not 
lymphoid restricted, and also possess myeloid, but not erythro-myeloid potential. 
5.1.3 NSG Xenotransplantation 
The laboratory mouse (Mus musculus) has been one of the best model systems for 
elucidating the cancer biology. Out of the ≈23,000 protein coding genes known to be 
present in mouse genome, only 75% of genes are in 1:1 orthologous relationships with 
human genes (total reported protein coding genes ≈ 21,000). Despite such 
differences, mouse models have proven to be useful in validating gene functions, 
identifying novel cancer genes and tumour biomarkers as well as providing better 
clinical models in which to test novel therapeutic strategies. This is due to various 
benefits including its relatively small size, lifespan of 3 years, an entirely sequenced 
genome and molecular as well as physiological similarities to humans.  
Over the past decade advances in the genetic technologies have led to the 
development of various mice models which can be broadly divided into two groups. 
First, genetically engineered transgenic and mutant mice that recapitulate a specific 
disease genotype; second group, the syngeneic and xenogeneic mice in which tumour 











Figure 44: Timeline for the Development of Immune-Deficient Mouse Models.  
Top half of the schematics shows the various mouse models developed since 1960s. Middle 
half of the diagram shows affected immune system in the mouse models with or without 
humanized element. Bar chart (bottom half) represents the level of human cell engraftment 
observed in the various mouse models. Alphabets present on top of each bar represents the 
type of engraftment (details underneath the bar chart).   
 
The development of xenogeneic models (Figure 44) has enabled the rapid and facile 
in-vivo assessment of the patient’s tumour tissues in immunocompromised mice. The 
first xenogeneic model developed in the late 1960s was the T-cell deficient BALB/c 
athymic nude (nude) mouse. In this model system, a single homozygous gene 
mutation in Foxn1 gene or the HNF-3/forkhead homolog 11 gene leads to the 
development of a hairless athymic (lack of functional thymus) mouse (Nehls et al., 
1994). The immune system of nude mice is mainly characterized by a small population 
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of mature T cells, an antibody response confined to IgM class and an increased NK 
cell response. In these animals, absence of T cells allowed engraftment of some 
human tissues and tumour cells; however, the presence of mouse B cells and NK cells 
prevents human hematopoietic cell engraftment. The establishment of the severe 
combined immunodeficiency (SCID) mouse on a CB17 background (Bosma and 
Carroll, 1991), was a major advance which not only allowed the efficient 
transplantation and propagation of human tumour tissues but also enabled 
engraftment of the human haematopoietic cells in the host. These mice lack adaptive 
immunity due to a homozygous deletion in an essential enzyme namely Prkdc (Bosma 
et al., 1983). This DNA-dependent protein kinase enzyme is essential for repairing 
non-homologous ends of double-stranded DNA breaks following VDJ recombination 
in T- and B-cells. The defect in this enzyme impairs the VDJ recombination in these 
mice and therefore mice do not respond to either T- or B-cell mitogens. The humoral 
and cellular immune systems fail to mature in SCID mice; however, the spontaneous 
generation of mouse T- and B-cells during aging (also known as leakiness) and high 
levels of host NK cell and other innate immune activity remains the limiting factors. As 
a result, SCID mice often require conditioning with sublethal irradiation to engraft 
primary patient derived leukaemia cells.   
The SCID-beige mouse model was developed by introducing a mutation in the 
lysosome trafficking regulating (Lyst) protein in the Prkdcscid mutant mice, on a 
Balb/corCB57/BL/6J background (Mosier et al., 1993). As a result, these mice not only 
lacked T and B cells but also developed neutropenia as well as had reduced NK 
activity. Moreover, these mice also avoided the late immune-reconstitution observed 
in SCID mice. RAG mice strain was developed by targeting either rag1 or rag2 
recombination activating genes. The RAG knockout mouse model harbours a germline 
mutation in which a large portion of the rag coding region is deleted (Shultz et al., 
2000). These genes are DNA recombinases that are involved in recognizing and 
cleaving signal specific sequences for somatic rearrangements of B and T cell 
receptors.  RAG mice strain do not show the leakiness or radio sensitivity as was 
observed in the SCID mice; however, these mice retained high levels of NK cell activity 
and show limited engraftment of human bone marrow stem cells. 
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Further attempts were made to manipulate the SCID mouse model to increase the 
human haematopoietic cell engraftment which led to the development of the non-
obese diabetic-SCID mice. This hybrid model was developed by crossing the SCID 
mice (Prkdcscid) to the non-obese diabetic (NOD) mouse background, resulting in 
immunological multidysfunction, including impaired NK cell function, reductions in 
macrophage function and complement-dependent hemolytic activity (Shultz et al., 
1995). NOD mice harbour an essential as well as unique major histocompatibility 
complex (MHC) haplotype, namely H-2g; as well as a polymorphism in the CTLA-4 and 
TNFα gene. All these factors together contribute to dysfunctional innate immune 
system observed in this mouse model. NOD-SCID mice showed marked improvement 
in the engraftment of the human haematopoietic cells in general, including primary 
bone marrow cells. Moreover, NK cell activity reduced significantly in this hybrid model 
and was lower in NOD-SCID mice than in CB17-SCID mice (Ito et al., 2002; Lowry et 
al., 1996). Lack of NK cell activity also reduced the requirement for conditioning with 
radiation prior to leukemic cell administration, however, conditioning with irradiation is 
still used by investigators. These mice have a propensity to developing thymic 
lymphomas. This mouse model enhanced the engraftability of the primary human cells 
including PBMC (Hesselton et al., 1995) as well as HSC (Lowry et al., 1996); and also 
enabled the maintenance of the leukemic characteristics of the tumour cells such as 
abnormal karyotype, stable antigenic markers and T- or B-cell receptor 
rearrangements. However, the use of this hybrid NOD-SCID mice model is limited due 
to relatively short life span (median survival of 257 days) and the residual activity of 
the NK cells as well as the other components of the innate immune system, thereby 
impeding the engraftment of the human lymphoid compartment.  
The development of NOD/SCID/IL2rg-/- (or NSG) mouse which was developed by 
crossing the common-gamma-chain (interleukin 2 receptor gamma, IL2rg-/-) knockout 
to the NOD-SCID mouse (Ishikawa et al., 2005; Ito et al., 2002; Shultz et al., 2005). 
IL2rg-/- mice produced independently in the early 1995 harbour homozygous mutation 
at the interleukin-2 receptor (IL-2R) γ-locus IL2rg (also known as common cytokine-
receptor γ- chain) that is a crucial signalling component of the high-affinity receptors 
for IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 (Ito et al., 2002; Traggiai et al., 2004). The 
lack of the IL-2R γ-chain in these hybrid mice leads to the multiple defects in both the 
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innate as well as the adaptive immune system, and prevents NK cell development. 
This hybrid model is resistant to developing lymphomas, therefore allowing for long-
term human cell engraftment experiments (median survival >89 weeks). Depending 
upon the type of the host background, these hybrid mice strains of Il2rg–/– mice also 
include NOD.Cg-PrkdcscidIl2rgtm1Wjl mice (NOD/LtSz-scid Il2rg–/–), NODShi.Cg-
PrkdcscidIl2rgtm1Sug mice (NOD/Shi-scid Il2rg–/–), C.Cg-Rag2tm1FwaIl2rgtm1Sug mice 
(BALB/c-Rag2–/–Il2rg–/–) and (H2d)-Rag2tm1FwaIl2rgtm1Krf  mice (H2d-Rag2–/–Il2rg–/–) 
(Doulatov et al., 2010; Shultz et al., 2007). A common feature of all of the hybrid Il2rg–
/– mice strains is that the host must be conditioned with sublethal γ-radiation before 
cell injection for optimal engraftment of the human cells.  
Engraftment of the human tissues including human PBMCs and stem/progenitor cells 
in these hybrid strains of mice harbouring the IL2rg- mutations is greater and more 
reproducible than in all the other mice models described previously. For the first time, 
transplantation of human haematopoietic stem cells in NODSCID-IL2rg-/- mice showed 
engraftment of well differentiated progenitor cell populations into many lineages of the 
haematopoietic cells, including platelets, red blood cells and lymphoid compartment 
(both T- and B- cell) that progress through the expected stages of intrathymic 
development (Ishikawa et al., 2005; Shultz et al., 2005). As human cancer cells are 
transplanted into increasingly immunocompromised NSG mice, fewer and fewer cells 
are required to transfer the disease in such hybrid models, therefore making them 
ideal to use for studying the clonal evolution (Bonnet and Dick, 1997; Feuring-Buske 
et al., 2003; Quintana et al., 2008). 
The landscape of somatic mutations in MDS patients with ring sideroblasts (MDS-RS) 
(Mufti et al., 2008) has become increasingly well defined (Makishima et al., 2012; Mian 
et al., 2013; Papaemmanuil et al., 2011; Visconte et al., 2012b; Yoshida et al., 2011b). 
To date, functional and mutational evaluations of hematopoietic cells in MDS in 
general, have predominantly relied on total nucleated cells or purified CD34+ bone 
marrow cells, which have limited power to identify cell lineage specific genomic 
aberrations. Specifically, the origin of SF3B1 mutations, the clonal composition, 
evolution as well as the engraftment kinetics of the haematopoietic progenitors that 
carry the SF3B1 mutations remain unknown. In addition, the specific step within the 
developmental schema at which a clone attains a particular genetic aberration 
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necessary to emerge or re-emerge as a dominant clone remains unknown. For 
instance, the sequential acquisition of oncogenic genetic alterations (such as FLT3 
and RUNX1) in SF3B1 mutant MDS-RS patients results in disease progression to 
acute myeloid leukaemia (Mian et al., 2013). However, the order in which these 
‘oncogenic’ mutations are acquired and the cell type in which these mutations arise in 
MDS-RS have yet to be determined. 
Over the years, it has been reported that self-renewing HSCs continuously acquire 
somatic aberrations, while most of them are passenger mutations, some ‘potent 
mutations’ can constitute a reservoir of pre-leukemic stem cells (Greaves and Maley, 
2012; Shackleton et al., 2009; Swanton, 2012). The first study to report clonal 
spectrum at single-cell level through multiplex FISH analysis was in childhood ALL 
(Anderson et al., 2011). However, the recent developments of genomic technologies, 
stem cell isolation as well as xenotransplantation models has started to lead to a better 
understanding of the complex clonal architecture and mutational hierarchy of 
phenotypically and functionally defined ‘malignant stem cells’ in AML (Klco et al., 
2014).  
Therefore, we hypothesized that NSG IL2rg-/- xenograft mouse model and single cell 
analysis would be attractive methods to investigate the SF3B1 mutant bone marrow 
cells. This in combination with FACS analysis, whole-exome sequencing and targeted 
mutational analysis were used in this study to determine the origins of SF3B1 
mutations as well as depict the clonal spectrum and evolution seen in the bone marrow 











5.2.1 SF3B1 mutation originates in a cell with an HSC phenotype and persists 
in mature myeloid progenitors  
WES data from bone marrow CD34+ cells from a cohort of 11 MDS-RS and 1 
congenital sideroblastic anaemia patient was available as described previously in 
section 3.1. All the patients had SF3B1 mutations (Lys700Glu, n=4; His662Gln, n=3; 
Glu622Asp, n=2 and Asp781Gly, n=1; Table 32). All the SF3B1 mutations were 
heterozygous in nature. Bone marrow cells from up to 6 patients were used for stem 
cell isolation as well as a number of in-vitro and in-vivo analyses (Table 32 and Table 
34). Three additional patients were used for single cell clonogenic assays (CFC) 
assays. A constitutional ALAS2 (Arg425Cys) gene mutation (Camaschella, 2009; 
Cotter et al., 1999; Kaneko et al., 2013) was detected in the patient with congenital 
sideroblastic anaemia, but no other somatic mutations including SF3B1 were observed 
in this case. Thus, this patient served as an ideal control for all the subsequent in-vivo 
















Table 32: Clinical characteristics of patients analysed. 
Sequential bone marrow samples were available from 2 patients as described in the table. TP-Time point, M-Male, F-Female, A-Alive, D-Dead.  
†Immunophenotyping demonstrates 2 separate populations of CD34+ cells:  (1) CD34+ (bright) ; CD13+ ; CD33+ ; weak CD117+ ; ~1/2 MPO+ ; TdT+ ; CD14- 
















































































































































































77 M RARS-T Epo/ 
GCSF 





-  RARS-T Epo/ 
Len 





75 M RCMD-RS Epo/ 
GCSF 





- - RCMD-RS Epo/ 
Len 









7.5 1.63 29 - - 46,XY,add(7)(q32),add(10)(p13)[7]/46,XY,
add(7)(q22),add(7)(q32),add(10)(p13)[3] 
Yes D Yes Yes 
MDS 
3 
N/A 63 M RARS Epo/ 
GCSF 
1 9.1 3.15 570 >15 Low NORMAL No A No No 
MDS 
4 
N/A 58 F RARS None 1 10.7 3.21 196 24 Low NORMAL No A No No 
MDS 
6 
N/A 74 M RCMD-RS Epo/ 
Len/ 
Aza 
1 12.1 3.44 151 35 Low NORMAL No A No No 
MDS 
5 
N/A 22 M Congenital 
sideroblastic 
anaemia 
None 1 10.6 4.7 400 32 N/A NORMAL Yes A No No 
201 
 
In order to identify the target cell within the hematopoietic compartment, which carries 
the SF3B1 mutation HSCs, MPPs, GMPs and MEPs were isolated from the bone 
marrow of 4 patients (MDS1, MDS2, MDS4 and MDS6; Figure 45, Appendix Figure 1 
and  Table 34).  
The cell surface antigens present in our antibody panel and used for separation of 
specific stem as well as progenitor cell compartments (Table 16) were similar to the 
ones used in previous studies (Pang et al., 2013). In addition, CD49f cell surface 
antigen was used to differentiate between HSCs and MPPs. CD49f (integrin 6) 
expressed within Lin−CD34+CD38−CD45RA− population have been shown to 
efficiently generate long-term multi-lineage grafts in in-vivo and the loss of CD49f 
expression identified transiently engrafting MPPs (Notta et al., 2011). Initially the 
antibody panel was optimised using bone marrow cells obtained from 
‘haematologically normal’ subjects as depicted in Figure 45. Subsequently, bone 
marrow cells from MDS-RS patients were prepared and sorted on a BD FACS Aria 
SORP (San Jose, CA) operating in 4-way purity sort mode, and collected into 1.5 ml 
microfuge tubes (see methods chapter for full details). After sorting, the purity of 
MPPs, GMPs and MEPs were checked and a sorting purity of ≥97% was routinely 
obtained. Cell number obtained for each compartment for all the patients are 





Figure 45: Representation of the isolated hematopoietic stem cell subpopulations. 
Viable lineage negative bone marrow CD34+ cells from ‘haematologically normal’ control were 
defined by hierarchical gating on a combination of forward (FSC) and side scatter (SSC), 
propidium iodide (not shown), CD45 and a lineage cocktail. These CD34+ cells were further 
gated first into CD34+CD38- and CD34+CD38+ populations and then subdivided into either 
HSCs (CD34+CD38-CD90+CD45RA-CD49f+) and MPPs (CD34+CD38-CD90-CD45RA-CD49f-) 
or into GMPs (CD34+CD38+CD135+CD45RA+) and MEPs (CD34+CD38+CD135-CD45RA). 
 
Following the cell separation, targeted mutational analysis specific to patients’ SF3B1 
mutations was performed on haematopoietic cell fractions (HSCs, MPPs, GMPs and 
MEPs). Using SF3B1 mutation specific primers, PCR was directly performed on 30-
50% of the FACS purified cells from each compartment with subsequent sequencing 
on MiSeq platform and/or Sanger sequencing (see methods section 2.2.6 for more 
details). Sequencing data revealed that patient specific SF3B1 mutation were present 
in HSC population (Figure 46). SF3B1 mutations were also detected in MPPs, GMP 
and MEP fractions from all patients (Figure 46). All the SF3B1 mutation detected in 
patients progenitor compartment were heterozygous in nature. Notably, the MAB was 
largely maintained between the HSCs, MPPs and more differentiated myeloid 




                
Figure 46: SF3B1 mutations propagates from HSCs to their progeny.  
Representation of the isolated haematopoietic stem cell subpopulations. Numbers present 
within the FACS plots represent the percentage of the cells of each progenitor compartment. 
SF3B1 mutations occurs in rare HSC phenotypic cells and largely maintained in more 
committed progenitors MPPs as well as in more differentiated progenitors GMPs and MEPs. 
Tables show the progenitor cell counts for each patient sample. Bar charts indicate the SF3B1 
MAB for respective cell fraction obtained through MiSeq sequencing platform. The cell count 
is based on the number of events detected by the FACS during cell sorting. The average 
sequencing coverage across all amplicons was ≥800 reads. MAB for each cell population was 
confirmed by independent PCRs. MAB- mutant allele burden. 
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5.2.2 SF3B1 mutations persist throughout myeloid but not lymphoid 
differentiation 
In order to determine the SF3B1 mutation status in lymphoid cell and mature erythroid 
cell compartment of the MDS-RS patients,  CD34-CD3+ T-cells, CD34-CD3+CD4+ T-
cells , CD34-CD19+ B-cells, CD34-CD71+CD235+ erythroblasts and CD34-CD3-
CD235- were isolated from total bone marrow cells using BD FACS Aria SORP (San 
Jose, CA; see methods section 2.2.8 for more details). Initially, three patients in whom 
SF3B1 mutations were detected in total bone marrow cells were used for this analysis. 
Using the appropriate flow cytometry values, the cells of interest were then gated by 
the following cell surface markers as described in methods chapter. After sorting, the 
purity of all the cell fractions was checked and a sorting purity of ≥97% was routinely 
obtained.  
Following the cell separation, targeted mutational analysis specific to patients’ SF3B1 
mutations was performed on DNA isolated from all cell fractions. PCR was performed 
using SF3B1 mutation specific primers and subsequently sequenced using Sanger 
sequencing (see methods section 2.2.7 for more details). Mutation load was also 
checked in total CD34+, CD34-CD71+CD235+ erythroblasts and CD34-CD3-CD235- 
cells showed approximately the same SF3B1 MAB (according to Sanger sequencing) 
as seen for paired total bone marrow and CD34+ cells (Figure 47). Importantly, no 
SF3B1 mutation was detected above background detection levels in  CD3+ T-cells, 
CD3+CD4+ T-cells or CD19+ B-cells according to Sanger sequencing (3/3 mutant 
patients), indicating that the mutant clone has a growth advantage only in the  myeloid 
lineage in MDS-RS (Figure 47).  
In addition, high-depth sequencing using MiSeq platform (Second-generation 
sequencing) performed on CD3+ T-cells from one additional patient (MDS1) confirmed 





Figure 47: SF3B1 mutation persists in the myeloid but not in lymphoid lineage.  
Sequencing analysis of myeloid and lymphoid cells from 3 RARS patients with SF3B1 
mutations. The three horizontal rows represent the 3 patient samples and the vertical columns 
represent the cell types isolated from the bone marrow. CD34-CD71+CD235+ erythroblasts 
and CD34-CD3-CD235- cells showed approximately the same SF3B1 mutant allele burden as 
seen in the CD34+ cells. No SF3B1 mutation was detected above background in CD3+ T-cells, 











5.2.3 WGA maintains the allelic burdens across the genome 
Technical difficulties in isolating and analysing rare haematopoietic stem cells and/or 
small number of cells (<1000 cells) have made limited progress to date. However, the 
recent developments of genomic technologies, stem cell isolation as well as high depth 
mutational analysis has started to lead to a better understanding of the complex clonal 
architecture (Klco et al., 2014), especially using small cell numbers. In this study, we 
had to perform genomic analysis on isolated stem/ progenitor cells and small numbers 
of cells (obtained from clonogenic assays and mice experiments). Therefore, we used 
whole genome amplification technology to increase the amount of DNA which could 
be used for downstream sequencing analysis. WGA of cells was performed with 
GenomePlex Single Cell Whole genome amplification kit (WGA4, Sigma-Aldrich Co, 
LLC) and/or GenomePlex SeqPlex XE kit (SEQXE, Sigma-Aldrich Co, LLC). WGA 
amplification was performed according to the instructions of the manufacturer (as 
detailed in methods chapter), along with a no cell reaction as a negative control and a 
reaction of human tissue genomic DNA as positive control.  
The degree of quantitative accuracy of the allele burdens for WGA DNA was validated 
independently by performing whole-exome sequencing on paired gDNA (non-WGA) 
and WGA DNA from the samples (Figure 48). LOH was mapped from WES data 
according to the following criteria: Variants found in 1000 genome project database 
with a population allele frequency less than 0.001 were selected and filtered out for 
known genomic duplicated regions, read depth <20 and somatic status according to 
VarScan (see methods section 2.2.4.6 and 2.2.4.8 for more details). The filtered set 
of variants were then plotted graphically for the required chromosome. Following the 
primary analysis, similar distribution of known SNPs across the exome between the 
gDNA (non-WGA) and WGA DNA was observed (Figure 48A). To validate this further, 
mutational screening for 10 genes on paired gDNA (non-WGA) and WGA DNA from 
2 samples (MDS1 and MDS2) was performed on independent patients (Figure 48B). 
MAB for specific mutations was also shown to be comparable between gDNA (non-





Figure 48: Validation of gDNA vs WGA-DNA through SNP profiling by WES and 
targeted-mutational analysis. 
(A) Comparison of SNV profiles from control exome experiments based on gDNA vs WGA-
DNA. Paired exome experiments (1-4) of gDNA (non-amplified) vs WGA-DNA were processed 
and analysed in VarScan. Variants were selected and plotted based on being called germline 
or LOH in VarScan, due to presence at similar levels in both samples of a pair or significant 
allele burden (AB) change between the two respectively, had >20 read depth and had >10% 
AB in unamplified experiment data. Chromosome 3 data is exampled here as representative 
Figure. Panel 1 and panel 2 are based on the experiment of human CD33+ cells isolated post 
mouse engraftment. Panel 3 is based on primary patient CD34+ cells. Panel 4 is based on 
patient skin material. Panel 1, panel 3 and panel 4 show all variations as detailed above. Panel 
2 shows sub-fraction of panel 1 that is found in dbSNP137. (B) Comparison of somatic 
mutations between paired gDNA vs WGA-DNA. Mutant allele burden of 5 gene mutations in 
primary CD34+ bone marrow and CD33+ HEC cells from MDS1 and MDS 2. MAB- Mutant 
Allele Burden, gDNA- Genomic DNA, WGA-Whole-genome amplified DNA. 
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5.2.4 SF3B1 mutant cells maintain their differentiation and proliferation 
potential in-vitro 
To evaluate the ex-vivo clonal growth potential of SF3B1 mutant bone marrow CD34+ 
cells from 6 MDS-RS patients (MDS1, MDS2, MDS3, MDS4, MDS6 and MDS142), 
one congenital sideroblastic anaemia patient (MDS6) and 3 ‘haematologically normal’ 
controls were plated in methylcellulose to assess their colony-forming cell abilities. 
Cells were cultured for 14 days. In addition, 3 patients (MDS1, MDS2, MDS3) were 
also grown in liquid culture (long-term culture, or LTC; See methods chapter for more 
details) to assess their long term proliferation potential.  
 
 
Figure 49: CFC-GM and BFU-E colonies. 
Cells cultured from CD34+ bone marrow cells of MDS-RS patients after 14 days of culture in 
methylcellulose-based medium. Each colony was picked and processed for mutational 
analysis. Cultured colonies were analysed based only on the granulocyte/macrophage and 





Overall no preferential bias towards any particular cell lineages in the short-term CFC 
culture was observed (as exampled in Figure 49 for three patients; Table 33) as 
compared to haematologically normal controls. MDS-RS patients with SF3B1 
mutations generated equal number of CFC-GM and BFU-Es.  However, MDS4 yielded 
low colony numbers as compared to other patients. Patient with congenital 
sideroblastic anaemia had more CFC-GM compared to BFU-Es.  
After 14 days culture, colonies were picked, harvested and washed twice with PBS. 
DNA was isolated from the pooled colonies from three patients (MDS1, MDS2 and 
MDS3).  In addition individual colonies collected were used in single cell colonogenic 
mutational analysis (discussed in detail section 5.2.9). 
 
Table 33: Colony-forming cell (CFC) assay analysis. 
Analysis of the differentiation capacity of CD34+ cells from 7 MDS-RS patients, one congential 
sideroblastic anaemia and 3 haematologically normal controls. The table show the numbers 
of granulocyte-macrophage (CFU-GM) and erythroid (BFU-E) colonies generated by total 
CD34+ cells in the presence of cytokines IL-3, Tpo and Epo, respectively. Cells were plated in 
triplicate.  Data are mean ± SD. CFU-GM and BFU-E frequency for some of the patients are 
shown as total colony numbers. † Congential sideroblastic anaemia 
 
Experiment no 
Number of CD34+ cells 
seeded 
Number of CFU-GM 
colonies at day 14 
Number of BFU-E 
colonies at day 14 
MDS1 500 27.7 ±6.3 23.7 ±0.9 
MDS2 500 71.7 ±11.4 
MDS3 500 37 ±10.6 34.3 ±3.9 
MDS4 500 5.3 ±3.3 7.3 ±0.9 
MDS5† 500 54.0 ±6.2 27 ±1.6 
Normal BM1 500 31 ±7.9 35.3 ± 3.1 
Normal BM2 500 35.7 ± 7.5 29.3 ±11.3 





SF3B1 mutated cells also maintained their proliferation potential in the LTC conditions. 
After 5 weeks culture, live cells were collected, stained using human CD45+ cell 
surface antigen and sorted by using the BD FACS Aria SORP (See methods section 
2.2.8 for more details). Sorted cells were washed in PBS, harvested and stored as cell 
pellet. DNA was also isolated from LTC cultured cells (MDS1, MDS2 and MDS3).  
Following on, targeted mutational analysis specific to patients’ SF3B1 mutations was 
performed on the DNA isolated from pooled-CFC and LTC derived cells (MDS1, MDS2 
and MDS3). Using SF3B1 mutation specific primers, all the samples were PCR 
amplified and subsequently sequenced using MiSeq/Roche 454-sequencing 
sequencing (See methods section 2.2.5 and 2.2.6 for more details). Sequencing data 
showed that SF3B1 mutations observed in patients CD34+ cells were present and 
maintained in both CFC and LTC from all 3 patients (as exampled for one patient 
MDS1 in Figure 50, data for MDS2 and MDS3 are shown in Figure 54). All the mutation 
were heterozygous aberrations (MAB up to 50%). These findings suggest that, in this 
subgroup of patients, the CD34+ SF3B1 mutant cells are clonal neoplastic cells with 
the ability to differentiate into mature erythroid and granulocytic colonies as well as 
maintain their long term proliferating potential.   
 
 
Figure 50: SF3B1 mutations are maintained in CFC and LTC culture conditions.  
Bone marrows cell from MDS1 patient were subjected to CFC and LTC culture conditions. 
Mutational analysis on the pooled CFC and LTC cultured cells show that the mutant allele 
burden (MAB) of SF3B1 mutation remained almost identical. 
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5.2.5 SF3B1 mutations persists in NOD/SCID/IL2rγ−mu Mice (NSG) 
NSG mice models in which primary human leukemic cells are transplanted have 
previously been used to expand our understanding of the pathogenesis of human 
leukaemia (Anderson et al., 2011; Bonnet and Dick, 1997). Although MDS patient cells 
are difficult to engraftment in xenograft models, the recent use of NSG mice as well as 
intra-bone injection (with or not the co-injection of mesenchymal stroma cells) have 
been reported to yield higher engraftment (Medyouf et al., 2014; Pang et al., 2013; 
Woll et al., 2014). For this reason, a murine xenograft model of SF3B1/MDS-RS using 
NSG mice was used to study the engraftment kinetics of SF3B1-mutant CD34+ cells 
(Figure 51, Figure 52 and Table 35).  
Next, CD34+ bone marrow cells from four SF3B1 mutated MDS-RS patients (MDS1, 
MDS2, MDS3 and MDS4) and one congenital sideroblastic anaemia patient (MDS5 
with ALAS1 mutation) were prepared (see methods section 2.2.8 for more details). 
The congenital and acquired sideroblastic anaemia’s share the same phenotypic 
characteristics mainly characterized by the presence of ring sideroblasts in the bone 
marrow. Therefore, to compare the engraftment kinetics of SF3B1 mutant 
haematopoietic stem cells, bone marrow cells from congenital sideroblastic anaemia 
patient served as an ideal control for in-vivo experiments. In order to assess whether 
the NSG mice biases the engraftment of any particular hematopoietic lineages 
(myeloid or lymphoid), we also injected ‘haematologically normal’ adult bone marrow 
CD34+ cells from 3 healthy donors into NSG mice. Prior to transplantation, mice 
received a sub-lethal dose of radiation (330-375 cGy) from a cesium-137 source. 
Depending upon the total number of CD34+ cells available from each patient, 0.65x105 








Table 34: Patient characteristics and engraftment of bone marrow CD34+ cells. 
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Percentage of Human Cell 

































































>15% N Yes Yes Yes Yes 
200,000 1/1 0.1 5.6 76.4 4.9 0 90 
200,000 1/1 1.1 19 75 3.6 0 96 








>15% N Yes No Yes Yes 
100,000 1/1 1.7 64 19 1.1 0.2 97 
100,000 1/1 0.1 33 28 0.3 0 97 














32% N Yes No No No 
100,000 1/1 5.35 1.36 93 0.5 28.3 61 
100,000 1/1 1 2.43 94 0.3 3.17 89.3 
Normal 
BM1 
Haematologically Normal  N/A N/A N/A No No No No 
100,000 1/1 N/A N/A N/A 2.87 87.00 12.2 
100,000 1/1 N/A N/A N/A 7.75 94.00 5.80 
100,000 1/1 N/A N/A N/A 9.9 89.00 10.00 
Normal 
BM2 
Haematologically Normal N/A N/A N/A No No No No 
100,000 1/1 N/A N/A N/A 1.4 94.00 4.30 
100,000 1/1 N/A N/A N/A 3.3 96.00 3.00 
100,000 1/1 N/A N/A N/A 3.6 92.00 6.60 
100,000 1/1 N/A N/A N/A 2.2 95.00 5.00 
Normal 
BM3 
Haematologically Normal N/A N/A N/A No No No No 
100,000 1/1 N/A N/A N/A 9.3 83.00 16.00 
100,000 1/1 N/A N/A N/A 21.2 56.00 43.00 
100,000 1/1 N/A N/A N/A 3.5 80.00 20.00 
100,000 1/1 N/A N/A N/A 9.8 84.00 15.00 
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Engraftment levels based on the recovery of human CD45+ cells from engrafted mice 
at week 18-20 ranged between 0.1% and 4.9% (Figure 51A-51B and Table 34). 
Notably, mice injected with a high cell number from MDS-RS patients showed greater 
human cell engraftment. Further analysis of the bone marrow cells retrieved from 
engrafted mice using lineage-specific markers (hCD33 for myeloid cells and hCD19 
for B-cells) revealed that the majority of the cells engrafted in mice were of myeloid 
lineage with little or no lymphoid cell engraftment. In contrast, mice injected with CD34+ 
cells from a congenital sideroblastic anaemia patient with constitutional ALAS mutation 
but no SF3B1 mutation showed myeloid as well as lymphoid cell engraftment (Figure 
52A and Table 34). Similarly, engraftment observed in mice transplanted with CD34+ 
cells from normal healthy controls exhibited a higher ratio of lymphoid/myeloid cell as 
compared to SF3B1 mutant cases (Figure 52C). Therefore data from our study 
suggests that the presence of SF3B1 mutations, perhaps along with additional 
‘cooperating factors’, adversely affects the lymphoid cell development in this model, 
which is in agreement with the previous xenotransplantation models proposed 





Figure 51: Engraftment and genotype of human RARS-originated and control 
hematopoietic cells in the bone marrow of NOD/SCID/IL2rγ−/− mice.  
(A) Schematic representation of the xenograft model. Right hand side FACS panel shows the 
flow cytometric profile of bone marrow cells recovered from one human cell engrafted mice 
(HEC). The majority of human CD45 expressing cells were positive for a myeloid marker 
CD33+ in all analysed cases in this study. (B) Percentage of human CD45+ cells in the bone 
marrow of NSG mice at 6 and 18-20 weeks after transplantation (MDS1, n=3; MDS2, n=1; 
MDS3, n=3 and MDS4, n=1). (C) Targeted mutational analysis shows the presence of 
concordant SF3B1 mutations in primary CD34+ bone marrow sample (grey) and xenograft 
(black) in all analysed cases. Three independent PCR/sequencing experiments were 
performed to confirm/determine the mutant allele burden throughout the experiments. The 








Figure 52: Engraftment of hematopoietic cells in the bone marrow of NOD/SCID/IL2rγ−/− 
(NSG) mice.  
(A) Percentage of human CD45+ cells in the bone marrow of NSG mice at 6 and 18-20 weeks 
after transplantation for MDS 5 patient. (B) Immunohistochemistry staining for human CD45+ 
cells in the Xenograft bone marrow sample. Femurs were collected from engrafted and non-
engrafted mice, and stained for human CD45 (in brown) and counterstained with Haematoxylin 
(in blue). (C)  Percentages of human hematopoietic cells and ratio of CD19+/CD33+ isolated 
from the bone marrow of mice engrafted with either MDS-RS (n=4 patients and transplanted 
in a total 8 mice) or healthy controls CD34+ cells (n=3 healthy donors and transplanted in a 
total of 11 mice) or congenital sideroblastic anaemia patient (n=1 patient transplanted in 2 
mice). Y-axis (left) represents the percentage of the human CD45+ cells present in the total 
mouse bone marrow. Y-axis (right) represents the ratio of the human CD19+ vs human CD33+ 
cells within the human CD45+ cells recovered following xenotransplant. MDS xenografts 
showed a significant skewing toward myeloid lineage. * p-value <0.05, **** p-value <0.0001.  
 
In order to determine the nature of the engrafted human CD45+CD33+ cells recovered 
from mice, mutational analysis was performed on HECs (human cells retrieved after 
the xenotransplantation; Table 35) using SF3B1 mutation specific primers and 
subsequent sequencing through MiSeq platform (See methods section 2.2.6 for more 
details). Interestingly, the genotypic characteristics of patients’ primary CD34+ bone 
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marrow cells were maintained in HEC, as demonstrated by the presence of SF3B1 
mutations. SF3B1 MAB remained largely unchanged between the primary CD34+ cells 
(≈43%), and post-transplant HEC (≈46%) in 3/4 cases (Figure 51C). This was 
irrespective of the type of SF3B1 mutations (Lys700Glu, n=2; His662Gln, n=2). In one 
RARS patient (MDS3), SF3B1 (Lys700GLu) MAB increased from 28% in primary 
CD34+ cells to 43% (average MAB between 3 mice) in xenografted HECs, therefore, 
suggesting a possible clonal advantage for the malignant mutant clone(s) over 



















Table 35: Table showing a complete list of somatic mutations in 4 MDS-RS patients studied for in-vivo and in-vitro experiments. 
Mutations present in paired primary CD34+ cells, HEC samples and LTC samples. All mutations were confirmed independently by sequencing 
from 3 independent PCR reactions from all experiments. HEC- Human engrafted cells retrieved from mice. LTC- Long-term culture, N/A- Not 
applicable, MAB- Mutant Allele Burden, BM-bone marrow.  














MDS1 SF3B1 NM_012433 2 198266834 Lys700Glu 43% 46% 46% 50% 40% 
MDS1 JAK2 NM_004972 9 5073770 Val617Phe 36% 17% 10% 17% 26% 
MDS1 DNMT3A NM_153759 2 25470588 Val107Leu 4% 10% 9% 12% 16% 
MDS1 FBLIM1 NM_017556 1 16091611 Ala45Thr 27% 11% 6% 8% 17% 
MDS1 HIST1H2AC NM_003512 6 26124820 Lys120Asn 31% 14% 10% 14% 17% 
MDS1 HSPA12A NM_025015 10 118434314 Gly669Glu 2% 7% 7% 6% 9% 
MDS1 RETNLB NM_032579 3 108475355 Gly70Arg 28% 15% 7% 12% 15% 
MDS1 SMC6 NM_024624 2 17897511 Lys456Met 2% 18% 16% 16% 9% 
MDS1 SP3 NM_001017371 2 174777831 Asp598Asn 4% 19% 12% 18% 10% 
MDS1 TH NM_000360 11 2189733 Ala159Thr 15% 5% 4% 5% 8% 
MDS2 SF3B1 NM_012433 2 198267371 His662Gln 42% 38% N/A N/A 39% 
MDS2 DNMT3A NM_175629 2 25467133 Trp581Ser 41% 39% N/A N/A 44% 
MDS2 NAGA NM_000262 22 42463872 Tyr74Phe 35% 44% N/A N/A 46% 
MDS2 NMNAT2 NM_170706 1 183230405 Val224Met 41% 40% N/A N/A 45% 
MDS2 NR0B2 NM_021969 1 27238545 Gly189Arg 29% 31% N/A N/A 25% 
MDS2 SPATA13 NM_001166271 13 24797870 Arg268Gln 41% 44% N/A N/A 47% 
MDS2 TLL2 NM_012465 10 98145885 Val647Ala 7% 1% N/A N/A 7% 
MDS2 G3BP1 NM_005754 5 151175137 SS Exon 6 G>C 40% 45% N/A N/A 44% 
MDS2 ABCB11 NM_003742 2 169833167 Gly410Ser 38% 32% N/A N/A 27% 
MDS2 CCDC17 NM_001190182 1 46088498 Leu213Pro 17% 17% N/A N/A 24% 
MDS3 SF3B1 NM_012433 2 198267371 His662Gln 28% 45% 36% 46% 41% 
MDS3 ME1 NM_002395 6 84108234 Tyr72His 31% 37% 48% 53% 40% 
MDS3 CAMTA1 NM_015215 1 7731086 Cys923Phe 33% 50% 53% 50% 39% 
MDS3 PTPDC1 NM_001253829 9 96860488 Pro357Leu 21% 39% 35% 44% 35% 
MDS4 SF3B1 NM_012433 2 198266834 Lys700Glu 40% 47% N/A N/A N/A 




5.2.6 SF3B1 mutant Haematopoietic stem cells engraft in NSG mice 
Next, we sought to determine which progenitor cells within the CD34+ hematopoietic 
compartment were able to engraft in NSG mice. To address this, bone marrow cells 
from one MDS-RS patients (MDS 14, SF3B1 His662Gln mutation) were prepared and 
sorted on a BD FACS Aria SORP (San Jose, CA) operating in 4-way purity sort mode, 
and collected into 1.5 ml microfuge tubes (see methods section 2.2.8 for more details). 
Bone marrow cells were gated within the FACS plots to isolate HSC, MPP, MLP, CMP 
and GMP. After sorting, the purity of MPP, MLP, CMP and GMP were checked, and a 
sorting purity of ≥97% was obtained. Cell number obtained for each compartment for 
all the patients are mentioned in Table 36. Subsequently, all the cell fractions were 
injected separately into NSG mice. After 12 weeks, mice were sacrificed and bone 
marrow cells were analysed. Interestingly, human cell engraftment (HEC) was 
observed in only one mouse that received SF3B1 mutated HSCs, which is similar to 
the recent data from Woll & colleagues (Woll et al., 2014) showing that MDS initiating 
cells (MDS-ICs) are restricted to the HSC compartment in 5q- MDS patients (Table 36 
and Figure 53). Mutational analysis targeting SF3B1 gene was performed on CD34+ 
cells and human engrafted cells obtained from mice. Our sequencing data confirmed 
that the engrafted cells carried the same SF3B1 H662Q mutation with the similar MAB 
as compared to the day 0 CD34+ cells from the patient (Figure 53). Therefore, our data 
suggest that CD49+ HSCs with SF3B1 mutations maintain their engraftment capacity. 
However, SF3B1 mutations in this case did not increase the engraftment potential 









Table 36: Table showing the engraftment of FACS isolated haematopoietic cell fractions 
injected into NSG mice.  
Progenitor cells from one MDS-RS patient were isolated and injected separately into NSG 
mice. 12 weeks later mice were sacrificed and bone marrow was analysed. Only the rare HSC 
faction gave rise to myeloid restricted engraftment indicating the nature of the MDS-SC in this 

































































































































































H662Q NSG 1629 
1/1 100% 




























































                   
Figure 53: SF3B1 mutation is maintained only in mice transplanted with HSCs.  
Targeted mutational analysis shows the presence of concordant SF3B1 mutations in primary 
CD34+ bone marrow sample (Blue) and xenograft (Red) using MiSeq sequencer (top). Three 
independent PCR/sequencing experiments were performed to confirm/determine the mutant 
allele burden throughout the experiments using MiSeq sequencer. Sanger sequencing 
(bottom) traces confirm the mutation in primary CD34+ bone marrow sample and xenograft. 
Error bars were generated from the PCR technical replicates. MAB- Mutant allele burden. 
 
5.2.7 RARS Xenograft mice exhibits subclonal evolution of SF3B1 mutant 
clones 
To study the clonal architecture of the SF3B1 mutant cells, WES and/or targeted 
mutational analysis was performed on HECs. This strategy enabled us to reliably trace 
SF3B1 and known additional patient specific mutations as well as detect any new gene 




Figure 54: Mutational architecture and sub-clonal evolution of SF3B1 mutated MDS-RS 
bone marrow cells. 
Panel A, B, C and D shows the gene mutations with their MABs in primary CD34+ bone marrow, HEC 
cells, LTC and pooled-CFC samples. Table on the right side of each panel represents the mutation 
status of the respective genes in the HSC, MPP, GMP and MEP cell populations for each patient. 
Bars representing the MABs for HEC samples is the average between ≥1 mouse samples (where 
applicable). Three independent PCRs were performed to confirm/determine the mutant allele burden 
throughout the experiments. (+) represents the increased MAB while (-) represent the decrease in the 
MAB in the HEC, LTC and CFC samples. *- represents the significant changes in the MABs (t-test P 
<0.05). P-mutant allele burden for gene mutations was same as the primary CD34+ cells. PL- mutant 
allele burden for gene mutations was ≤ 2-fold as compared to the primary CD34+ cells. PH- mutant 
allele burden for gene mutations was ≥2-fold as compared to the primary CD34+ cells. ND- Not 
detected or below background noise level. MAB-Mutant allele burden. HEC-Human engrafted cells. 




Interestingly, patient-specific somatic mutations were generally maintained in HEC. 
However, changes in the MAB for some of these mutations were observed in 2/4 
cases, indicating a subclonal population shift (Figure 54 and Table 35). In MDS1, 
SF3B1 (Lys700Glu) MAB in primary CD34+ cells and HEC remained almost identical 
at 43% and 47%, respectively (Figure 54). In contrast, JAK2 (Val617Phe) MAB 
decreased from 36% in primary CD34+ cells to 15% in HECs (average MAB for 3 
mice). Likewise, a similar change in MAB for some additional gene mutations was also 
observed. Furthermore, HEC samples showed the emergence of divergent subclones 
with mutations in DNMT3A (≈10%) and other genes including SMC6 (≈17%), SP3 
(≈16%) and HSPA12A (≈7%). These mutations were not initially detected in primary 
CD34+ cells by WES. However, a follow-up high-depth targeted mutational analysis 
confirmed the presence of these mutations at a low level (<5%) in the primary CD34+ 
cells (Figure 54). Similar results were observed for all gene mutations in pooled-CFCs 
and LTCs (Figure 54).  
In MDS2, SF3B1 (H662Q) mutation and additional gene mutations including DNMT3A 
MAB remained similar in the primary CD34+ cells, HECs and LTCs as well as in 
pooled-CFCs (Figure 54). However, the TLL2 gene MAB decreased from 7% in the 
primary CD34+ cells to 1% in human engrafted mice (Figure 54).  
In MDS3, where the SF3B1 (His662Gln) mutation was detected at 28% in the primary 
CD34+ cells, an increase in the MAB was observed in HEC (≈43%, average MAB 
between 3 mice). A similar increase was observed for additional gene mutations in 
HEC samples, LTC derived cells and pooled-CFC as compared to the primary CD34+ 
cells (Figure 54), suggestive of the presence of a single SF3B1 clone with multiple 
gene mutations.  
In MDS4, only one aberration of MYH14 gene was detected in addition to SF3B1 
where both had an MAB that was similar in primary CD34+ cells (≈44%) and HEC 
sample (≈46%) (Figure 54), suggesting again the presence of a single clone carrying 
both SF3B1 and MYH14 mutations and as such no potential subclonal evolution in 
transplantation experiments.  
Together this data demonstrates that SF3B1 mutant clones are maintained in NSG 
mice and that subclonal fluctuation are detected in certain patients. Of note, all the 
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mutations present in the NSG mice were traced back to the patients’ primary CD34+ 
cells and no new mutations were detected or arose in the human engrafted stem cells 
from MDS-RS patients in NSG mice.  
5.2.8 Patient Specific mutations are present in haematopoietic progenitors 
WES data from 3 of the patients (MDS1, MDS2 and MDS4) identified additional patient 
specific mutations in CD34+ cells. We sought to determine whether these patient 
specific mutations originate from the same HSC pool as SF3B1 or whether they occur 
downstream of the stem cell differentiation in the progenitors. Mutational analysis 
demonstrated that the majority of the patient specific mutations including clinically 
important myeloid specific genes such as DNMT3A and JAK2 were present in the rare 
HSC population as well as in the mature myeloid progenitors i.e. MPPs, GMPs and 
MEPs (Figure 54). However, NORB2 and TLL2 gene mutations for MDS2 were not 
detected in the HSCs but were present in the MPPs, GMPs and MEPs, suggesting 
that these mutations originate from a more mature progenitor compartment or are 
below the level of detection in HSC compartment. Furthermore, SMC6, SP3, FLIMB1 
and TH gene mutations were observed in the HSCs and MPP populations, and not in 
mature progenitors obtained from MDS1. This could be due to the fact that these 
mutations are present as minor clones (<10% MAB) in the HSC and MPP progenitor 
compartments and are as such diluted further in mature progenitors. Furthermore, we 
and others have shown that SF3B1 mutations are not detected in T- or B-cells in MDS-
RS patients. Taken together, this data suggests that SF3B1 mutations are clonally 
propagated by HSCs to their mature myeloid progenitors but not to the lymphoid 
progenitors in MDS-RS patients.  
5.2.9 Single cell clonal analysis reveals sub-clonal mutational architecture in 
MDS patients with RS 
Previous studies have described mutational spectrum of SF3B1 mutated patient bone 
marrow cells (Haferlach et al., 2014; Mian et al., 2013; Papaemmanuil et al., 2011; 
Yoshida et al., 2011b). However, these studies have inferred the clonal architecture in 
the total bone marrow samples through the identification of clusters of coexisting 
mutations with similar MABs and this does not necessarily recapitulate the actual 
subclonal architecture of the patients’ bone marrow compartment. Therefore, to gain 
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insight into the clonal architecture of co-existing mutations in SF3B1 mutant MDS-RS 
patients, we performed a single cell clonogenic assay using CD34+ cells from 7 
patients (MDS1, MDS2, MDS3, MDS4, MDS6 and MDS142).  
After a 14 day CFC culture, individual colonies were picked, harvested and washed 
twice with PBS. Individual colonies (Table 33) were collected and stored in PBS. 
Following on, whole-genome amplification was performed on CFC colonies (WGA; 
See methods section 2.2.13 for more details). WGA amplified colonies were subjected 
targeted mutational analysis of the patient specific mutations (mutational profile 
obtained from WES, Table 35) using MiSeq platform (See methods section 2.2.6 for 
more details). Gene mutation for each single colony was called when ≥30% of the 






Figure 55: SF3B1 mutations in single cell colonies.  
Mutational analysis was performed on BFU-E and CFU-GM colonies derived from primary 
CD34+ patient cells (MDS1, MDS2, MDS3 and MDS4). Each column represents an individual 
CFC colony. Circle (MDS1 and MDS2) on the right represent the clonality observed in the 
CD34+ cells in MDS1 and MDS2. WT- Wild Type. Coloured boxes represent a mutant colony 





             
Figure 56: In-vitro analysis of SF3B1 mutant MDS1 patient CD34+ cells.  
Mutational analysis performed on BFU-E and CFU-GM colonies derived from primary CD34+ 
patient cells from MDS1. 96 individual colonies were screened for JAK2 and SF3B1 mutations. 
SF3B1 mutations are seen equally in BFU-E and CFU-GM colonies.  
 
Initial mutational analysis performed on individual CFC colonies from MDS1 (SF3B1 
and JAK2 screened in 96 colonies; other patient specific mutations screened in 48/96 
colonies), MDS2 (47 colonies), MDS3 (46 colonies) and MDS4 (30 colonies) using 
gene specific primers targeting SF3B1 mutations revealed that 97%, 98%, 96% and 
77% of the screened colonies carried SF3B1 mutant gene respectively (Figure 55 and 
Figure 56). However, further analysis of the ‘patient specific’ gene mutations in these 
cases revealed the complex heterogeneity within the SF3B1 mutated colonies. For 
example, MDS 2 had a marked subclonal heterogeneity with 7 SF3B1 subclones 
containing 11 mutated genes with majority (46/47 colonies) of them related via a 
branching ancestral tree (Figure 54). Notably, driver mutations such as DNMT3A were 
present in 44/47 colonies, suggesting that it may have been acquired at a later time 
point during disease progression. Furthermore, 48/96 colonies analysed from MDS1 
demonstrated 6 different SF3B1 subclones; only 15/48 colonies had SF3B1 mutations 
alone (Figure 55 and Figure 56). Six SF3B1 subclones were mutually exclusive 
especially subclones with known driver mutant genes such as JAK2 and DNMT3A, 
therefore representing a branching multi-clonal evolution (Figure 56). In contrast, the 




























MDS4 where only one, two and three mutant SF3B1 subclones were observed, 
respectively (Figure 56). 
It is noteworthy that CFC individual colonies with wild-type SF3B1 (MDS1, n =2; 
MDS2, n=1; MDS3, n=2, MDS4, n=7, MDS6, n= 20) had no additional gene mutations 
amongst those screened (Figure 55 and Figure 56). This provide further evidence that 
SF3B1 mutations are present in the majority of the CD34+ cells and, importantly, 
precede other driver mutations such as DNMT3A and JAK2 as evidenced here. This 
implies that SF3B1 mutation is the ‘founder mutation’ in these MDS-RS patients.  
5.2.10 Sequential acquisition of genetic lesions in SF3B1 mutant clones leads 
to disease transformation  
MDS2 patient transformed to AML 29 months after the first MDS sample was taken 
(MDS2, Time point 1). Initially, FACS analysis was performed to examine the 
phenotypic changes that could have occurred in the bone marrow compartment 
leading to AML (Figure 57A). The frequency of CD34+ cells in bone marrow MNCs at 
AML stage (at 29 months) was significantly higher as compared to the MDS stage 
(MDS stage time point 1, CD34+ = 1.54% of total MNCs; AML stage CD34+ = 35.3% 
of total MNCs). A remarkable shift of cell populations was observed within the 
CD34+CD38- compartment (HSCs, MPPs and MLPs) as well as CD34+CD38+ more 
mature progenitors (CMPs, GMPs and MEPs) at the AML stage as compared to MDS 
stage of the disease (Figure 57A). By contrast to MDS stage, the majority (>99%) of 
the cells observed at the AML stage within the CD34+CD38- compartment were MLPs. 
Similarly, >99% of the cells detected in the CD34+CD38+ compartment at the AML 




Figure 57: Clonal evolution from MDS to AML in RCMD-RS patient with SF3B1 mutation.  
(A) FACS profiles of Stem cell progenitors in BM MNCs in serial samples at MDS stage and 
AML stage of the disease. (B) Interphase FISH for tracking the del(7q) aberration in cells 
obtained at AML stage of the disease. Two chromosome 7 aberrations del(7q36) and 
del(7q22-7q36) were detected as two separate clones. Two individual cells are shown in the 
figure with one harbouring del(7q36) represented by green probe and the other cell has 
del(7q22-7q36) as represented by probes orange/green. (C) SNV profile derived from whole-
exome sequencing. The profile depicts a heterozygous deletion (horizontal red line) of 
chromosome 7q in patient CD34+ bone marrow cells (bottom) and paired control CD3+ cells 
(top). (D) Bar chart (FISH analysis) showing percentage of CD34+ cells (MDS stage), CD34+ 




























































































































































































Figure 58: FISH and SNP (whole-exome) profiling for MDS2.  
(A) Detailed map of locus specific probe targeting q arm of chromosome 7. XL 7q22/7q36 
probe detects a specific region at 7q22 (orange) including the MLL5 gene while as the green 
labelled probe hybridizes specifically to 7q36 (green) and includes the EZH2 gene. In addition, 
a blue (aqua) labelled probe which hybridizes to the centromeric region of chromosome 7 acts 
as a reference probe. Chr-Chromosome. (B) Single nucleotide variations (SNVs) profiles from 
whole-exome experiments based on CD34+ cells (AML stage), paired constitutional DNA 
(CD3+), CD34+ (MDS stage time point1),  Human engrafted cells (post engraftment, MDS 
stage time point 1) and LTC derived cells (MDS stage time point 1). SNVs were selected that 
were called germline or LOH in VarScan, due to presence at similar levels in both samples of 
a pair or significant allele burden change between the two respectively, had >20 read depth. 
LOH- Loss of heterozygosity. 
We sought to investigate the contribution of SF3B1 and additional genomic lesions 
(chromosomal aberrations; gene mutations, known ‘driver’ or ‘passenger’ mutations) 
were acquired at the AML stage. Metaphase cytogenetics at the AML stage revealed 
complex chromosomal changes (Table 32) including del(7q). In order to explore this 
further and trace back the del(7q) aberration, FISH analysis (Figure 58A-58B and 
Figure 58B) for chromosome 7 was performed on the whole bone marrow sample 






























































(MDS stage, Time point 1). Two chromosome 7 aberrations were detected in the whole 
bone marrow sample taken at the AML stage of the disease with 93% (140/150 cells) 
having del (7q36) and 7% (10/150 cells) containing del(7q22-7q36). Similar results 
were observed in the MLPs (del7q36, 292/300 cells; del7q22-7q36, 8/300 cells) and 
GMPs (del7q36, 262/300 cells; del7q22-7q36, 38/300 cells) obtained at AML 
transformation (Figure 57B-57C). Only del(7q36) was traced back to the MDS stage 
of the disease, however, the frequency was significantly less i.e. 2% (12/600 cells) 
(Figure 57D-57E). FISH analysis couldn’t be performed on the phenotypically defined 
HSCs, MPPs, CMPs and MEPs due to the low frequency of these progenitors in the 
bone marrow at the AML stage. It is noteworthy that FISH analysis on the LTC derived 
cells (MDS stage Time point 1) showed low level del (7q36) clone (3%, 8/300 cells; 
Figure 57D), therefore suggesting that the major clone containing del (7q36) is an early 
lesion acquired in the SF3B1 mutant rare HSCs at an MDS stage of the disease. 
However, SNV profile through WES on LTC showed no change in the LOH at 
chromosome 7 and similar results were observed for CD34+ cells (MDS stage), HEC 






Figure 59: Clonal evolution from MDS to AML in RCMD-RS patient with SF3B1 mutation.  
(A) Mutational status of the gene mutations in sequential bone marrow samples (MDS stage-
time point 1, MDS stage-time point 2 and AML stage). Coloured circles represent the mutant 
allele burdens for each screened gene mutation. Black *- represent absence of gene mutations 
in AML stage sample. Red*- represents acquisition of additional mutation at the AML stage. 
(B) Mutational analysis of SF3B1, DNMT3A and SUV420H1 in HSCs, MLPs and GMPs from 
AML stage of the disease. Sequencing depth for HSCs was >10000 reads. (C)Proposed 
sequential acquisition of genetic lesions based on analysis of sequential samples, LTC derived 




















































































































































































WES of the whole bone marrow sample (AML stage) showed that SF3B1 and other 
additional gene mutations including DNMT3A were maintained, however, CCDC17 
and TLL2 were not detected (Figure 59A). Further analysis revealed additional patient 
specific mutations, including SUV420H1 (Leu645Phe) novel mutation (Figure 59A), 
which is a histone methyltransferase that specifically trimethylates 'Lys-20' of histone 
H4. Due to the functional importance of this gene and its known association with breast 
cancer (Fraga et al., 2005; Tryndyak et al., 2006), we followed this gene mutation and 
performed high depth targeted mutational screening on MDS stage samples (Time 
point 1 and Time point 2). Unlike del(7q), this mutation was not detected in any of the 
previous MDS samples (Figure 59B).  
 
                          
Figure 60: Mutational profile of sequential MLP sample for MDS2 obtained at AML stage 
of the disease. MAB- Mutant allele burden. 
 
Furthermore, mutational analysis of the HSC, MLP and GMP compartments (AML 
stage) revealed that SF3B1 and DNMT3A mutations were present in all the 
compartments. However, SUV420H1 mutation was not detected in HSCs but 
originated from MLPs and propagated to GMPs. (Figure 59B and Figure 60). Taken 
together, our data suggests that SF3B1 mutation precedes del(7q) aberration and is 











5.2.11 RARS Xenograft model recapitulates the clonal changes occurring in 
patients bone marrow compartment 
In order to ascertain whether the xenograft clonal changes observed, occur in the 
MDS-RS patient bone marrow, targeted mutational screening was performed on 
sequential samples (total nucleated cells) obtained from 2 patients (MDS1, ≈18 
months after initial sampling with no progression and MDS2, ≈29 months after the first 











Figure 61: Xenograft recapitulates the clonal changes occurring in RARS patient bone 
marrow compartment.  
Mutational analysis of sequential primary TNC (total nucleated cells) sample from 1 patient 
(MDS1). Primary patient sample was received at two different time points, MDS1 CD34+ (TP1, 
first sample) and MDS1 TNC (TP2, second sample). Mutational analysis was also performed 
on human engrafted cells which were obtained from mice transplanted with patient sample 
received at time point 1. The length of the arc represents the mutant allele burdens. Gene 
MAB for human engrafted cells is the average between three animal experiments. Three 
independent PCR/sequencing experiments were performed to confirm/determine the mutant 
allele burden throughout the experiments. MAB- Mutant allele burden. TP-Time point, HEC-





Mutational analysis of these sequential samples revealed that SF3B1 mutations were 
largely unchanged between the two time points (Figure 61 and Figure 62) in both 
patients. By contrast, a change in the MAB of additional somatic mutations was 
observed in the latter sample obtained from MDS1 (Time point 2; Figure 61). In this 
case, MABs of some of the gene mutations including JAK2 (Val617Phe, 36% to 13%) 
diminished (Figure 61), whereas DNMT3A, HSP12A and SMC6 MABs increased from 
4% to 15%, 2% to 8% and 2% to 8% in the patients sequential sample (Time point 2; 
Figure 61), respectively.  Strikingly, xenografted cells (mice transplanted with sample 
at time point 1) from the same patient at week-20, demonstrated similar sub-clonal 
changes as observed in the sequential patient sample after ≈18 months (Time point 
2, Figure 61). This data along with our clonogenic data suggest that 4 SF3B1 
subclones exist in this patient, however, “isolated-SF3B1” and “SF3B1 plus DNMT3A” 
clone have a growth advantage over the rest of the clones, especially over “SF3B1-






Figure 62: Xenograft recapitulates the clonal changes occurring in the patient bone 
marrow compartment. 
Mutational analysis of sequential primary TNC sample from MDS 2. Primary samples were 
received at two different time points, MDS 2 CD34+ (TP1, MDS stage) and MDS 2 TNC (TP3, 
AML Stage). Mutational analysis was also performed on human engrafted cells which were 
obtained from mice transplanted with patient sample taken at time point 1. Three independent 
PCR/sequencing experiments were performed to confirm/determine the mutant allele burden 
throughout the experiments. MAB- Mutant allele burden. TP-Time point, HEC-human 
engrafted cells, TNC- Total nucleated cells, ND- Not detected. 
 
In MDS2, CCDC17 and TLL2 mutations were not detected in the sequential sample 
while the rest of the mutations were largely maintained. A similar trend was observed 
in our NSG mice where TLL2 gene mutation diminished from 7% in the primary patient 
samples (MDS stage Time point 1) to 1% in the HEC sample (Figure 62). SUV420H1 
mutation which was detected in the AML stage after MDS2 transformed, was not 
detected in the HEC sample, perhaps reinforcing the fact that this mutation was 
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acquired at a later time point in the patients’ primary bone marrow cells and was not 
part of the initial MDS clones injected in mice.  
Altogether, this data suggest that xenograft model does recapitulate some of the clonal 
changes occurring in the patients’ bone marrow compartment in one case while as in 
another case where AML transformation occurred, a partial recapitulation was 
observed most probably due to the stochastic acquisition of additional genomic lesion 
at this later stage of the disease (in this case SUV420H1 mutation). Meanwhile, it is 
noteworthy that the ‘incubation period’ of the MDS bone marrow cells in NSG mice 
was only 20 weeks while patient (MDS2) transformed to AML 29 months after the first 
MDS sampling.  
5.2.12 Proposed model for existence of a ‘Master Switch’ causing leukaemia 
transformation 
SF3B1 mutation(s) in MDS patients with ring sideroblasts arise from CD34+CD38-
CD45RA-CD90+CD49f+HSCs and is the initiating event in disease pathogenesis. 
However, acquisition of additional ‘potent’ mutations such as SUV420H1 in a patient 
with “SF3B1-del(7q)” subclone in the MLP compartment leads to the expansion of this 







Figure 63: Proposed model for sequential acquisition of genetic lesions in MDS to AML 
transformation.  
SF3B1 mutations are acquired in CD34+CD38-CD90+CD45RA-CD49f+ HSCs. As HSCs 
replenish downstream progenitors, mutations acquired in stem cells are also propagated to 
mature progenitors but without conferring self-renewal potential. However, as the mature 
progenitors such as MLPs harbouring a mutant SF3B1 acquires a more “potent hit” such as 





































Next-generation sequencing technologies have greatly improved our understanding of 
the genetic landscape in cancer. Previous work in AML and MDS demonstrated the 
existence of clonal heterogeneity that evolves upon disease progression and/or 
relapse (Ding et al., 2012; Klco et al., 2014; Mardis et al., 2009; Walter et al., 2011; 
Welch et al., 2012). To date, various studies including ours have shown that SF3B1 is 
the most frequently mutated gene in MDS with remarkably strong association with a 
specific disease phenotype i.e. the presence of ring sideroblasts (Mian et al., 2013; 
Papaemmanuil et al., 2011; Yoshida et al., 2011b) suggesting that this mutation is 
casually linked to event defining ring sideroblastic anaemia. However, it is noteworthy 
that studies so far have not determined the origins of SF3B1 mutations within the 
hematopoietic compartment and the composition of the SF3B1 subclones. Similarly, 
the functional heterogeneity of genetically defined SF3B1 mutant subclones has not 
been delineated.  
Here WES, capture-based targeted high-depth sequencing, long-term culture assay, 
xenotransplantation as well as single cell clonogenic assays were used to study the 
characteristics of SF3B1 mutant hematopoietic cells. Mutational analysis of the SF3B1 
gene in hematopoietic stem/progenitor cells reveals that SF3B1 mutations arise in 
phenotypically defined CD34+CD38-CD45RA-CD90+CD49f+ stem cells therefore 
unveils the MDS-SCs existence in RARS that propagate mutations to their myeloid 
progenitors such as MPPs, GMPs and MEPs. This was also reflected in clonogenic 
assays where SF3B1 mutations were detected either alone or in combination with 
other mutations in individual CFC colonies, therefore implying that SF3B1 aberrations 
precede other gene mutations. Similar results have been described recently, in MDS 
patients with concurrent SF3B1 and del(5q) aberrations, where SF3B1 mutations were 
shown to be present in CD34+CD38-CD90+ stem cells in these patients (Woll et al., 
2014).  
In our study, xenotransplantation of CD34+ bone marrow from MDS samples in 
immuno-deficient mice demonstrated the persistent long-term myeloid restricted 
engraftment in the majority of cases. In contrast, NSG data from one congenital 
sideroblastic anaemia patient carrying an ALAS2 mutation and other healthy donors 
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showed a multi-lineage engraftment with high percentage of lymphoid/myeloid cell 
ratio. It is noteworthy that all 4 patients in our study had only one common genomic 
aberrations i.e. SF3B1. In addition, 2/4 patients (MDS 2 and MDS3) had a lower 
mutation rate (2 to 4 mutations/exome) which is less as compared to that in AML (≈13), 
chronic lymphocytic leukaemia (≈12), and was significantly lower as compared to 
multiple myeloma (≈33), hence representing a much more homogenous clonal 
population. 
Notably, the genotypic analysis of pre- and post-transplanted cells demonstrate that 
in most of the cases SF3B1 mutations were maintained, however, in one case (MDS3), 
SF3B1 mutant clone increased from 27% in primary CD34+ cells to 47% in HEC 
samples. This suggests the presence of a mixed stem cell population (i.e. SF3B1-
mutant/wild type), which when injected into immuno-deficient mice resulted in the 
expansion of SF3B1 mutant clones preferentially.  
Exclusive myeloid engraftment and the maintenance/increase in the SF3B1 clone(s) 
in NSG xenografts suggests that a malignant HSC clone with SF3B1 mutations either 
alone or in-conjunction with other “co-operating factors” has a growth advantage or 
provides a negative feedback over the cohabitating normal HSC.  
Interestingly, in all mice that have detectable human engrafted cells, we could see a 
similar subclonal architecture compared to MDS cells injected. Nevertheless, in some 
cases, the engrafting SF3B1 daughter subclones represented only a small fraction of 
the injected cells (<5%), implying that some SF3B1 subclones have a cell-intrinsic 
advantage (due to better engraftment ability, enhanced proliferation potential, and/or 
additional factors) following xenotransplantation. Malignant clones with ‘isolated 
SF3B1’ mutations are not always driven away by more ‘potent’ mutant subclones 
(such as DNMT3A and/or JAK2) in NSG mice as was reflected by its MAB which 
remained stable even though other subclones were fluctuating. Perhaps additional 
driver mutations when acquired by the SF3B1 clones confer a subtle advantage to the 
new daughter subclone representative of early stages in disease progression as 
evidence for MDS1 (Time point 1 vs Time point 2). However, when these clones 
acquire more aggressive mutation(s) as it is the case here for MDS2, a more 
‘aggressive’ mature progenitor clone with self-renewing capacity is generated, 
enabling the disease to evolve into AML. It is tempting to speculate that SUV420H1 
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mutations confers a growth advantage based on the evidence that Suv420h (referred 
to both Suv420h1 and Suv420h2) deficient MEFs and ES cells have been reported to 
have telomere elongation and epigenetic defects (Benetti et al., 2007). Further work 
needs to be done to study the role of SUV420H1 mutation(s) in haematological 
diseases.  
It is noteworthy that small subclone with SF3B1 mutation harbouring del(7q36) 
becomes a predominant clone in the sequential AML sample (MDS2) but with the 
additional acquisition of del(7q22). Therefore, SF3B1 mutation in isolation might only 
have a minor role in disease transformation or progression to AML. However, like 
del(5q) aberrations (Woll et al., 2014), it may instead be a strong driver mutation in 
MDS-RS and acquires additional mutations during the course of the disease 
progression.  
Previous studies of functional heterogeneity in human leukaemias have used NSG 
mice to characterize leukemia stem cells in order to decipher their engraftment 
potential, self-renewal capacity (Eppert et al., 2013; Goardon et al., 2011; Taussig et 
al., 2008; Taussig et al., 2010). Nevertheless, Tim Ley’s group was the first to report 
functional heterogeneity of genetically defined subclones in AML (Klco et al., 2014). 
Their data suggested that xenotransplantation results in a dramatic decrease in the 
subclonal complexity of the AML samples and were not able to reliably predict disease 
relapse.  However, the combination of our WES in xenotransplanted NSG mice and 
serial patient sampling enabled us to compare the clonal evolution observed in mice 
with that of patient bone marrow compartment in MDS1 and MDS2. The changes in 
the spectrum of SF3B1 mutant clones observed in the NSG mice were largely reflected 
in the patient’s sequential bone marrow cells where similar clonal changes were 
detected. Although the SF3B1 clonal fluctuation observed in NSG mice for MDS1 was 
more remarkable as compared to MDS2. 
This is the first study to demonstrate SF3B1 mutations originate in rare CD34+CD38-
CD90+CD49f+ HSCs and MDS-initiating cells are restricted to these rare HSCs 
fractions in MDS patients with ring sideroblasts. Although our data is limited to five 
patients, the presence of SF3B1 mutations in CD34+CD38-CD90+CD45RA-CD49f+ 
HSCs provides new insight into the MDS stem cells. Furthermore our data 
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demonstrates that SF3B1 mutations acts as an initiating event in MDS-RS disease, as 
has been suggested by previous studies (Papaemmanuil et al., 2011; Yoshida et al., 
2011b). Moreover, MDS2 patient progression to AML illustrates the concept of a switch 
from “HSC disease” to a “Progenitor disease”.  Here, we show that MDS-RS originates 
from the stem cells and at a later stage of the disease, de novo mutation(s) acquired 
by the progenitor cells confers the self-renewal capability to the MDS-progenitor cells 
that drives the leukemic transformation. This novel observation confirming the 
presence of MDS-SC at the AML stage provides new insight into the MDS/AML 
hierarchy. Our results also suggest that MDS-SC at the AML stage can constitute a 
pool of pre-leukemic cells providing a reservoir of cells that could be responsible for 
relapse. Although mutations such as SF3B1 are not driving mutations at the AML 
stage, they provide a genuine target for curative therapies and give the opportunity to 











































Complete genomic characterization of MDS in-general has revealed a relatively 
restricted number of genes that are recurrently mutated and these genes encode 
proteins that are involved in a small number of key biological pathways. Among them, 
defects of pre-mRNA splicing genes, particularly SF3B1 which is a key component of 
the spliceosome complex is mutated in up to 85% of the RARS/RCMD-RS patients as 
has been shown here and elsewhere (Papaemmanuil et al., 2011; Yoshida et al., 
2011b). In addition, recurrent somatic mutations observed in a number of additional 
spliceosomal genes (such as SRSF2, U2AF35, ZRSR2) suggests that dysregulated 
RNA splicing may be driving the clonal dominance in at least 50% of the MDS patients. 
Homozygosity is the exception to the rule for most of the spliceosome mutations, 
especially SF3B1, and spliceosome mutations are mutually exclusive. Therefore, both 
these scenarios are either functionally redundant or that more significant disruption of 
canonical and/or non-canonical spliceosome pathways is not tolerated by the cells.  
Although spliceosome mutations are frequent in MDS, the consequences of these 
aberrations have not been fully elucidated yet. Among the immediate questions raised 
by these findings are, why different spliceosome mutations result in varied 
morphological changes as observed in MDS patients. It is noteworthy that 
spliceosome mutations are largely restricted to proteins involved in the recognition of 
3/ splice-site. Therefore, the disruption of 3/ spice-site recognition as a result of these 
mutations could potentially alter the splicing in a systematic manner by either affecting 
exon recognition/utilization or perhaps activating alternative splice junctions. As a 
result, dysfunctional spliceosome could generate downstream novel protein isoforms 
with altered function, stimulate ectopic expression of tissue-inappropriate protein 
isoforms or drive premature activation of nonsense-mediated decay of proteins 
resulting in quantitative changes in gene expression which can causes downstream 
changes in the cells.  In support of this, a strong genotype-phenotype correlation exists 
between SF3B1 mutations and the presence of ringed sideroblasts. This highly 
specific relationship has been confirmed in all subsequent studies (Papaemmanuil et 
al., 2013). This makes SF3B1 the first gene to be strongly associated with a specific 
morphologic feature in myeloid malignancies, and implies that these aberrations are 
not benign spectators and are central to the pathogenesis of the disease. Recent 
studies have shown that SRSF2 and U2AF1 mutations alter the normal sequence-
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specific RNA binding specificity of these gene, thereby modifying the recognition of 
specific exonic splicing enhancer motifs to drive recurrent mis-splicing of key genes 
involved in the haematopoiesis (Ilagan et al., 2015; Kim et al., 2015).  A study 
investigating the relationship of SF3B1 and ring sideroblasts reported the presence of 
ring sideroblasts in SF3B1+/- mice (Visconte et al., 2012b). A long term follow-up of the 
SF3B1+/- mice also revealed macrocytic anaemia, extramedullary haematopoiesis, 
and thrombocytosis (Visconte et al., 2014).  In-vitro targeting of the SF3B1 using 
meayamycin, a pharmacologic inhibitor of the splicing factor 3b complex (Albert et al., 
2009), induced the formation of ring sideroblasts in healthy bone marrow cells 
(Visconte et al., 2012b). Although, the percentage of ring sideroblasts in MDS patients 
is highly correlated to the SF3B1 mutant allele burden, however, the amount of ring 
sideroblasts still ranges considerably. Therefore, the above variability suggests that 
additional factors must play a role in the ring sideroblasts phenotypic expression. Initial 
transcriptome analysis including ours, however, have not revealed compelling, 
systematic evidence suggesting patterns of mutation-associated splicing 
abnormalities, therefore raising the possibility that these SF3B1 mutations may exert 
their function by disrupting alternative non-splicing pathways. In addition to their role 
in precursor mRNA processing, SF3B1 has been shown to influence histone 
modifications via physical interactions with polycomb group proteins, influence cellular 
response to DNA damage and activate transcription via direct and indirect regulation 
of RNA polymerase elongation (Isono et al., 2005; Kfir et al., 2015; Te Raa et al., 
2015). In addition, SF3B1 contains several cyclin-dependent kinase (cdk) consensus 
phosphorylation sites within its N terminus.  In in-vitro studies, it has been shown that 
cyclin E-cdk2 targets SF3B1 and phosphorylation of SF3B1 occurs prior or during the 
catalytic step II of the splicing pathway (Seghezzi et al., 1998) and subsequently gets 
dephosphorylated by PP1/PP2A phosphatases concomitant with the second step of 
splicing (Wahl et al., 2009). Interestingly, in MDS patients, a link between cell cycle 
progression and splicing has also been seen where particular isoforms of the CDC25C 
cell cycle regulator have been shown in association with disease (Caudill et al., 2008). 
Weather the cause of the unusual pattern of iron deposition within the erythroid cells 
is solely as a result of defects in the splicing machinery or through an alternative 
SF3B1 target gene(s) or pathway(s) remains to be determined.   
246 
 
In our study and all other studies published to date, up to 15% of the RARS patients 
have no evidence of mutations in SF3B1. This could be partly due to inaccuracies in 
the diagnosis of these patients related to difficulties in the identification of ring 
sideroblasts. However, the possibility exists that other unidentified spliceosome genes 
may also be mutated in these patients which may lead to formation of ring sideroblasts. 
Somatic mutations are known to occur in the hematopoietic stem cells (HSCs) at a 
lower frequency during normal DNA replication. Although most of the mutations are 
rapidly corrected by DNA repair mechanisms or perhaps kept under control by immune 
system, those aberrations that persist are propagated during HSC self-renewal. Each 
individual stem cell accumulates exonic mutations at a rate of approximately 0.13 per 
year, therefore by the age of 60, each HSC would have accumulated approximately 
upto 8 mutations with the potential to have an effect on the protein function. MDS being 
an old age-related disease has long been considered to be an oligoclonal stem cell 
disorder. However, the experimental evidence describing the existence of such human 
cancer stem cells (or MDS initiating stem cells) remain extensively contested and in-
vivo tracing of candidate MDS initiating stem cells (MDS-ISC) in such patients has not 
been successful. Here, we demonstrated for the first time that SF3B1 mutation(s) arise 
from early CD34+CD38-CD45RA-CD90+CD49f+ HSCs providing the strongest 
evidence for the existence of MDS-ISCs in RARS that leads to the expansion and 
dominance of a heterozygous clone, propagating to its myeloid progeny. This is the 
first report to isolate the CD49f+ HSC fraction from MDS bone marrow and study the 
genetics as well as engraftment kinetics of these cells. The existence of such MDS-
ISCs has also recently been revealed in 5q-MDS patients (Woll et al., 2014). Notably, 
SF3B1 mutations were not detected in lymphoid compartment, unlike chronic 
lymphocytic leukaemia (CLL) where mutations are solely observed in lymphoid cells. 
In contrast to RARS/RCMD-RS, SF3B1 mutation in CLL occurs during the clonal 
progression of the disease and determine the emergence of more aggressive 
subclones. The available evidence suggests that SF3B1 mutations are very unlikely 
to be founding mutations and must be originating in the late progenitors in CLL. 
Nonetheless, the notion that lymphoid and myeloid diseases can share mutant genes 
is potentially interesting, as shown by a study on TET2 mutations in malignant 
lymphomas (Quivoron et al., 2011). This is at least consistent with the concept that the 
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same effected genes can cause 2 completely different diseases depending upon the 
cell type in which it occurs.  
The significance of functional follow-up in xenograft models is recognized but still 
expensive as well as time consuming. It is also worth to note that very few of the novel 
mutations receive functional validation in in-vitro and in-vivo studies due to the fact 
that unlike leukaemia, engraftment and propagation of MDS-derived cells has proven 
difficult (Nilsson et al., 2002; Thanopoulou et al., 2004). Although acquired 
sideroblastic anaemia has been recognized as a relatively homogenous disease from 
the early days of experimental cancer research, the intra-tumor genetic heterogeneity 
has not been studied in detail. For the first time, genetically distinguishable sub-clonal 
populations in a mixture of cancer stem cells were revealed by single-nucleus and 
single-cell sequencing (Hou et al., 2012; Navin et al., 2011; Xu et al., 2012). Using 
combination of techniques including single cell clonogenic assays, we have clearly 
demonstrated the co-existence of genetically divergent sub-clones within SF3B1 
mutant cell population. This intra-tumor heterogeneity has long been suggested as a 
common feature in both haematological malignancies such as AML and solid tumours. 
Recent studies have evaluated the clonal relationships among primary and metastatic 
cancers (Campbell et al., 2010; Gerlinger et al., 2012; Navin et al., 2011; Yachida et 
al., 2010). These studies demonstrated that seeding metastases need few, if any, 
additional driver lesions beyond those found in the primary malignant cells. The basic 
premise of this long-standing idea is that a cell that is endowed with an advantageous 
mutation produces a progeny that has a survival advantage over other cells that lack 
this mutation. Our data suggest that SF3B1 is such a ‘first’, or “gatekeeping” mutation 
which enables the outgrowth of malignant clone over the cohabitating normal HSCs 
initially as a microscopic clone. Consequently, the progeny of this malignant cell with 
increased fitness does flourish and produces a clonal population that dominates. 
Subsequently, this mutant clone also starts to have downstream effects on the clonal 
erythroid cells, ultimately causing the ring sideroblasts, through a direct or indirect 
mechanism. This is also evident from our in-vivo (NSG mice) as well as in-vitro 
experiments, where SF3B1 mutant present in a mix population of cells (SF3B1 
mutant/wildtype), eventually grows and outcompetes normal HSCs. Over time, 
additional ‘co-operating/advantageous’ mutations arise (in epigenetic regulator or 
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transcription/cell signalling genes), endowing a further growth advantage to a cell 
within the clone. As unique sub-clones arise within the SF3B1 clone, different 
outcomes are possible: less fit sub-clones can be completely lost with the most fit sub-
clone dominating, or many minor sub-clones can persist alongside the dominant clone, 
forming reservoirs from which evolution (or disease progression) can continue as 
evident from our NSG xenograft experiments which shows more potent clones such 
as “SF3B1- DNMT3A” can out-compete “SF3B1- JAK2” clones. This was also seen in 
our patient data where continuous acquisition of mutations and clonal expansion 
during the progression of the disease caused an assemblage of subclones that were 
represented by a branching multi-clonal as well as ancestral evolutionary tree. It has 
been estimated that each acquired “driver” mutation gives only a small selective 
growth advantage, on the order of a 0.4% increase in the difference between cell birth 
and cell death. Over the years, however, this slight increase, compounded once or 
twice per week, can result in a large expansion of the malignant clones (Bozic et al., 
2010). With this model in mind, as disease progresses, clonal hierarchies become 
shallower within genetic subclones. In some cases, once the disease has progressed 
to such an advanced state, the frequency of ‘lethal’ malignant clones may be so high 
that the tumour subclone essentially becomes functionally homogeneous without 
evidence of a hierarchy as evidenced in some patients (MDS2) in our study. However, 
the finding that all subclones were detected in the founding clone suggests that SF3B1 
is a “gatekeeping-driver” mutation which requires additional ‘potent’ aberrations for 
disease progression/transformation. Overall, such models where sub-clones persist 
and/or contribute to independent phylogenetic lineage trees within the founding clone 
are reminiscent of the branching evolution that Darwin proposed as leading to 
increased fitness and overall robustness of a particular organism.  
Another major factor to consider here is the role of the bone marrow non-malignant (or 
malignant) cell elements associated with tumour cells, referred to collectively as the 
bone marrow microenvironment (or niches) (Morrison and Scadden, 2014). The 
juxtaposition of a malignant cell carrying the SF3B1 mutation within the micro-
environment might have an influence on the function as well as the evolution of that 
clone, resulting in significant variation in path it takes during the course of the disease. 
The complexity imposed by the microenvironment is amplified due to crosstalk 
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between these malignant cells and the bone marrow microenvironment. This bone 
marrow microenvironment pressure might also be the defining feature which 
determines if the SF3B1 clone follows a branching multi-clonal or ancestral 
evolutionary path during the course of the disease.  
From a conceptual standpoint, it is clear that therapy failure and MDS disease 
recurrence (or transformation to AML) are not just simply due to the acquisition of new 
mutations in a normal stem cell. Rather, the surviving malignant clones must escape 
the therapy, remain dormant and also have regenerative potential in order to cause 
the disease relapse/transformation; therefore, cells contributing to recurrence must 
behave like MDS-ISCs or disease transforming cells. Certainly, the only critical cells 
in a malignant bone marrow are the ones that are responsible for long-term clonal 
maintenance and expansion; any other cell will ultimately lead to clonal exhaustion 
(Greaves, 2013). Our data suggests that a cell like HSC with highest self-renewal 
capacity and carrying an SF3B1 mutation seems to survive various treatments during 
the course of the disease, remains dormant and then acquires additional mutations 
(such as FLT3 or RUNX1) enabling the disease to transform at the HSC level. 
However, this is not true in all the cases as evident from our sequencing analysis of 
the sequential samples in MDS-AML patient (MDS2) which uncovered the clonal 
evolution in hematopoietic progeny (with the acquisition of SUV420H1 mutation) and 
selection of this malignant driving clone leading to leukemic transformation. This 
paradigm illustrates the concept of a switch from “HSC disease” to a “Progenitor 
disease”. This is consistent with the thinking in the field that pre-leukemia must initiate 
in a self-renewing HSC but leukemia may be generated from mutations acquired in a 
more mature progenitor cell in some patients. Therefore, our data suggests that in 
some cases minor HSC populations carrying the SF3B1 mutations are escaping the 
treatment (later acquires additional mutations) while as in other cases the proliferation 
pressure caused as a result of the treatment results in the acquisition of additional 
mutation at the progenitor level turning them into leukaemia-initiating cells. In support 
of this, there is a strong evidence emerging to suggest a link between stemness and 
therapy resistance in MDS with del(5q), multiple myeloma, lymphoid malignancies, 
breast cancer and colon cancer where studies show that cancer initiating stem cell 
carrying the mutations are more resistant to therapy (Diehn et al., 2009; Leung-
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Hagesteijn et al., 2013; Tehranchi et al., 2010; Zhang et al., 2010). Together, these 
studies highlight the interplay between cancer stem cell properties and genetics that 
drive clinical parameters such as response to therapy and ultimately survival of the 
malignant clone which could also be true for SF3B1 mutant MDS patients.  
The emerging evidence linking stemness to prognosis and therapy failure in other 
haematological malignancies, indicates that therapeutic targeting of SF3B1 clone 
along with the elements of stemness might be an effective means to eradicate MDS-
ISCs and prevent disease recurrence or transformation. Although, it still unclear as to 
how stemness is regulated, several factors of the self-renewal machinery such as 
BMI1 have been strongly linked to self-renewal and have been implicated in the 
maintenance of stem cells in several tissues (Lessard and Sauvageau, 2003; Molofsky 
et al., 2003). A recent study by Kreso et al., demonstrated that by targeting BMI1, 
inhibits the ability of colorectal stem cells to self-renew, resulting in abrogation of their 
tumorigenic potential in mouse xenografts (Kreso et al., 2014).  These studies point to 
the need for the development of combination therapies (using nanoparticle 
technology) to attempt targeting of SF3B1 mutations along with other predicted 
components of the self-renewal machinery as well as altering the microenvironment 
supporting these cells. It is important to note that because stemness-associated 
factors are likely to be shared between normal stem cells and MDS-ISCs, successful 
eradication of MDS-ISCs will require understanding to what extent MDS-ISCs differ 
from normal stem cells to minimize the impact of therapies on these HSCs. The 
application of single cell RNA-Seq might be able to delineate this difference in the 
transcription and signalling networks (hence identifying the cell surface 
markers/signals) that must exist between normal stem cells and SF3B1 mutant MDS-
ISCs.  
Furthermore, delineating genetic from nongenetic stemness influences is also 
important factor which can help to tease apart the aspects of SF3B1 mutant MDS 
disease. Moreover, the dynamics of interactions between sub-clones, each with their 
own superimposed developmental hierarchy - weather they compete or are co-depend 
upon each other and hence coordinate clonal evolution, needs to be elucidated. 
Darwinian Theory dictates how the evolution creates biodiversity and this in-turn 
makes an entire ecosystem robust. Therefore, clonal diversity within the hierarchy at 
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the genetic and functional level together with their ‘cross-talk’ with the 
microenvironment could also increase clonal fitness, allowing these SF3B1 malignant 
cells to offset survival pressures imposed by therapy. Therefore, more effective 






























7 Future Work 
In recent years the heterogeneity of MDS in-general has been deciphered further by 
the discovery of defects in spliceosome genes as reported here and elsewhere. Our 
knowledge has taken an enormous step forward with the unearthing of potential 
connections between RNA splicing defects, the specific structural features of pre-
RNAs and many of the processes such as RNA processing kinetics, genome stability 
as well as cell cycle processes.  
This study shows for the first time shows the presence of SF3B1 mutants MDS-ICs in 
MDS patients with ring sideroblasts and how these cells inherent a clonal superiority 
over the cohabitating cells in the bone marrow. The main question which arises is how 
could basal splicing machinery itself possibly be deranged without causing 
catastrophic cellular consequences? The mRNA splicing process itself is so 
fundamental to every normal cells’ behaviour that any serious defect in the small 
nuclear ribonucleoproteins (snRNPs) or the >200 associated proteins that catalyses 
splicing should be lethal. Therefore, are there other non-spliceosome pathways 
through which SF3B1 is acting and causing the phenotypic changes i.e. ring 
sideroblasts in MDS patients. Therefore, there are two major lines of investigation that 
could be undertaken 
 
1. Transcriptome analysis of SF3B1 mutant bone marrow cells at a single cell level 
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